Topical nerve stimulator and sensor for bladder control

Information

  • Patent Grant
  • 11077301
  • Patent Number
    11,077,301
  • Date Filed
    Friday, February 19, 2016
    8 years ago
  • Date Issued
    Tuesday, August 3, 2021
    2 years ago
  • Inventors
  • Original Assignees
    • NeurostimOAB, Inc. (Waltham, MA, US)
  • Examiners
    • Malamud; Deborah L
    Agents
    • Potomac Law Group, PLLC
Abstract
What is provided is a method and apparatus for modifying bladder function comprising: applying a dermal patch having an integral electrode in proximity to a sacral or pudendal nerve; selecting the sacral or pudendal nerve by a sensor integral on the dermal patch; determining a stimulation corresponding to the sacral or pudendal nerve, by logic of the dermal patch; applying the stimulation by the electrodes and a stimulator integral to the dermal patch to produce an electric field; and selectively activating the sacral or pudendal nerve by the electric field.
Description
TECHNICAL PROBLEM

Mammalian and human nerves control organs and muscles. Artificially stimulating the nerves elicits desired organ and muscle responses. Accessing the nerves to selectively control these responses from outside the body, without invasive implants or needles penetrating the dermis, muscle or fat tissue is desired.


A Topical Nerve Stimulator and Sensor (TNSS) device described in the related U.S. Patent Application Serial No. PCT/US 14/40240 filed May 30, 2014 is used to stimulate nerves. A TNSS may apply electrode generated electric field(s) in a low frequency to dermis in the proximity of a nerve. The TNSS also includes hardware and logic for high frequency (GHz) communication to mobile devices.


A wireless system including a TNSS device is described herein. Its components, features and performance characteristics are set forth in the following technical description. Advantages of a wireless TNSS system over existing transcutaneous electrical nerve stimulation devices are:


fine control of all stimulation parameters from a remote device such as a smartphone, either directly by the user or by stored programs;


multiple electrodes of a TNSS can form an array to shape an electric field in the tissues;


multiple TNSS devices can form an array to shape an electric field in the tissues;


multiple TNSS devices can stimulate multiple structures, coordinated by a smartphone;


selective stimulation of nerves and other structures at different locations and depths in a volume of tissue;


mechanical, acoustic or optical stimulation in addition to electrical stimulation;


transmitting antenna of TNSS device can focus beam of electromagnetic energy within tissues in short bursts to activate nerves directly without implanted devices;


inclusion of multiple sensors of multiple modalities, including but not limited to position, orientation, force, distance, acceleration, pressure, temperature, voltage, light and other electromagnetic radiation, sound, ions or chemical compounds, making it possible to sense electrical activities of muscles (EMG, EKG), mechanical effects of muscle contraction, chemical composition of body fluids, location or dimensions or shape of an organ or tissue by transmission and receiving of ultrasound;


TNSS devices are expected to have service lifetimes of days to weeks and their disposability places less demand on power sources and battery requirements;


combination of stimulation with feedback from artificial or natural sensors for closed loop control of muscle contraction and force, position or orientation of parts of the body, pressure within organs, and concentrations of ions and chemical compounds in the tissues;


multiple TNSS devices can form a network with each other, with remote controllers, with other devices, with the internet and with other users;


collection of large amounts of data from one or many TNSS devices and one or many users regarding sensing and stimulation, collected and stored locally or through the internet;


analysis of large amounts of data to detect patterns of sensing and stimulation, apply machine learning, and improve algorithms and functions;


creation of databases and knowledge bases of value;


convenience;

    • absence of wires to become entangled in clothing
    • showerproof and sweat proof
    • low profile, flexible, camouflaged or skin colored
    • integrated power, communications, sensing and stimulating
    • inexpensive
    • disposable TNSS, consumable electronics


power management that utilizes both hardware and software functions will be critical to the convenience factor and widespread deployment of TNSS device.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a depiction of a neuron activating a muscle by electrical impulse;



FIG. 2 is a representation of the electrical potential activation time of an electrical impulse in a nerve;



FIG. 3 is a graph showing pulses applied to the skin;



FIG. 4 is a graph showing symmetrical and asymmetrical pulses applied to the skin;



FIG. 5 is a cross-sectional diagram showing a field in underlying tissue produced by application of two electrodes to the skin;



FIG. 6 is a cross-sectional diagram showing a field in underlying tissue produced by application of two electrodes to the skin, with two layers of tissue of different electrical resistivity;



FIG. 7 is a cross-sectional diagram showing a field in underlying tissue when the stimulating pulse is turned off;



FIG. 8 shows potential applications of electrical stimulation to the body;



FIG. 9A is a system diagram of an example software and hardware components showing an example of a Topical Nerve Stimulator/Sensor (TNSS) interpreting a data stream from a control device;



FIG. 9B is a flow chart showing an example of a function of a master control program;



FIG. 10 is a block diagram of an example TNSS component configuration including a system on a chip (SOC);



FIG. 11 is a nerve diagram showing the nerve signals related to bladder function: and



FIG. 12 is a system diagram showing an example TNSS system.





DESCRIPTION OF ACTION POTENTIALS AND NERVE PHYSIOLOGY

Referring to FIG. 1, a nerve cell normally has a voltage across the cell membrane of 70 millivolts with the interior of the cell at a negative voltage with respect to the exterior of the cell. This is known as the resting potential and it is normally maintained by metabolic reactions which maintain different concentrations of electrical ions in the inside of the cell compared to the outside. Ions can be actively “pumped” across the cell membrane through ion channels in the membrane that are selective for different types of ion, such as sodium and potassium. The channels are voltage sensitive and can be opened or closed depending on the voltage across the membrane. An electric field produced within the tissues by a stimulator can change the normal resting voltage across the membrane, either increasing or decreasing the voltage from its resting voltage.


Referring to FIG. 2, a decrease in voltage across the cell membrane to about 55 millivolts opens certain ion channels, allowing ions to flow through the membrane in a self-catalyzing but self-limited process which results in a transient decrease of the trans membrane potential to zero, and even positive, known as depolarization followed by a rapid restoration of the resting potential as a result of active pumping of ions across the membrane to restore the resting situation which is known as repolarization. This transient change of voltage is known as an action potential and it typically spreads over the entire surface of the cell. If the shape of the cell is such that it has a long extension known as an axon, the action potential spreads along the length of the axon. Axons that have insulating myelin sheaths propagate action potentials at much higher speeds than those axons without myelin sheaths or with damaged myelin sheaths.


If the action potential reaches a junction, known as a synapse, with another nerve cell, the transient change in membrane voltage results in the release of chemicals known as neuro-transmitters that can initiate an action potential in the other cell. This provides a means of rapid electrical communication between cells, analogous to passing a digital pulse from one cell to another.


If the action potential reaches a synapse with a muscle cell it can initiate an action potential that spreads over the surface of the muscle cell. This voltage change across the membrane of the muscle cell opens ion channels in the membrane that allow ions such as sodium, potassium and calcium to flow across the membrane, and can result in contraction of the muscle cell.


Increasing the voltage across the membrane of a cell below −70 millivolts is known as hyper-polarization and reduces the probability of an action potential being generated in the cell. This can be useful for reducing nerve activity and thereby reducing unwanted symptoms such as pain and spasticity


The voltage across the membrane of a cell can be changed by creating an electric field in the tissues with a stimulator. It is important to note that action potentials are created within the mammalian nervous system by the brain, the sensory nervous system or other internal means. These action potentials travel along the body's nerve “highways”. The TNSS creates an action potential through an externally applied electric field from outside the body. This is very different than how action potentials are naturally created within the body.


Electric Fields that can Cause Action Potentials


Referring to FIG. 2, electric fields capable of causing action potentials can be generated by electronic stimulators connected to electrodes that are implanted surgically in close proximity to the target nerves. To avoid the many issues associated with implanted devices, it is desirable to generate the required electric fields by electronic devices located on the surface of the skin. Such devices typically use square wave pulse trains of the form shown in FIG. 3. Such devices may be used instead of implants and/or with implants such as reflectors, conductors, refractors, or markers for tagging target nerves and the like, so as to shape electric fields to enhance nerve targeting and/or selectivity.


Referring to FIG. 3, the amplitude of the pulses, A, applied to the skin, may vary between 1 and 100 Volts, pulse width, t, between 100 microseconds and 10 milliseconds, duty cycle (t/T) between 0.1% and 50%, the frequency of the pulses within a group between 1 and 100/sec, and the number of pulses per group, n, between 1 and several hundred. Typically, pulses applied to the skin will have an amplitude of up to 60 volts, a pulse width of 250 microseconds and a frequency of 20 per second, resulting in a duty cycle of 0.5%. In some cases balanced-charge biphasic pulses will be used to avoid net current flow. Referring to FIG. 4, these pulses may be symmetrical, with the shape of the first part of the pulse similar to that of the second part of the pulse, or asymmetrical, in which the second part of the pulse has lower amplitude and a longer pulse width in order to avoid canceling the stimulatory effect of the first part of the pulse.


Formation of Electric Fields by Stimulators


The location and magnitude of the electric potential applied to the tissues by electrodes provides a method of shaping the electrical field. For example, applying two electrodes to the skin, one at a positive electrical potential with respect to the other, can produce a field in the underlying tissues such as that shown in the cross-sectional diagram, FIG. 5.


The diagram in FIG. 5 assumes homogeneous tissue. The voltage gradient is highest close to the electrodes and lower at a distance from the electrodes. Nerves are more likely to be activated close to the electrodes than at a distance. For a given voltage gradient, nerves of large diameter are more likely to be activated than nerves of smaller diameter. Nerves whose long axis is aligned with the voltage gradient are more likely to be activated than nerves whose long axis is at right angles to the voltage gradient.


Referring to FIG. 6, applying similar electrodes to a part of the body in which there are two layers of tissue of different electrical resistivity, such as fat and muscle, can produce a field such as that shown in FIG. 6. Layers of different tissue may act to refract and direct energy waves and be used for beam aiming and steering. An individual's tissue parameters may be measured and used to characterize the appropriate energy stimulation for a selected nerve.


Referring to FIG. 7, when the stimulating pulse is turned off the electric field will collapse and the fields will be absent as shown.


It is the change in electric field that will cause an action potential to be created in a nerve cell, provided sufficient voltage and the correct orientation of the electric field occurs. More complex three-dimensional arrangements of tissues with different electrical properties can result in more complex three-dimensional electric fields, particularly since tissues have different electrical properties and these properties are different along the length of a tissue and across it, as shown in Table 1.













TABLE 1







Electrical





Conductivity



(siemens/m)
Direction
Average




















Blood

.65



Bone
Along
.17



Bone
Mixed
.095



Fat

.05



Muscle
Along
.127



Muscle
Across
.45



Muscle
Mixed
.286



Skin (Dry)

.000125



Skin (Wet)

.00121











Modification of Electric Fields by Tissue


An important factor in the formation of electric fields used to create action potentials in nerve cells is the medium through which the electric fields must penetrate. For the human body this medium consists of various types of tissue including bone, fat, muscle, and skin. Each of these tissues possesses different electrical resistivity or conductivity and different capacitance and these properties are anisotropic. They are not uniform in all directions within the tissues. For example, an axon has lower electrical resistivity along its axis than perpendicular to its axis. The wide range of conductivities is shown in Table 1. The three-dimensional structure and resistivity of the tissues will therefore affect the orientation and magnitude of the electric field at any given point in the body.


Modification of Electric Fields by Multiple Electrodes


Applying a larger number of electrodes to the skin can also produce more complex three-dimensional electrical fields that can be shaped by the location of the electrodes and the potential applied to each of them. Referring to FIG. 3, the pulse trains can differ from one another indicated by A, t/T, n, and f as well as have different phase relationships between the pulse trains. For example with an 8×8 array of electrodes, combinations of electrodes can be utilized ranging from simple dipoles, to quadripoles, to linear arrangements, to approximately circular configurations, to produce desired electric fields within tissues.


Applying multiple electrodes to a part of the body with complex tissue geometry will thus result in an electric field of a complex shape. The interaction of electrode arrangement and tissue geometry can be modeled using Finite Element Modeling, which is a mathematical method of dividing the tissues into many small elements in order to calculate the shape of a complex electric field. This can be used to design an electric field of a desired shape and orientation to a particular nerve.


High frequency techniques known for modifying an electric field, such as the relation between phases of a beam, cancelling and reinforcing by using phase shifts, may not apply to application of electric fields by TNSSs because they use low frequencies. Instead, the present system uses beam selection to move or shift or shape an electric field, also described as field steering or field shaping, by activating different electrodes, such as from an array of electrodes, to move the field. Selecting different combinations of electrodes from an array may result in beam or field steering. A particular combination of electrodes may shape a beam and/or change the direction of a beam by steering. This may shape the electric field to reach a target nerve selected for stimulation.


Activation of Nerves by Electric Fields


Usually in the past selectivity in activating nerves has required electrodes to be implanted surgically on or near nerves. Using electrodes on the surface of the skin to focus activation selectively on nerves deep in the tissues has many advantages. These include avoidance of surgery, avoidance of the cost of developing complex implants and gaining regulatory approval for them, and avoidance of the risks of long-term implants.


The features of the electric field that determine whether a nerve will be activated to produce an action potential can be modeled mathematically by the Activating Function described by Rattay (Rattay F. The basic mechanism for the electrical stimulation of the nervous system. Neuroscience Vol. 89, No. 2, pp. 335-346, 1999). The electric field can produce a voltage, or extracellular potential, within the tissues that varies along the length of a nerve. If the voltage is proportional to distance along the nerve, the first order spatial derivative will be constant and the second order spatial derivative will be zero. If the voltage is not proportional to distance along the nerve, the first order spatial derivative will not be constant and the second order spatial derivative will not be zero. The Activating Function is proportional to the second-order spatial derivative of the extracellular potential along the nerve. If it is sufficiently greater than zero at a given point it predicts whether the electric field will produce an action potential in the nerve at that point. This prediction may be input to a nerve signature.


In practice this means that electric fields that are varying sufficiently greatly in space or time can produce action potentials in nerves. These action potentials are also most likely to be produced where the orientation of the nerves to the fields change, either because the nerve or the field changes direction. The direction of the nerve can be determined from anatomical studies and imaging studies such as MRI scans. The direction of the field can be determined by the positions and configurations of electrodes and the voltages applied to them, together with the electrical properties of the tissues.


As a result it is possible to activate certain nerves at certain tissue locations selectively while not activating others.


To accurately control an organ or muscle, the nerve to be activated must be accurately selected. This selectivity may be improved by using the system described herein, and described herein as a nerve signature, in several ways, as follows:


Improved algorithms to control the effects when a nerve is stimulated, for example, by measuring the resulting electrical or mechanical activity of muscles and feeding back this information to modify the stimulation and measuring the effects again. Repeated iterations of this process can result in optimizing the selectivity of the stimulation, either by classical closed loop control or by machine learning techniques such as pattern recognition and artificial intelligence;


Improving nerve selectivity by labeling or tagging nerves chemically; for example, introduction of genes into some nerves to render them responsive to light or other electromagnetic radiation can result in the ability to activate these nerves and not others when light or electromagnetic radiation is applied from outside the body;


Improving nerve selectivity by the use of electrical conductors to focus an electric field on a nerve; these conductors might be implanted, but could be passive and much simpler than the active implantable medical devices currently used;


Improving nerve selectivity by the use of reflectors or refractors, either outside or inside the body, to focus a beam of electromagnetic radiation on a nerve. If these reflectors or refractors are implanted, they may be passive and much simpler than the active implantable medical devices currently used;


Improving nerve selectivity by the use of feedback from the person upon whom the stimulation is being performed; this may be an action taken by the person in response to a physical indication such as a muscle activation or a feeling from one or more nerve activations;


Improving nerve selectivity by the use of feedback from sensors associated with the TNSS, or separately from other sensors, that monitor electrical activity associated with the stimulation; and


Improving nerve selectivity by the combination of feedback from both the person or sensors and the TNSS that may be used to create a unique profile of the user's nerve physiology for selected nerve stimulation.


Potential applications of electrical stimulation to the body are shown in FIG. 8.


Logic Components


Referring to FIG. 9A, the TNSS 934 human and mammalian interface and its method of operation and supporting system are managed by a Master Control Program (MCP) 910 represented in function format as block diagrams. It provides the logic for the nerve stimulator system.


Master Control Program


The primary responsibility of the MCP 910 is to coordinate the activities and communications among the various control programs, the Data Manager 920, the User 932, and the external ecosystem and to execute the appropriate response algorithms in each situation. The MCP 910 accomplishes electric field shaping and/or beam steering by providing an electrode activation pattern to the TNSS device 934 to selectively stimulate a target nerve. For example, upon notification by the Communications Controller 930 of an external event or request, the MCP 910 is responsible for executing the appropriate response, working with the Data Manager 920 to formulate the correct response and actions. It integrates data from various sources such as Sensors 938 and external inputs such as TNSS devices 934, and applies the correct security and privacy policies, such as encryption and HIPAA required protocols. It will also manage the User Interface (UI) 912 and the various Application Program Interfaces (APIs) 914 that provide access to external programs.


The MCP is also responsible for effectively managing power consumption by the TNSS device through a combination of software algorithms and hardware components that may include, among other things: computing, communications, and stimulating electronics, antenna, electrodes, sensors, and power sources in the form of conventional or printed batteries.


Communications Controller


The communications controller is responsible for receiving inputs from the User 932, from a plurality of TNSS devices 934, and from 3rd party apps 936 via communications sources such as Internet or cellular networks. The format of such inputs will vary by source and must be received, consolidated, possibly reformatted, and packaged for the Data Manager 920.


User inputs may consist of simple requests for activation of TNSS devices 934 to status and information concerning the User's 932 situation or needs. TNSS devices 934 will provide signaling data that may consist of voltage readings, TNSS 934 status data, responses to control program inquiries, and other signals. The Communications Controller 930 is also responsible for sending data and control requests to the plurality of TNSS devices 934. 3rd party applications 936 can send data, requests, or instructions for the Master Control Program 910 or User 932 via Internet or cellular networks. The Communications Controller 930 is also responsible for communications via the cloud where various software applications reside.


Data Manager


The Data Manager (DM) 920 has primary responsibility for the storage and movement of data to and from the Communications Controller 930, Sensors 938, Actuators 940, and the Master Control Program 910. The DM 920 has the capability to analyze and correlate any of the data under its control. It provides logic to select and activate nerves. Examples of such operations upon the data include: statistical analysis and trend identification; machine learning algorithms; signature analysis and pattern recognition, correlations among the data within the Data Warehouse 926, the Therapy Library 922, the Tissue Models 924, and the Electrode Placement Models 928, and other operations. There are several components to the data that is under its control as described in the following paragraphs.


The Data Warehouse (DW) 926 is where incoming data is stored; examples of this data can be real-time measurements from TNSS devices 934 or from Sensors (938), data streams from the Internet, or control and instructional data from various sources. The DM 920 will analyze data, as specified above, that is held in the DW 926 and cause actions, including the export of data, under MCP 910 control. Certain decision making processes implemented by the DM 920 will identify data patterns both in time, frequency, and spatial domains and store them as signatures for reference by other programs. Techniques like EMG, even multi-electrode EMG, gather a lot of data that is the sum of hundreds to thousands of individual motor units and the normal procedure is to perform complex decomposition analysis on the total signal to attempt to tease out individual motor units and their behavior. The DM 920 will perform big data analysis over the total signal and recognize patterns that relate to specific actions or even individual nerves or motor units. This analysis can be performed over data gathered in time from an individual, or over a population of TNSS Users.


The Therapy Library 922 contains various control regimens for the TNSS devices 934. Regimens specify the parameters and patterns of pulses to be applied by the TNSS devices 934. The width and amplitude of individual pulses may be specified to stimulate nerve axons of a particular size selectively without stimulating nerve axons of other sizes. The frequency of pulses applied may be specified to modulate some reflexes selectively without modulating other reflexes. There are preset regimens that may be loaded from the Cloud 942 or 3rd party apps 936. The regimens may be static read-only as well as adaptive with read-write capabilities so they can be modified in real-time responding to control signals or feedback signals or software updates. Referring to FIG. 3 one such embodiment of a regimen has parameters A=40 volts, t=500 microseconds, T=1 millisecond, n=100 pulses per group, and f=20 per second. Other embodiments of regimens will vary the parameters within ranges previously specified.


The Tissue Models 924 are specific to the electrical properties of particular body locations where TNSS devices 934 may be placed. As noted previously, electric fields for production of action potentials will be affected by the different electrical properties of the various tissues that they encounter. Tissue Models 924 are combined with regimens from the Therapy Library 922 and Electrode Placement Models 928 to produce desired actions. Tissue Models 924 may be developed by MRI, Ultrasound or other imaging or measurement of tissue of a body or particular part of a body. This may be accomplished for a particular User 932 and/or based upon a body norm. One such example embodiment of a desired action is the use of a Tissue Model 924 together with a particular Electrode Placement Model 928 to determine how to focus the electric field from electrodes on the surface of the body on a specific deep location corresponding to the pudendal nerve in order to stimulate that nerve selectively to reduce incontinence of urine. Other example embodiments of desired actions may occur when a Tissue Model 924 in combination with regimens from the Therapy Library 22 and Electrode Placement Models 928 produce an electric field that stimulates a sacral nerve. Many other embodiments of desired actions follow for the stimulation of other nerves.


Electrode Placement Models 928 specify electrode configurations that the TNSS devices 934 may apply and activate in particular locations of the body. For example, a TNSS device 934 may have multiple electrodes and the Electrode Placement Model 928 specifies where these electrodes should be placed on the body and which of these electrodes should be active in order to stimulate a specific structure selectively without stimulating other structures, or to focus an electric field on a deep structure. An example embodiment of an electrode configuration is a 4 by 4 set of electrodes within a larger array of multiple electrodes, such as an 8 by 8 array. This 4 by 4 set of electrodes may be specified anywhere within the larger array such as the upper right corner of the 8 by 8 array. Other example embodiments of electrode configurations may be circular electrodes that may even consist of concentric circular electrodes. The TNSS device 934 may contain a wide range of multiple electrodes of which the Electrode Placement Models 928 will specify which subset will be activated. These Electrode Placement Models 928 complement the regimens in the Therapy Library 922 and the Tissue Models 924 and are used together with these other data components to control the electric fields and their interactions with nerves, muscles, tissues and other organs. Other examples may include TNSS devices 934 having merely one or two electrodes, such as but not limited to those utilizing a closed circuit.


Sensor/Actuator Control


Independent sensors 938 and actuators 940 can be part of the TNSS system. Its functions can complement the electrical stimulation and electrical feedback that the TNSS devices 934 provide. An example of such a sensor 938 and actuator 940 include, but are not limited to, an ultrasonic actuator and an ultrasonic receiver that can provide real-time image data of nerves, muscles, bones, and other tissues. Other examples include electrical sensors that detect signals from stimulated tissues or muscles. The Sensor/Actuator Control module 950 provides the ability to control both the actuation and pickup of such signals, all under control of the MCP 910.


Application Program Interfaces


The MCP 910 is also responsible for supervising the various Application Program Interfaces (APIs) that will be made available for 3rd party developers. There may exist more than one API 914 depending upon the specific developer audience to be enabled. For example many statistical focused apps will desire access to the Data Warehouse 926 and its cumulative store of data recorded from TNSS 934 and User 932 inputs. Another group of healthcare professionals may desire access to the Therapy Library 922 and Tissue Models 924 to construct better regimens for addressing specific diseases or disabilities. In each case a different specific API 914 may be appropriate.


The MCP 910 is responsible for many software functions of the TNSS system including system maintenance, debugging and troubleshooting functions, resource and device management, data preparation, analysis, and communications to external devices or programs that exist on the smart phone or in the cloud, and other functions. However, one of its primary functions is to serve as a global request handler taking inputs from devices handled by the Communications Controller 930, external requests from the Sensor Control Actuator Module (950), and 3rd party requests 936.


Examples of High Level Master Control Program (MCP) functions are set forth in the following paragraphs.


The manner in which the MCP handles these requests is shown in FIG. 9B. The Request Handler (RH) 960 accepts inputs from the User 932, TNSS devices 934, 3rd party apps 936, sensors 938 and other sources. It determines the type of request and dispatches the appropriate response as set forth in the following paragraphs.


User Request: The RH 960 will determine which of the plurality of User Requests 961 is present such as: activation; display status, deactivation, or data input, e.g. specific User condition. Shown in FIG. 9B is the RH's 960 response to an activation request. As shown in block 962, RH 960 will access the Therapy Library 922 and cause the appropriate regimen to be sent to the correct TNSS 934 for execution, as shown at block 964 labeled “Action.”


TNSS/Sensor Inputs: The RH 960 will perform data analysis over TNSS 934 or Sensor inputs 965. As shown at block 966, it employs data analysis, which may include techniques ranging from DSP decision making processes, image processing algorithms, statistical analysis and other algorithms to analyze the inputs. In FIG. 9B two such analysis results are shown; conditions which cause a User Alarm 970 to be generated and conditions which create an Adaptive Action 980 such as causing a control feedback loop for specific TNSS 934 functions, which of course can iteratively generate further TNSS 934 or Sensor inputs 965 in a closed feedback loop.


3rd Party Apps: Applications can communicate with the MCP 910, both sending and receiving communications. A typical communication would be to send informational data or commands to a TNSS 934. The RH 960 will analyze the incoming application data, as shown at block 972. FIG. 9B shows two such actions that result. One action, shown at block 974 would be the presentation of the application data, possibly reformatted, to the User 932 through the MCP User Interface 912. Another result would be to perform a User 932 permitted action, as shown at 976, such as requesting a regimen from the Therapy Library 922.


Referring to FIG. 10, an example TNSS is shown. The TNSS has one or more electronic circuits or chips 1000 that perform the functions of: communications with the controller, nerve stimulation via one or more electrodes 1008 that produce a wide range of electric field(s) according to treatment regimen, one or more antennae 1010 that may also serve as electrodes and communication pathways, and a wide range of sensors 1006 such as, but not limited to, mechanical motion and pressure, temperature, humidity, chemical and positioning sensors. In another example, TNSS interfaces to transducers 1014 to transmit signals to the tissue or to receive signals from the tissue.


One arrangement is to integrate a wide variety of these functions into an SOC, system on chip 1000. Within this is shown a control unit 1002 for data processing, communications, transducer interface and storage and one or more stimulators 1004 and sensors 1006 that are connected to electrodes 1008. An antenna 1010 is incorporated for external communications by the control unit. Also present is an internal power supply 1012, which may be, for example, a battery. An external power supply is another variation of the chip configuration. It may be necessary to include more than one chip to accommodate a wide range of voltages for data processing and stimulation. Electronic circuits and chips will communicate with each other via conductive tracks within the device capable of transferring data and/or power.


The TNSS interprets a data stream from the control device, such as that shown in FIG. 9A, to separate out message headers and delimiters from control instructions. In one arrangement, control instructions contain information such as voltage level and pulse pattern. The TNSS activates the stimulator 1004 to generate a stimulation signal to the electrodes 1008 placed on the tissue according to the control instructions. In another arrangement the TNSS activates a transducer 1014 to send a signal to the tissue. In another embodiment, control instructions cause information such as voltage level and pulse pattern to be retrieved from a library stored in the TNSS.


The TNSS receives sensory signals from the tissue and translates them to a data stream that is recognized by the control device, such as the example in FIG. 9A. Sensory signals include electrical, mechanical, acoustic, optical and chemical signals among others. Sensory signals come to the TNSS through the electrodes 1008 or from other inputs originating from mechanical, acoustic, optical, or chemical transducers. For example, an electrical signal from the tissue is introduced to the TNSS through the electrodes 1008, is converted from an analog signal to a digital signal and then inserted into a data stream that is sent through the antenna 1010 to the control device. In another example an acoustic signal is received by a transducer 1014 in the TNSS, converted from an analog signal to a digital signal and then inserted into a data stream that is sent through the antenna 1010 to the control device. In certain cases sensory signals from the tissue are directly interfaced to the control device for processing.


Application to Bladder Control


Bladder function may be modified directly or indirectly using the principles described above. Referring to FIG. 11, in some cases, electrical stimulation of sacral sensory nerves 1110 causes action potentials that travel to the spinal cord 1100 where they reduce the activity in motor nerves 1160 from the spinal cord back to the bladder 1170, producing relaxation of the bladder. This is known as reflex inhibition of the bladder and is one form of neuromodulation. Reduction of unwanted bladder contraction may provide useful function such as reduced urgency in needing to pass urine, reduced frequency of passing urine and reduced urge incontinence of urine. This pattern of symptoms is sometimes considered as a syndrome called Over Active Bladder.


In other cases, electrical stimulation of these sensory nerves causes action potentials that travel to the spinal cord 1100 where they reduce the activity in motor nerves from the spinal cord to the sphincter, allowing relaxation of the sphincter. This form of neuromodulation can reduce unwanted contraction of the sphincter and provide useful function such as reduced straining to pass urine, an improved stream of urine and more complete bladder emptying, for example in a condition known as Fowler's Syndrome.


In other cases, electrical stimulation of sacral sensory nerves 1110 causes action potentials that travel to the spinal cord 1100 where they increase the activity in nerves from the spinal cord to the internal and external urethral sphincters, producing contraction of these sphincter muscles that surround the exit of the bladder. In other cases, electrical stimulation of motor axons in the pudendal nerve 1130 to the external urethral sphincter muscle can produce contraction of that muscle. Whether the contraction of the sphincters is produced indirectly, as a reflex response to stimulation of sensory nerves, or directly, as a response to stimulation of motor nerves, it can reduce incontinence or leaking of urine, for example during straining, coughing or sneezing. This may benefit some people with stress incontinence.


Electrodes can be applied to the skin on the back of the penis in proximity to the dorsal penile nerve 1140, or to the skin on or near the back of the clitoris in proximity to the dorsal clitoral nerve, at the base of the spine or other sites around the pelvis in proximity to the sacral nerves 1120 or their branches and tributaries or the pudendal nerves 1130 or their branches and tributaries, or the back of the lower leg adjacent to the posterior tibial nerve 1150.


The electrodes are typically used in pairs to apply electrical stimuli in the form of square waves having amplitudes of between 20 and 100 volts, pulse widths of between 100 and 500 microseconds, and a pulse repetition rate of between 3 and 30 pulses per second.


Non-invasive methods of directing or focusing electrical stimulation from electrodes on the surface of the skin towards nerves deeper in the body may also be used to allow selective stimulation of deep nerves such as the sacral nerves 1120 or pudendal nerves 1130 without the need for surgical implantation of electrodes or stimulators.


The electrodes on the surface of the skin are connected to or part of a Topical Nerve Stimulator and Sensor (TNSS) 934 (FIG. 9A).


Operation


The stimulator may be operated voluntarily by the user or may be operated automatically in response to signals from sensors in the TNSS or elsewhere in a TNSS system shown in FIG. 12.


Voluntary Operation by the User for Control of Over Active Bladder or Urge Incontinence


As the bladder 1204 fills, there are usually signals transmitted by sensory nerves 1211 to the brain 1209 resulting in awareness by the user of a sensation of bladder fullness, or an urge to pass urine, or a fear of incontinence; these sensations may or may not be associated with contraction of the bladder.


When these sensations are felt, the user can press a button on the TNSS 934 (FIG. 9A) or a Control Device 1206 which may be a smartphone or a dedicated device. A dedicated device is a small portable device resembling a key fob and containing electronic circuits for storage and operation of programs and buttons that the user can operate. When the user presses a button on the Control Device this can cause it to transmit radio-frequency signals to the TNSS to control the operation of the TNSS. The Control Device can also receive radio-frequency signals from the TNSS 934 (FIG. 9A).


The TNSS 934 (FIG. 9A) and the Control Device are under software control, responding to actions from the user. There will be safeguards to prevent false activations or unnecessary repetitive activations. The activation by the user causes a stimulator in the TNSS 934 (FIG. 9A) to send electrical stimulation signals 1202 to activate nerves 1203 affecting the bladder and sphincter, such as pudendal nerves 1130 (FIG. 11), dorsal genital nerves 1140, posterior tibial nerves 1150 or other nerves, as described above.


The TNSS 934 (FIG. 9A) can stimulate the appropriate nerve(s) to relax the bladder. This stimulation can be with a preset pulse signal, or the user can select from variety of pulse signals, and their intensities; this might be implemented as one or more of a plurality of virtual buttons on the interface of a smartphone or physical buttons on a dedicated device. The user selects from programs to deal with a weak urge, a moderate urge, or a strong urge; the programs may provide an intermittent or a continuous pulse signal and the signal may have a timeout of a duration chosen by the user. The user can reactivate the TNSS 934 either immediately if the urge is not completely abated, or the next time he/she feels the urge to urinate.


Voluntary Operation by the User for Control of Stress Incontinence


When a user becomes aware that they are about to engage in an activity such as straining, coughing or sneezing that may cause stress incontinence, the user can press a button on the TNSS 934 or a control device 1206 to cause electrical stimulation of sacral sensory or motor nerves to produce reflex or direct activation of the urethral sphincters. The contraction of these sphincters may reduce stress incontinence.


Automatic Operation for Control of Over Active Bladder or Urge Incontinence


In some cases it will be possible to control the urge to empty the bladder automatically, without the intervention of the user. The normal feedback to cause the TNSS 934 to be activated for this purpose comes from the user's perception of an urge to urinate, which is communicated to the control device 1206 as described previously. There is a plurality of other non-invasive portable methods of obtaining feedback that can control the bladder in parallel with or separately from this feedback. For example, the TNSS 934 may include an acoustic transceiver that can send an acoustic pulse into the body and detect acoustic echoes from the pelvic region indicating bladder position, shape or volume, or a sensor of bladder pressure may transmit a signal to the TNSS 934 or control device 1206.


The TNSS 934 will then automatically stimulate bladder nerves as described above to inhibit bladder contraction before the user becomes aware of the urge. This automatic mode of operation will make use of the various feedback loops shown in FIG. 12. For example, the state of the bladder 1204 may be sensed and transmitted 1205 to the TNSS 934, which may act upon the signal to send a signal 1202 to stimulate the nerves 1203 that control the bladder 1204. The TNSS 934 may also send signals 1207 to a control device 1206 that can respond with signals 1205 to control the TNSS 934. The control device 1206 may also send signals 1210 to the user who may respond with signals 1208 to modify the actions of the control device 1206. The control device 1206 may also send signals 1213 via the Internet to other users who may respond with signals 1214 to modify the actions of the control device 1206.


Automatic Operation for Control of Stress Incontinence


In some cases it will be possible to reduce stress incontinence automatically, without the intervention of the user. The normal feedback to cause the TNSS 934 to be activated for this purpose comes from the user's awareness that they are about the engage in an activity that may cause stress incontinence. There is a plurality of other methods of obtaining feedback that can control the sphincters in parallel with or separately from this feedback. For example, sensors and associated pattern recognition software may detect a pattern of activity indicating an impending sneeze, cough or episode of straining. The control device 1206 and TNSS 934 will then automatically stimulate nerves to cause sphincter contraction and reduce stress incontinence.


Adaptive Operation


With training using data from one or many individuals, software in the TNSS 934 or in the control device 1206 or in other computing systems available via the internet may use machine learning to recognize patterns in time or space and improve determination of when incontinence is about to occur.


There may be additional functions in addition to the operations described above. These include logging functions, incorporating data from the cloud, and data from other sensors and sources.


Upon activation of the TNSS 934 one or more of the following functions can occur.


The user's activation profile is recorded by the TNSS 934 and shared with the control device 1206. The activation profile consists of a User ID, stimulation signal identifier and stimulus parameters, date and time of day, and if the user interface permits, user conditions at the time of activation. Historical data can be gathered and analyzed for the user's benefit.


The control device 1206 and/or the TNSS 934 may accept data from other users via the Internet. Types of data may be instructions from a healthcare professional, population data, statistical analyses and trend data relative to the individual user or across populations. This data can be passed through to the user, or cause actions to be taken, such as alarms or notifications.


Data can be gathered from other sensors, from other sensors, which may be located in the TNSS 1401, in the control device, and other patches, or in other devices, on a continuous basis or only when the TNSS 934 is activated. When the TNSS 934 is activated, these data can be used to alter or modify the stimulation signals that the TNSS 934 transmits to the user. An example would be an acoustic transceiver that may be implemented in MEMS that can both transmit and receive acoustic data to create acoustic images of the bladder and pelvic region. This would allow the TNSS 934 to gather image data of the pelvic region over time and learn the state of bladder, as compared to historical conditions.

Claims
  • 1. A method of modifying bladder function of a user comprising: applying a dermal patch on an external surface of a skin of the user on a lower leg of the user adjacent to a tibial nerve, the dermal patch comprising electrodes, a sensor, communications, a control unit and a stimulator, the electrodes, the sensor, the communications, the control unit and the stimulator integral to the dermal patch;automatically determining a state of a bladder of the user using the sensor;determining an electrical stimulation corresponding to the tibial nerve, by the control unit of the dermal patch, the control unit processing instructions comprising: in response to the automatically determined state of the bladder, automatically initiating an applying, without user intervention, on the external surface of the skin, of the electrical stimulation by the electrodes and the stimulator to produce an electric field; andselectively activating the tibial nerve by the electric field using the electrodes on the external surface of the skin to inhibit a contraction of the bladder.
  • 2. The method of claim 1, further comprising applying the dermal patch in the proximity of a sacral or pudendal nerve.
  • 3. The method of claim 1, the dermal patch comprising a system on a chip that includes the control unit, the electrodes and the stimulator and determining a subset of the electrodes that are active by the selectively activating, the subset of electrodes less than all of the electrodes that are integral to the dermal patch, the determining based on a determination of a type of nerve to be stimulated.
  • 4. The method of claim 1, further comprising applying the dermal patch in the proximity of a branch or tributary of the tibial nerve.
  • 5. The method of claim 1, the electric stimulation comprising square waves having an amplitude between 20 and 100 volts, pulse widths between 100 and 500 microseconds, and a pulse repetition rate of between 3 and 30 pulses per second.
  • 6. The method of claim 1, the state of the bladder indicating an urge to urinate by the user and the automatically initiating the applying occurring before the user is aware of the urge.
  • 7. The method of claim 1, further comprising sensing physiological feedback based upon the activation of the stimulator and activating the electrodes based at least in part on the feedback.
  • 8. The method of claim 1, further comprising selecting from a plurality of pulse strengths or pulse types and applying the stimulation in accordance with the selected pulse strength or pulse type.
  • 9. The method of claim 1, further comprising the electric field targeting a urethral sphincter for reflex or direct activation.
  • 10. The method of claim 1, further comprising modifying stress incontinence, overactive bladder incontinence or urge incontinence.
  • 11. The method of claim 1, the automatically determining the state of the bladder comprising detecting by an acoustic transceiver integral to the dermal patch an acoustic echo from a pelvic region indicating a position of a bladder, a shape of the bladder or a volume of the bladder; and automatically activating the electrodes, by the stimulator, to inhibit bladder contraction based at least in part on the acoustic echo.
  • 12. The method of claim 1, further comprising modifying the stimulation based upon a manual input received at a wireless device wirelessly connected to the dermal patch or a sensor input.
  • 13. The method of claim 1, the automatically determining the state of the bladder of the user comprising: sensing a physiological pattern of activity indicating an impending sneeze, cough or episode of straining.
  • 14. The method of claim 1, further comprising: recording by the dermal patch an activation profile;assimilating a plurality of activation profiles for multiple dermal patches by wireless communication from the dermal patch to a remote controller;analyzing the activation profiles by the controller;communicating the activation profile analysis results by the controller wirelessly to the dermal patch; andmodifying the stimulation based at least in part on the activation profile analysis results.
  • 15. A bladder control system for modifying bladder function of a user, the system comprising: a dermal patch configured to be applied on an external surface of a skin of the user on a lower leg of the user adjacent to a tibial nerve, comprising electrodes, a sensor, communications, a control unit and a stimulator, the electrodes, the sensor, the communications, the control unit and the stimulator integral to the dermal patch;the control unit processing instructions that, when executed, configure the control unit to: automatically determine a state of a bladder of the user using the sensor;determine an electrical stimulation corresponding to the tibial nerve;in response to the automatically determined state of the bladder, automatically initiate an applying, without user intervention, on the external surface of the skin, the electrical stimulation by the electrodes and the stimulator to produce an electric field; andselectively activating the tibial nerve by the electric field using the electrodes on the external surface of the skin to inhibit a contraction of the bladder.
  • 16. The bladder control system of claim 15, the dermal patch comprising a system on a chip that includes the control unit, the electrodes and the stimulator, the control unit further configured to determining a subset of the electrodes that are active by the selectively activating, the subset of electrodes less than all of the electrodes that are integral to the dermal patch, the determining based on a determination of a type of nerve to be stimulated.
  • 17. The bladder control system of claim 15, the control unit further configured to receive a manual command received from a wireless device to activate the stimulator.
  • 18. The bladder control system of claim 15, the control unit further configured to sense physiological feedback based upon the activation of the stimulator and activating the electrodes based at least in part on the feedback.
  • 19. The bladder control system of claim 15, the electric stimulation comprising square waves having an amplitude between 20 and 100 volts, pulse widths between 100 and 500 microseconds, and a pulse repetition rate of between 3 and 30 pulses per second.
  • 20. The bladder control system of claim 15, the state of the bladder indicating an urge to urinate by the user and the automatically initiate the applying occurring before the user is aware of the urge.
RELATED APPLICATIONS AND CLAIM OF PRIORITY

This application claims priority to and the benefit of the filing date of United States provisional patent application Ser. No. 62/119,134 filed Feb. 21, 2015. This application also claims priority to and the benefit of the filing date as a continuation-in-part application of U.S. utility patent application Ser. No. 14/893,946 filed Nov. 25, 2015, which claims priority to and the benefit of the filing date as a national stage application of PCT patent application serial no. PCT/US14/40240, filed May 30, 2014, which in turn claims priority to U.S. provisional patent application Ser. No. 61/828,981, filed May 30, 2013.

US Referenced Citations (1230)
Number Name Date Kind
4277980 Coats et al. Jul 1981 A
4532930 Crosby et al. Aug 1985 A
4542753 Brenman et al. Sep 1985 A
4549556 Tarjan et al. Oct 1985 A
4553549 Pope et al. Nov 1985 A
4590949 Pohndorf May 1986 A
4614395 Peers-Trevarton Sep 1986 A
4658835 Pohndorf Apr 1987 A
4677989 Robblee Jul 1987 A
4690144 Rise et al. Sep 1987 A
4702254 Zabara Oct 1987 A
4706682 Stypulkowski et al. Nov 1987 A
4717581 Robblee Jan 1988 A
4759228 Butler et al. Jul 1988 A
4800898 Hess et al. Jan 1989 A
4817628 Zealear et al. Apr 1989 A
4881526 Johnson et al. Nov 1989 A
4883666 Sabel et al. Nov 1989 A
4919148 Muccio Apr 1990 A
4940453 Cadwell Jul 1990 A
4959532 Owechko Sep 1990 A
5031621 Grandjean et al. Jul 1991 A
5035242 Franklin et al. Jul 1991 A
5047005 Cadwell Sep 1991 A
5092332 Lee et al. Mar 1992 A
5092835 Schurig et al. Mar 1992 A
5095905 Klepinski Mar 1992 A
5211657 Yamada et al. May 1993 A
5265608 Lee et al. Nov 1993 A
5381801 McShane et al. Jan 1995 A
5476494 Edell et al. Dec 1995 A
5501703 Holsheimer et al. Mar 1996 A
5569307 Schulman et al. Oct 1996 A
5575813 Edell et al. Nov 1996 A
5584869 Heck et al. Dec 1996 A
5597381 Rizzo, III Jan 1997 A
5603726 Schulman et al. Feb 1997 A
5609616 Schulman et al. Mar 1997 A
5628769 Saringer May 1997 A
5643330 Holsheimer et al. Jul 1997 A
5679340 Chappel Oct 1997 A
5713922 King Feb 1998 A
5738625 Gluck Apr 1998 A
5741314 Daly et al. Apr 1998 A
5792209 Varner Aug 1998 A
5795790 Schinstine et al. Aug 1998 A
5824022 Zilberman et al. Oct 1998 A
5830651 Cauley et al. Nov 1998 A
5837236 Dinsmore Nov 1998 A
5853370 Chance et al. Dec 1998 A
5871534 Messick et al. Feb 1999 A
5876425 Gord et al. Mar 1999 A
5891437 Pietropaolo et al. Apr 1999 A
5916870 Lee et al. Jun 1999 A
5921245 O'Donnell, Jr. Jul 1999 A
5922012 Sakano Jul 1999 A
5937318 Warner, Jr. et al. Aug 1999 A
5938691 Schulman et al. Aug 1999 A
5948428 Lee et al. Sep 1999 A
5987361 Mortimer Nov 1999 A
5989445 Wise et al. Nov 1999 A
5992769 Wise et al. Nov 1999 A
6002960 Sternberger et al. Dec 1999 A
6011018 Crabtree et al. Jan 2000 A
6016449 Fischell et al. Jan 2000 A
6058331 King May 2000 A
6060048 Cherksey May 2000 A
6060054 Staerz May 2000 A
6066084 Edrich et al. May 2000 A
6067474 Schulman et al. May 2000 A
6085115 Weaver et al. Jul 2000 A
6096537 Chappel Aug 2000 A
6119071 Gorenflo et al. Sep 2000 A
6120538 Rizzo, III et al. Sep 2000 A
6140116 Dinsmore Oct 2000 A
6178349 Kieval Jan 2001 B1
6203792 Filbin Mar 2001 B1
6204053 Dinsmore Mar 2001 B1
6258353 Isacson et al. Jul 2001 B1
6264950 Staerz Jul 2001 B1
6265175 Gage et al. Jul 2001 B1
6270831 Kumar et al. Aug 2001 B2
6277372 Fraser et al. Aug 2001 B1
6284245 Edge Sep 2001 B1
6288527 Sugihara et al. Sep 2001 B1
6294383 Isacson et al. Sep 2001 B1
6304784 Allee et al. Oct 2001 B1
6304787 Kuzma et al. Oct 2001 B1
6359550 Brisebois et al. Mar 2002 B1
6374140 Rise Apr 2002 B1
6379393 Mavroidis et al. Apr 2002 B1
6392118 Hammang et al. May 2002 B1
6392550 Najor May 2002 B1
6393327 Scribner May 2002 B1
6415186 Chim et al. Jul 2002 B1
6421232 Sallam Jul 2002 B2
6427083 Owen et al. Jul 2002 B1
6444205 Dinsmore et al. Sep 2002 B2
6472181 Mineau-Hanschke Oct 2002 B1
6510347 Borkan Jan 2003 B2
6517833 Edge Feb 2003 B2
6533732 Urmey Mar 2003 B1
6537200 Leysieffer et al. Mar 2003 B2
6546291 Merfeld et al. Apr 2003 B2
6561975 Pool et al. May 2003 B1
6565503 Leysieffer et al. May 2003 B2
6575894 Leysieffer et al. Jun 2003 B2
6599695 Gage et al. Jul 2003 B2
6640118 Van Heerden et al. Oct 2003 B2
6640121 Telischi et al. Oct 2003 B1
RE38323 Sugihara et al. Nov 2003 E
6647297 Scribner Nov 2003 B2
6690974 Archer et al. Feb 2004 B2
6697674 Leysieffer Feb 2004 B2
6727696 Kruspe et al. Apr 2004 B2
6744367 Forster Jun 2004 B1
6788976 Gesotti Sep 2004 B2
6795737 Gielen et al. Sep 2004 B2
6807445 Baumann et al. Oct 2004 B2
6839596 Nelson et al. Jan 2005 B2
6850802 Holsheimer Feb 2005 B2
6879855 Schulman et al. Apr 2005 B2
6884122 Robinson et al. Apr 2005 B2
6892097 Holsheimer May 2005 B2
6893812 Woltering et al. May 2005 B2
6894616 Forster May 2005 B1
6902547 Aves et al. Jun 2005 B2
6931273 Groenewegen et al. Aug 2005 B2
6949251 Dalal et al. Sep 2005 B2
6970745 Scribner Nov 2005 B2
6976998 Rizzo et al. Dec 2005 B2
7001608 Fishman et al. Feb 2006 B2
7003335 Briancon Feb 2006 B2
7010351 Firlik et al. Mar 2006 B2
7027873 Pajunk et al. Apr 2006 B2
7030411 Krulevitch et al. Apr 2006 B2
7037603 Lasater May 2006 B2
7047080 Palanker et al. May 2006 B2
7058455 Huie, Jr. et al. Jun 2006 B2
7079882 Schmidt Jul 2006 B1
7101542 Vallera et al. Sep 2006 B1
7106190 Owens Sep 2006 B1
7107104 Keravel et al. Sep 2006 B2
7115071 Sunbeck Oct 2006 B1
7117034 Kronberg Oct 2006 B2
7120499 Thrope et al. Oct 2006 B2
7127301 Okandan et al. Oct 2006 B1
7155278 King et al. Dec 2006 B2
7167750 Knudson et al. Jan 2007 B2
7174223 Dalton et al. Feb 2007 B2
7181288 Rezai et al. Feb 2007 B1
7191018 Gielen et al. Mar 2007 B2
7193414 Kruspe et al. Mar 2007 B2
7206632 King Apr 2007 B2
7209787 DiLorenzo Apr 2007 B2
7218216 Uehran May 2007 B1
7218964 Hill et al. May 2007 B2
7228178 Carroll et al. Jun 2007 B2
7228727 Discenzo Jun 2007 B2
7239918 Strother et al. Jul 2007 B2
7249998 van Esbroeck et al. Jul 2007 B2
7283867 Strother et al. Oct 2007 B2
7297420 Jiang Nov 2007 B2
7299034 Kates Nov 2007 B2
7308303 Whitehurst et al. Dec 2007 B2
7308317 Okandan et al. Dec 2007 B1
7333851 Echauz et al. Feb 2008 B2
7337004 Classen et al. Feb 2008 B2
7349169 Lee et al. Mar 2008 B2
RE40209 Sugihara et al. Apr 2008 E
7376467 Thrope et al. May 2008 B2
7384145 Hetling et al. Jun 2008 B2
7392093 Khan Jun 2008 B2
7398255 Lauer et al. Jul 2008 B2
7415309 McIntyre Aug 2008 B2
7420760 Zhang et al. Sep 2008 B2
7422564 Parsons et al. Sep 2008 B2
7435443 Jiang Oct 2008 B2
7435585 Tykocinski et al. Oct 2008 B2
7437193 Parramon et al. Oct 2008 B2
7437196 Wyler et al. Oct 2008 B2
7483747 Gliner et al. Jan 2009 B2
7499745 Littrup et al. Mar 2009 B2
7499748 Moffitt et al. Mar 2009 B2
7502652 Gaunt et al. Mar 2009 B2
7519419 Jiang et al. Apr 2009 B2
7529582 DiLorenzo May 2009 B1
7553307 Bleich et al. Jun 2009 B2
7555343 Bleich Jun 2009 B2
7561919 Shalev et al. Jul 2009 B2
7565199 Sheffield et al. Jul 2009 B2
7565200 Wyler et al. Jul 2009 B2
7571002 Thrope et al. Aug 2009 B2
7571006 Gordon et al. Aug 2009 B2
7578819 Bleich et al. Aug 2009 B2
7584004 Caparso et al. Sep 2009 B2
7587238 Moffitt et al. Sep 2009 B2
7598031 Liew Oct 2009 B2
7599737 Yomtov et al. Oct 2009 B2
7620456 Gliner et al. Nov 2009 B2
7622303 Soykan et al. Nov 2009 B2
7636597 Gross et al. Dec 2009 B2
7643874 Nitzan et al. Jan 2010 B2
7657308 Miles et al. Feb 2010 B2
7658707 Topolev Feb 2010 B2
7662558 Liew Feb 2010 B2
7676274 Hung et al. Mar 2010 B2
7680526 McIntyre et al. Mar 2010 B2
7684866 Fowler et al. Mar 2010 B2
7689285 Garabet Mar 2010 B2
D613868 Lhuillery et al. Apr 2010 S
7699768 Kishawi et al. Apr 2010 B2
7704740 Schindler et al. Apr 2010 B2
7706888 Jolly Apr 2010 B2
7706893 Hung et al. Apr 2010 B2
7711416 Akkin et al. May 2010 B1
7715919 Osorio et al. May 2010 B2
7715924 Rezai et al. May 2010 B2
7725196 Machado et al. May 2010 B2
7732407 Hunter Jun 2010 B2
7738968 Bleich Jun 2010 B2
7738969 Bleich Jun 2010 B2
7740631 Bleich et al. Jun 2010 B2
7747318 John et al. Jun 2010 B2
7756583 Demarais et al. Jul 2010 B2
7756584 Sheffield et al. Jul 2010 B2
7769462 Meadows et al. Aug 2010 B2
7769470 Rezai et al. Aug 2010 B1
7798982 Zets et al. Sep 2010 B2
7799021 Leung et al. Sep 2010 B2
7801603 Westlund et al. Sep 2010 B2
7813809 Strother et al. Oct 2010 B2
7819801 Miles et al. Oct 2010 B2
7819869 Godara et al. Oct 2010 B2
7831305 Gliner Nov 2010 B2
7844340 Pawlowicz, III Nov 2010 B2
7877136 Moffitt et al. Jan 2011 B1
7892180 Epley Feb 2011 B2
7894911 Greenberg et al. Feb 2011 B2
7894914 Stahmann et al. Feb 2011 B2
7899542 Cowan et al. Mar 2011 B2
7914842 Greenberg et al. Mar 2011 B1
7917231 Farah et al. Mar 2011 B2
7918802 Urmey Apr 2011 B2
7922676 Daskal et al. Apr 2011 B2
7943632 Katzman et al. May 2011 B2
7945330 Gliner et al. May 2011 B2
7947448 Couillard-Despres et al. May 2011 B2
RE42449 Forster Jun 2011 E
7959577 Schmitz et al. Jun 2011 B2
7963915 Bleich Jun 2011 B2
7967751 Goscha et al. Jun 2011 B2
7974689 Volpe et al. Jul 2011 B2
7981144 Geist et al. Jul 2011 B2
7988688 Webb et al. Aug 2011 B2
7991475 Tang et al. Aug 2011 B1
7991480 Stahmann et al. Aug 2011 B2
7992521 Bocquier Aug 2011 B2
8000782 Gharib et al. Aug 2011 B2
8000796 Tass et al. Aug 2011 B2
8000804 Wessendorf et al. Aug 2011 B1
8010202 Shah et al. Aug 2011 B2
8014868 Greenberg et al. Sep 2011 B2
8014878 Greenberg et al. Sep 2011 B2
8025632 Einarsson Sep 2011 B2
8027716 Gharib et al. Sep 2011 B2
8033996 Behar Oct 2011 B2
8060210 Carroll Nov 2011 B1
8065012 Firlik et al. Nov 2011 B2
8067173 Liew Nov 2011 B2
8073526 Graham et al. Dec 2011 B2
8073546 Sheffield et al. Dec 2011 B2
8075556 Betts Dec 2011 B2
8078252 Kipke et al. Dec 2011 B2
8090446 Fowler et al. Jan 2012 B2
8092398 Weinberg et al. Jan 2012 B2
8095209 Flaherty Jan 2012 B2
8101358 Liew Jan 2012 B2
8110358 Liew Feb 2012 B2
8114019 Miles et al. Feb 2012 B2
8114597 Liew Feb 2012 B2
8116875 Osypka et al. Feb 2012 B2
8126562 Fowler et al. Feb 2012 B2
8131376 Faraji et al. Mar 2012 B1
8133674 Liew Mar 2012 B2
8133675 Liew Mar 2012 B2
8135472 Fowler et al. Mar 2012 B2
8137258 Dennis et al. Mar 2012 B1
8137284 Miles et al. Mar 2012 B2
8140152 John et al. Mar 2012 B2
8140162 Jiang et al. Mar 2012 B1
8140170 Rezai et al. Mar 2012 B2
8148072 Liew Apr 2012 B2
8155757 Neisz et al. Apr 2012 B1
8160713 Greenberg et al. Apr 2012 B2
8162846 Epley Apr 2012 B2
8165685 Knutson et al. Apr 2012 B1
8170676 Greenberg et al. May 2012 B2
8174371 Schwieger May 2012 B2
8180453 Greenberg et al. May 2012 B2
8180460 Nevsmith et al. May 2012 B2
8192357 Miles et al. Jun 2012 B2
8195300 Gliner et al. Jun 2012 B2
8195307 Vilims Jun 2012 B2
8200338 Grennberg et al. Jun 2012 B2
8215773 Gibson-Horn et al. Jul 2012 B2
8216135 Goscha et al. Jul 2012 B2
8226661 Balling et al. Jul 2012 B2
8228202 Buchner et al. Jul 2012 B2
8239036 Shah et al. Aug 2012 B2
8255044 Miles et al. Aug 2012 B2
8257922 Liew Sep 2012 B2
8260428 Fink et al. Sep 2012 B2
8260439 DiUbaldi et al. Sep 2012 B2
8280516 Graupe Oct 2012 B2
8301266 Zilberman et al. Oct 2012 B1
8303516 Schmitz et al. Nov 2012 B2
8308665 Harry et al. Nov 2012 B2
8313443 Tom Nov 2012 B2
8323320 Lowry et al. Dec 2012 B2
8328354 Li et al. Dec 2012 B2
8332037 Imran Dec 2012 B2
8332044 McIntyre Dec 2012 B2
8346367 Carroll Jan 2013 B2
8352022 Akkin et al. Jan 2013 B2
8359083 Clark et al. Jan 2013 B2
8364257 Van Den Eerenbeemd Jan 2013 B2
8364258 Della Rocca et al. Jan 2013 B2
8374698 Ok et al. Feb 2013 B2
8374701 Hyde et al. Feb 2013 B2
8382656 Brown Feb 2013 B1
8386032 Bachinski et al. Feb 2013 B2
8386053 Kornet Feb 2013 B2
8388678 Singhal et al. Mar 2013 B2
8391970 Tracey et al. Mar 2013 B2
8391986 Graupe et al. Mar 2013 B2
8391987 Faraji et al. Mar 2013 B2
8396556 Libbus et al. Mar 2013 B2
8403841 Miles et al. Mar 2013 B2
8406886 Gaunt et al. Mar 2013 B2
8412328 Whelan et al. Apr 2013 B2
8412335 Gliner et al. Apr 2013 B2
8417345 Machado et al. Apr 2013 B2
8419653 Bleich et al. Apr 2013 B2
8428732 Nishida et al. Apr 2013 B2
8428738 Valencia Apr 2013 B2
8428739 Ahuja et al. Apr 2013 B2
8430882 Lowry et al. Apr 2013 B2
8444640 Demarais et al. May 2013 B2
8457764 Ramachandran et al. Jun 2013 B2
8460167 Chornenky et al. Jun 2013 B2
8463383 Sakai et al. Jun 2013 B2
8473048 Greenberg et al. Jun 2013 B2
8494640 Peterson et al. Jul 2013 B2
8494642 Cowan et al. Jul 2013 B2
8498717 Lee et al. Jul 2013 B2
8498720 Pellinen et al. Jul 2013 B2
8506613 Webb et al. Aug 2013 B2
8509903 York et al. Aug 2013 B2
8512235 Miles et al. Aug 2013 B2
8515533 Rofougaran Aug 2013 B2
8515543 Greenberg et al. Aug 2013 B2
8517961 Imran et al. Aug 2013 B2
8524311 Greenberg et al. Sep 2013 B1
8532776 Greenberg et al. Sep 2013 B2
8538537 Hulvershorn et al. Sep 2013 B2
8543210 Sharma Sep 2013 B2
8548600 Deem et al. Oct 2013 B2
8554328 Faraji et al. Oct 2013 B2
8554337 Barolat Oct 2013 B2
8556838 Moutray Oct 2013 B2
8560041 Flaherty et al. Oct 2013 B2
8562521 Miles et al. Oct 2013 B2
8565894 Vetter et al. Oct 2013 B2
8568331 Bertagnoli et al. Oct 2013 B2
8571665 Moffitt et al. Oct 2013 B2
8579837 Makower et al. Nov 2013 B1
8583238 Heldman et al. Nov 2013 B1
8588918 Bighetti Nov 2013 B2
8594798 Osorio et al. Nov 2013 B2
8600514 Carroll Dec 2013 B1
8608664 Kunitake et al. Dec 2013 B2
8612002 Faltys et al. Dec 2013 B2
8615308 Hung et al. Dec 2013 B2
8617808 Braesch-Andersen et al. Dec 2013 B2
8626265 Hempel et al. Jan 2014 B2
8626305 Nielsen et al. Jan 2014 B2
8628469 Miles et al. Jan 2014 B2
8634930 Dalal et al. Jan 2014 B2
8634932 Ye et al. Jan 2014 B1
8639344 Greenberg et al. Jan 2014 B2
8644900 Balberg et al. Feb 2014 B2
8644937 Greenberg et al. Feb 2014 B2
8644938 Craggs Feb 2014 B2
8647346 Bleich et al. Feb 2014 B2
8649845 McIntyre et al. Feb 2014 B2
8649868 Greenberg et al. Feb 2014 B2
8652129 Wu et al. Feb 2014 B2
8652187 Wells et al. Feb 2014 B2
8655455 Mann et al. Feb 2014 B2
8660655 Peterson et al. Feb 2014 B2
8666500 Greenberg et al. Mar 2014 B2
8667971 Makkar et al. Mar 2014 B2
8667972 Makkar et al. Mar 2014 B2
8669058 Liew Mar 2014 B2
8670837 Daneshvar et al. Mar 2014 B2
8674838 Konishi et al. Mar 2014 B2
8676274 Li Mar 2014 B2
8682443 Faraji et al. Mar 2014 B2
8698637 Raichman Apr 2014 B2
8702685 Schwartz et al. Apr 2014 B2
8706241 Firlik et al. Apr 2014 B2
8708899 Miles et al. Apr 2014 B2
8712517 Jolly Apr 2014 B2
8712538 Greenberg et al. Apr 2014 B2
8712549 Zdeblick et al. Apr 2014 B2
8721637 Zarins et al. May 2014 B2
8725251 Della Rocca et al. May 2014 B2
8734339 Rao et al. May 2014 B2
8740783 Gharib et al. Jun 2014 B2
8740896 Zarins et al. Jun 2014 B2
8744570 Lee et al. Jun 2014 B2
8750957 Tang et al. Jun 2014 B2
8753271 Miles et al. Jun 2014 B1
8755896 Humayun et al. Jun 2014 B2
8761889 Wingeier et al. Jun 2014 B2
8774922 Zarins et al. Jul 2014 B2
8774937 Mercanzini et al. Jul 2014 B2
8777942 Wu et al. Jul 2014 B2
8781603 Ye et al. Jul 2014 B2
8784461 Webb et al. Jul 2014 B2
8788064 Mercanzini et al. Jul 2014 B2
8788065 Rezai et al. Jul 2014 B2
8790338 Asirvatham et al. Jul 2014 B2
8798756 McClure et al. Aug 2014 B2
8801589 Peterchev et al. Aug 2014 B2
8805467 Yobas et al. Aug 2014 B2
8805517 Radivojevic et al. Aug 2014 B2
8805521 Carroll Aug 2014 B2
8821396 Miles et al. Sep 2014 B1
8831750 Ramachandran et al. Sep 2014 B2
8834545 Stafford et al. Sep 2014 B2
8835163 Zhao et al. Sep 2014 B2
8843201 Heldman et al. Sep 2014 B1
8843204 Garnham et al. Sep 2014 B2
8843210 Simon et al. Sep 2014 B2
8849412 Perryman et al. Sep 2014 B2
8855767 Faltys et al. Oct 2014 B2
8862236 Wolpaw et al. Oct 2014 B2
8864665 Rotondo et al. Oct 2014 B2
8864759 Godara et al. Oct 2014 B2
8866621 Wolfe et al. Oct 2014 B2
8868164 Kabakov et al. Oct 2014 B2
8868172 Leyde et al. Oct 2014 B2
8868216 Dunagan Oct 2014 B2
8870857 Seymour et al. Oct 2014 B2
8874216 Kim et al. Oct 2014 B2
8874239 Greenberg et al. Oct 2014 B2
8880189 Lipani Nov 2014 B2
8886324 Beuter et al. Nov 2014 B2
8888773 Chang et al. Nov 2014 B2
8892215 Lipani Nov 2014 B2
8903494 Goldwasser et al. Dec 2014 B2
8903501 Perryman Dec 2014 B2
8909343 Towe Dec 2014 B2
8909344 Arle et al. Dec 2014 B2
8909345 Danilov et al. Dec 2014 B1
8912149 Rawat et al. Dec 2014 B1
8915846 Miles et al. Dec 2014 B2
8915867 Imran et al. Dec 2014 B2
8918178 Simon et al. Dec 2014 B2
8921473 Hyman Dec 2014 B1
8926959 Deisseroth et al. Jan 2015 B2
8929990 Moffitt et al. Jan 2015 B2
8932196 Chornenky et al. Jan 2015 B2
8942797 Bartol et al. Jan 2015 B2
8942812 Machado et al. Jan 2015 B2
8942821 Barolat Jan 2015 B2
8945004 Miles et al. Feb 2015 B2
8945216 Parker et al. Feb 2015 B2
8948884 Ramachandran et al. Feb 2015 B2
8951193 Ong et al. Feb 2015 B2
8954144 Anderson et al. Feb 2015 B2
8954150 Swanson et al. Feb 2015 B2
8954157 Faraji et al. Feb 2015 B2
8954167 Zarembo et al. Feb 2015 B2
8956387 Naghavi et al. Feb 2015 B2
8958862 Hetke et al. Feb 2015 B2
8958883 Mueller et al. Feb 2015 B2
8958890 Kipke et al. Feb 2015 B2
8965513 Wingeier et al. Feb 2015 B2
8969532 DeFrees et al. Mar 2015 B2
8972026 Kipke et al. Mar 2015 B2
8974402 Oddsson et al. Mar 2015 B2
8983593 Bartol et al. Mar 2015 B2
8983601 Fukamachi et al. Mar 2015 B2
8983628 Simon et al. Mar 2015 B2
8983629 Simon et al. Mar 2015 B2
8985057 Woodward Mar 2015 B2
8986294 Demarais et al. Mar 2015 B2
8992522 Pellegrino et al. Mar 2015 B2
8996131 Owen et al. Mar 2015 B1
8998894 Mauch et al. Apr 2015 B2
9002458 Pal et al. Apr 2015 B2
9002477 Burnett Apr 2015 B2
9005191 Azamian et al. Apr 2015 B2
9008784 Chan et al. Apr 2015 B2
9014810 Sauter-Starace et al. Apr 2015 B2
9014811 Pal et al. Apr 2015 B2
9014823 Simon et al. Apr 2015 B2
9019106 Alameh et al. Apr 2015 B2
9020598 Simon et al. Apr 2015 B2
9020612 Danilov et al. Apr 2015 B1
9023037 Zarins et al. May 2015 B2
9034640 Matos et al. May 2015 B2
9037268 Knight May 2015 B2
9042958 Karmarkar et al. May 2015 B2
9043001 Simon et al. May 2015 B2
9044596 Mahadevan-Jansen et al. Jun 2015 B2
9044611 Zhao et al. Jun 2015 B2
9056197 Kishawi et al. Jun 2015 B2
9061097 Holt et al. Jun 2015 B2
9061134 Askin, III et al. Jun 2015 B2
9061135 Keller et al. Jun 2015 B1
9072886 Gaunt et al. Jul 2015 B2
9072889 Guarraia et al. Jul 2015 B1
9072891 Rao Jul 2015 B1
9084550 Bartol et al. Jul 2015 B1
9084610 Goshgarian et al. Jul 2015 B2
9084895 Greenberg et al. Jul 2015 B2
9084900 Hershey et al. Jul 2015 B2
9089341 Chomas et al. Jul 2015 B2
9089687 Lee et al. Jul 2015 B2
9089691 Libbus et al. Jul 2015 B2
9095267 Halpern et al. Aug 2015 B2
9095320 Littrup et al. Aug 2015 B2
9095538 Yu et al. Aug 2015 B2
9101279 Ritchey et al. Aug 2015 B2
9113912 Mehta et al. Aug 2015 B1
9114261 Yonce Aug 2015 B2
9119628 Mehta et al. Sep 2015 B1
9119964 Marnfeldt Sep 2015 B2
9126197 Orwar et al. Sep 2015 B2
9132058 Imboden et al. Sep 2015 B2
9138579 Wolpaw et al. Sep 2015 B2
9144677 Garnham et al. Sep 2015 B2
9155887 Miller, III et al. Oct 2015 B2
9158890 Meredith et al. Oct 2015 B2
9162010 Lenarz et al. Oct 2015 B2
9162064 Faltys et al. Oct 2015 B2
9173585 Tsampazis et al. Nov 2015 B2
9179850 Wingeier et al. Nov 2015 B2
9179875 Hua Nov 2015 B2
9189613 Tuthill et al. Nov 2015 B1
9192757 Seymour Nov 2015 B2
9192767 Mercanzini et al. Nov 2015 B2
9199089 Perryman et al. Dec 2015 B2
9205275 Pan et al. Dec 2015 B2
9220897 Perryman et al. Dec 2015 B2
9220899 Cattaneo et al. Dec 2015 B2
9220900 Libbus et al. Dec 2015 B2
9221177 Herr et al. Dec 2015 B2
9227051 Fisk et al. Jan 2016 B1
9227056 Heldman et al. Jan 2016 B1
9254382 Ahmad et al. Feb 2016 B2
9855427 Bennett et al. Jan 2018 B2
9895546 Jiang et al. Feb 2018 B2
10118040 Zhu Nov 2018 B2
10342977 Raghunathan Jul 2019 B2
10412828 Yamakawa Sep 2019 B1
20010034477 Mansfield Oct 2001 A1
20010055776 Greenwalt Dec 2001 A1
20020009461 Isacson Jan 2002 A1
20020019652 Silva et al. Feb 2002 A1
20020031497 Fraser Mar 2002 A1
20020034819 Smith Mar 2002 A1
20020055779 Andrews May 2002 A1
20020090722 Dominko Jul 2002 A1
20020136705 Dinsmore Sep 2002 A1
20020176849 Slepian Nov 2002 A1
20030002297 Nemtsev Jan 2003 A1
20030004547 Owen Jan 2003 A1
20030049328 Dalal Mar 2003 A1
20030088274 Gliner May 2003 A1
20030097161 Firlik May 2003 A1
20030100367 Cooke May 2003 A1
20030104993 Rueger Jun 2003 A1
20030109901 Greatbatch Jun 2003 A1
20030125786 Gliner Jul 2003 A1
20030149450 Mayberg Aug 2003 A1
20030157712 Daniel Aug 2003 A1
20030195441 Firouzgar Oct 2003 A1
20030198664 Sullivan Oct 2003 A1
20030232055 Medzhitov Dec 2003 A1
20040005291 Rogers Jan 2004 A1
20040014662 Lindquist Jan 2004 A1
20040028613 Quay Feb 2004 A1
20040030365 Rubin Feb 2004 A1
20040038888 Mercer et al. Feb 2004 A1
20040048279 Olek et al. Mar 2004 A1
20040048373 Gage et al. Mar 2004 A1
20040049134 Tosaya Mar 2004 A1
20040054300 Hung et al. Mar 2004 A1
20040062755 Smith et al. Apr 2004 A1
20040064052 Chance Apr 2004 A1
20040081652 Zack Apr 2004 A1
20040093093 Andrews May 2004 A1
20040097401 Datta May 2004 A1
20040097839 Epley May 2004 A1
20040102525 Kozachuk May 2004 A1
20040106966 Scribner Jun 2004 A1
20040121464 Rathjen Jun 2004 A1
20040143170 DuRousseau Jul 2004 A1
20040147975 Popovic Jul 2004 A1
20040156826 Dangond Aug 2004 A1
20040162583 Bingham Aug 2004 A1
20040172100 Humayun Sep 2004 A1
20040172102 Leysieffer Sep 2004 A1
20040185557 Smith et al. Sep 2004 A1
20040199235 Younis Oct 2004 A1
20040212504 Forcier et al. Oct 2004 A1
20040219184 Brown et al. Nov 2004 A1
20040228831 Belinka, Jr. Nov 2004 A1
20040229702 Cooke Nov 2004 A1
20040230226 Bingham Nov 2004 A1
20040243021 Murphy Dec 2004 A1
20050003998 Bertilsson Jan 2005 A1
20050015133 Ibrahim Jan 2005 A1
20050020519 Albiston Jan 2005 A1
20050020945 Tosaya Jan 2005 A1
20050038473 Tamarkin Feb 2005 A1
20050054096 Piniella Mar 2005 A1
20050054907 Page et al. Mar 2005 A1
20050070819 Poux Mar 2005 A1
20050073649 Spector Apr 2005 A1
20050107859 Daglow et al. May 2005 A1
20050125044 Tracey Jun 2005 A1
20050165323 Montgomery Jul 2005 A1
20050203366 Donoghue Sep 2005 A1
20050203601 Palanker Sep 2005 A1
20050222631 Dalal et al. Oct 2005 A1
20050226852 Toda Oct 2005 A1
20050234370 Beal Oct 2005 A1
20050267552 Conquergood Dec 2005 A1
20050272097 Calenoff Dec 2005 A1
20050273890 Flaherty Dec 2005 A1
20050277918 Shah Dec 2005 A1
20060034767 Lum Feb 2006 A1
20060047326 Wheeler Mar 2006 A1
20060049950 Lockhart Mar 2006 A1
20060049957 Surgenor Mar 2006 A1
20060058627 Flaherty Mar 2006 A1
20060118035 Lasater Jun 2006 A1
20060122458 Bleich Jun 2006 A1
20060122529 Tsau Jun 2006 A1
20060122864 Gottesman Jun 2006 A1
20060140930 Rodriguez Jun 2006 A1
20060149345 Boggs, II Jul 2006 A1
20060161225 Sormann Jul 2006 A1
20060167498 DiLorenzo Jul 2006 A1
20060167564 Flaherty Jul 2006 A1
20060171933 Short Aug 2006 A1
20060184219 Pajunk Aug 2006 A1
20060190056 Fowler Aug 2006 A1
20060195146 Tracey et al. Aug 2006 A1
20060195153 Diubaldi et al. Aug 2006 A1
20060206167 Flaherty Sep 2006 A1
20060206178 Kim Sep 2006 A1
20060234376 Mistry Oct 2006 A1
20060263336 Caplan Nov 2006 A1
20060265037 Kuzma Nov 2006 A1
20060281130 Bock Dec 2006 A1
20070005106 Adducci Jan 2007 A1
20070021803 Deem Jan 2007 A1
20070043591 Meretei Feb 2007 A1
20070049814 Muccio Mar 2007 A1
20070049842 Hill Mar 2007 A1
20070067004 Boveja Mar 2007 A1
20070073361 Goren Mar 2007 A1
20070088335 Jolly Apr 2007 A1
20070100393 Whitehurst May 2007 A1
20070102009 Wong May 2007 A1
20070107071 Couillard-Despres May 2007 A1
20070123778 Kantorovich May 2007 A1
20070129769 Bourget Jun 2007 A1
20070134657 Poznansky Jun 2007 A1
20070135846 Knudson Jun 2007 A1
20070165322 Strom Jul 2007 A1
20070173893 Pitts Jul 2007 A1
20070173903 Goren Jul 2007 A1
20070179558 Gliner Aug 2007 A1
20070180542 Brinster Aug 2007 A1
20070192881 Brinster Aug 2007 A1
20070203533 Goren Aug 2007 A1
20070208212 DiLorenzo Sep 2007 A1
20070208385 Carroll Sep 2007 A1
20070219074 Pride Sep 2007 A1
20070239211 Lorincz Oct 2007 A1
20070249952 Rubin Oct 2007 A1
20070276449 Gunter Nov 2007 A1
20070282396 Overstreet Dec 2007 A1
20070287613 Adducci Dec 2007 A1
20070293893 Stolen Dec 2007 A1
20070299483 Strother Dec 2007 A1
20080002276 Strom Jan 2008 A1
20080033520 Jolly Feb 2008 A1
20080040951 Kates Feb 2008 A1
20080057028 Alitalo et al. Mar 2008 A1
20080064946 Greenberg Mar 2008 A1
20080071321 Boggs, II Mar 2008 A1
20080074794 Lee Mar 2008 A1
20080077192 Harry et al. Mar 2008 A1
20080095747 Rutishauser Apr 2008 A1
20080097530 Muccio Apr 2008 A1
20080120029 Zelek et al. May 2008 A1
20080125870 Carmichael May 2008 A1
20080133016 Heinz Jun 2008 A1
20080139907 Rao Jun 2008 A1
20080154335 Thrope Jun 2008 A1
20080161879 Firlik Jul 2008 A1
20080161882 Firlik Jul 2008 A1
20080161887 Hagen Jul 2008 A1
20080170234 Kim Jul 2008 A1
20080170316 Kim Jul 2008 A1
20080195163 Scharmer Aug 2008 A1
20080200967 Ponomarev Aug 2008 A1
20080208280 Lindenthaler et al. Aug 2008 A1
20080215112 Firlik Sep 2008 A1
20080221653 Agrawal Sep 2008 A1
20080241208 Shanley Oct 2008 A1
20080242607 DeFrees Oct 2008 A1
20080243218 Bottomley Oct 2008 A1
20080248959 DeFrees Oct 2008 A1
20080249439 Tracey Oct 2008 A1
20080253992 DeFrees Oct 2008 A1
20080255582 Harris Oct 2008 A1
20080262557 Brown Oct 2008 A1
20080262584 Bottomley Oct 2008 A1
20080274958 DeFrees Nov 2008 A1
20080275546 Storey Nov 2008 A1
20080280818 DeFrees Nov 2008 A1
20080312538 Shahar et al. Dec 2008 A1
20080318314 Fulga et al. Dec 2008 A1
20090012586 Kepecs Jan 2009 A1
20090012590 Inman Jan 2009 A1
20090029912 Gronthos Jan 2009 A1
20090036938 Shipley Feb 2009 A1
20090036945 Chancellor Feb 2009 A1
20090054800 Martinerie Feb 2009 A1
20090054950 Stephens Feb 2009 A1
20090076421 Grant, Jr. Mar 2009 A1
20090076444 Machado Mar 2009 A1
20090086015 Larsen Apr 2009 A1
20090105149 Albrechtsen Apr 2009 A1
20090112278 Wingeier Apr 2009 A1
20090112279 Wingeier Apr 2009 A1
20090118777 Iki et al. May 2009 A1
20090118788 Firlik May 2009 A1
20090124965 Greenberg May 2009 A1
20090131995 Sloan et al. May 2009 A1
20090132018 DiUbaldi et al. May 2009 A1
20090149782 Cohen Jun 2009 A1
20090149900 Moffitt et al. Jun 2009 A1
20090157091 Buysman Jun 2009 A1
20090171381 Schmitz Jul 2009 A1
20090182393 Bachinski Jul 2009 A1
20090201671 Huntley Aug 2009 A1
20090214474 Jennings Aug 2009 A1
20090215896 Morseman Aug 2009 A1
20090220466 Ratajczak Sep 2009 A1
20090226598 Feng Sep 2009 A1
20090227025 Nichols Sep 2009 A1
20090227831 Burnett et al. Sep 2009 A1
20090227965 Wijesiriwardana Sep 2009 A1
20090234265 Reid, Jr. Sep 2009 A1
20090258048 Ward Oct 2009 A1
20090270958 Greenberg Oct 2009 A1
20090292338 Gordon Nov 2009 A1
20090299439 Mire et al. Dec 2009 A1
20090306728 Wright Dec 2009 A1
20090306745 Parker Dec 2009 A1
20090326612 Distler Dec 2009 A1
20100004654 Schmitz Jan 2010 A1
20100010550 Ponomarev Jan 2010 A1
20100016732 Wells Jan 2010 A1
20100035299 DeFrees Feb 2010 A1
20100037755 McMillen Feb 2010 A1
20100042180 Mueller et al. Feb 2010 A1
20100042185 Curtis Feb 2010 A1
20100045595 Bakke Feb 2010 A1
20100047915 Soykan Feb 2010 A1
20100092983 Liew Apr 2010 A1
20100092984 Liew Apr 2010 A1
20100094311 Jolly et al. Apr 2010 A1
20100099786 Dias Apr 2010 A1
20100112026 Karp May 2010 A1
20100114195 Burnes May 2010 A1
20100124745 Liew May 2010 A1
20100124746 Liew May 2010 A1
20100145427 Gliner Jun 2010 A1
20100168739 Wu Jul 2010 A1
20100179284 Ward Jul 2010 A1
20100185042 Schneider Jul 2010 A1
20100189712 L'Heureux Jul 2010 A1
20100203520 Liew Aug 2010 A1
20100204538 Burnett et al. Aug 2010 A1
20100204777 Storey Aug 2010 A1
20100211172 Bellamkonda Aug 2010 A1
20100222630 Mangrum Sep 2010 A1
20100222844 Troosters Sep 2010 A1
20100241195 Meadows Sep 2010 A1
20100268055 Jung et al. Oct 2010 A1
20100268125 Epley Oct 2010 A9
20100280570 Sturm Nov 2010 A1
20100280571 Sloan Nov 2010 A1
20100286067 DeFrees Nov 2010 A1
20100292759 Hahn Nov 2010 A1
20100298916 Rabischong Nov 2010 A1
20100304864 Johnson Dec 2010 A1
20100305674 Zarembo Dec 2010 A1
20100310529 Aizman Dec 2010 A1
20100324355 Spitaels Dec 2010 A1
20100324626 Lefkovitz Dec 2010 A1
20110009959 Tiedtke Jan 2011 A1
20110014189 Soula et al. Jan 2011 A1
20110022105 Owen Jan 2011 A9
20110022131 Giuliano Jan 2011 A1
20110028345 Fang et al. Feb 2011 A1
20110040204 Ivorra et al. Feb 2011 A1
20110040349 Graupe Feb 2011 A1
20110059447 Liew Mar 2011 A1
20110060266 Streeter Mar 2011 A1
20110082531 Swanson Apr 2011 A1
20110092863 Kim Apr 2011 A1
20110098777 Silverstone Apr 2011 A1
20110106207 Cauller May 2011 A1
20110106219 Cauller May 2011 A1
20110112352 Pilla et al. May 2011 A1
20110118556 Siegel May 2011 A1
20110124959 Murison May 2011 A1
20110137189 Kuo Jun 2011 A1
20110158444 Waldmann Jun 2011 A1
20110177029 DeFrees Jul 2011 A1
20110184269 Sauter-Starace Jul 2011 A1
20110190882 Parker Aug 2011 A1
20110195106 McMurtrey Aug 2011 A1
20110196454 Strand Aug 2011 A1
20110202120 Ball et al. Aug 2011 A1
20110208226 Fatone et al. Aug 2011 A1
20110218593 Rubinstein et al. Sep 2011 A1
20110224565 Ong Sep 2011 A1
20110224754 Wei Sep 2011 A1
20110257501 Huys et al. Oct 2011 A1
20110257504 Hendricks Oct 2011 A1
20110262501 Webster Oct 2011 A1
20110264178 Mehregany Oct 2011 A1
20110268776 Schapira Nov 2011 A1
20110270345 Johnston Nov 2011 A1
20110270361 Borsody Nov 2011 A1
20110295156 Arturi Dec 2011 A1
20110301662 Bar-Yoseph Dec 2011 A1
20110313270 Pereira Neves Dec 2011 A1
20110319703 Wiskerke Dec 2011 A1
20120016431 Paul Jan 2012 A1
20120016440 Muccio Jan 2012 A1
20120022616 Garnham Jan 2012 A1
20120035684 Thompson Feb 2012 A1
20120045487 Lahann Feb 2012 A1
20120046702 Gibson Feb 2012 A1
20120059389 Larson Mar 2012 A1
20120064628 Blick Mar 2012 A1
20120076830 Sitharaman Mar 2012 A1
20120078327 Sloan et al. Mar 2012 A1
20120089047 Ryba et al. Apr 2012 A1
20120095166 Ward Apr 2012 A1
20120095524 Nelson Apr 2012 A1
20120101326 Simon Apr 2012 A1
20120101413 Beetel Apr 2012 A1
20120109233 Lee et al. May 2012 A1
20120123508 Wentz May 2012 A1
20120124470 West May 2012 A1
20120130360 Buckley May 2012 A1
20120134965 Kim et al. May 2012 A1
20120136232 Jeong May 2012 A1
20120143293 Mauch et al. Jun 2012 A1
20120158095 Jolly Jun 2012 A1
20120158104 Huynh Jun 2012 A1
20120158113 Jolly et al. Jun 2012 A1
20120158114 Debruyne Jun 2012 A1
20120179076 Bavelier Jul 2012 A1
20120185173 Yamamoto Jul 2012 A1
20120191052 Rao Jul 2012 A1
20120191086 Moll Jul 2012 A1
20120197092 Luo et al. Aug 2012 A1
20120197252 Deem Aug 2012 A1
20120197374 Vogt Aug 2012 A1
20120214737 Marchionni Aug 2012 A1
20120221072 Fukamachi Aug 2012 A1
20120226331 Banna et al. Sep 2012 A1
20120237557 Lewitus et al. Sep 2012 A1
20120238924 Avni Sep 2012 A1
20120239363 Durrani et al. Sep 2012 A1
20120244503 Neveldine Sep 2012 A1
20120245534 Jolly Sep 2012 A1
20120253236 Snow Oct 2012 A1
20120259255 Tomlinson Oct 2012 A1
20120259390 Canion Oct 2012 A1
20120277825 Mawson Nov 2012 A1
20120277842 Kunis Nov 2012 A1
20120282228 Bhasin Nov 2012 A1
20120283800 Perryman Nov 2012 A1
20120296191 McGrath Nov 2012 A1
20120296230 Davis Nov 2012 A1
20120296444 Greenberg Nov 2012 A1
20120302856 Chang Nov 2012 A1
20120310140 Kramer Dec 2012 A1
20120323288 Anderson Dec 2012 A1
20130006322 Tai Jan 2013 A1
20130012831 Schmitz Jan 2013 A1
20130018240 McCoy Jan 2013 A1
20130018444 Glenn Jan 2013 A1
20130035745 Ahmed Feb 2013 A1
20130041432 Tucker et al. Feb 2013 A1
20130052712 Cha Feb 2013 A1
20130053853 Schmitz Feb 2013 A1
20130053934 Gluckman Feb 2013 A1
20130066147 Brown Mar 2013 A1
20130066216 Park Mar 2013 A1
20130066391 Hulvershorn Mar 2013 A1
20130066392 Simon Mar 2013 A1
20130066395 Simon Mar 2013 A1
20130072808 Neves Mar 2013 A1
20130072835 Harry et al. Mar 2013 A1
20130090542 Kipke et al. Apr 2013 A1
20130090711 Ramachandran Apr 2013 A1
20130101635 Park et al. Apr 2013 A1
20130116685 Deem et al. May 2013 A1
20130116744 Blum May 2013 A1
20130122528 Tyrell May 2013 A1
20130123568 Hamilton May 2013 A1
20130123570 Ly et al. May 2013 A1
20130131743 Yamasaki May 2013 A1
20130131753 Simon May 2013 A1
20130137955 Kong et al. May 2013 A1
20130144143 Kim et al. Jun 2013 A1
20130144369 Elias Jun 2013 A1
20130144370 Debruyne Jun 2013 A1
20130150653 Borsody Jun 2013 A1
20130154838 Alameh Jun 2013 A1
20130157229 Lauritzen Jun 2013 A1
20130178765 Mishelevich Jul 2013 A1
20130184792 Simon Jul 2013 A1
20130184795 Kipke et al. Jul 2013 A1
20130184799 Kipke et al. Jul 2013 A1
20130204122 Hendler et al. Aug 2013 A1
20130204317 Sauter-Starace Aug 2013 A1
20130210041 Anderberg Aug 2013 A1
20130218456 Zelek Aug 2013 A1
20130231725 Williams Sep 2013 A1
20130238066 Boggs, II Sep 2013 A1
20130238074 Zimmerling Sep 2013 A1
20130245480 Crockford Sep 2013 A1
20130245486 Simon et al. Sep 2013 A1
20130245711 Simon Sep 2013 A1
20130245712 Simon Sep 2013 A1
20130245717 Stohl et al. Sep 2013 A1
20130245765 Lowry et al. Sep 2013 A1
20130248226 Sime Sep 2013 A1
20130253299 Weber Sep 2013 A1
20130274540 Pilla Oct 2013 A1
20130274658 Steinke Oct 2013 A1
20130274842 Gaunt Oct 2013 A1
20130280233 Kahn et al. Oct 2013 A1
20130282001 Hezi-Yamit Oct 2013 A1
20130282090 Decre Oct 2013 A1
20130288233 Murray Oct 2013 A1
20130289659 Nelson Oct 2013 A1
20130289678 Clark Oct 2013 A1
20130289686 Masson Oct 2013 A1
20130296767 Zarins et al. Nov 2013 A1
20130309278 Peyman Nov 2013 A1
20130310909 Simon Nov 2013 A1
20130317400 Ferezy Nov 2013 A1
20130317580 Simon Nov 2013 A1
20130324994 Pellegrino et al. Dec 2013 A1
20130331869 Runge et al. Dec 2013 A1
20130338729 Spector Dec 2013 A1
20130341185 Collaert et al. Dec 2013 A1
20140003696 Taghva Jan 2014 A1
20140018792 Gang et al. Jan 2014 A1
20140022162 Yu et al. Jan 2014 A1
20140023999 Greder Jan 2014 A1
20140024981 Chun et al. Jan 2014 A1
20140025301 Storm, Jr. et al. Jan 2014 A1
20140030735 Merali et al. Jan 2014 A1
20140046423 Rajguru Feb 2014 A1
20140051938 Goldstein et al. Feb 2014 A1
20140058481 Perryman et al. Feb 2014 A1
20140058483 Zao et al. Feb 2014 A1
20140066924 Azamian et al. Mar 2014 A1
20140073883 Rao et al. Mar 2014 A1
20140074186 Faltys et al. Mar 2014 A1
20140081682 Perlmuter Mar 2014 A1
20140094674 Nurmikko et al. Apr 2014 A1
20140099352 Matheny Apr 2014 A1
20140107397 Simon et al. Apr 2014 A1
20140107398 Simon et al. Apr 2014 A1
20140114168 Block et al. Apr 2014 A1
20140127171 Nocera et al. May 2014 A1
20140128939 Embrey et al. May 2014 A1
20140135607 Lee et al. May 2014 A1
20140135680 Peyman May 2014 A1
20140142374 Makower et al. May 2014 A1
20140148649 Miles et al. May 2014 A1
20140148871 Southwell et al. May 2014 A1
20140148872 Goldwasser et al. May 2014 A1
20140155811 Gibson Jun 2014 A1
20140155973 Grigsby et al. Jun 2014 A1
20140163580 Tischendorf et al. Jun 2014 A1
20140163641 Yao et al. Jun 2014 A1
20140163658 Faraji et al. Jun 2014 A1
20140171807 Akkin et al. Jun 2014 A1
20140180036 Bukkapatnam et al. Jun 2014 A1
20140180196 Stone et al. Jun 2014 A1
20140180365 Perryman et al. Jun 2014 A1
20140187872 Stivoric et al. Jul 2014 A1
20140194951 Gong et al. Jul 2014 A1
20140197937 Huang et al. Jul 2014 A1
20140200432 Banerji et al. Jul 2014 A1
20140200466 Sereno et al. Jul 2014 A1
20140200496 Hyde et al. Jul 2014 A1
20140200681 Kennedy et al. Jul 2014 A1
20140206947 Isserow et al. Jul 2014 A1
20140207292 Ramagem et al. Jul 2014 A1
20140213842 Simon et al. Jul 2014 A1
20140213971 Dolan et al. Jul 2014 A1
20140220555 Chen et al. Aug 2014 A1
20140222125 Glenn et al. Aug 2014 A1
20140225763 Kavaler et al. Aug 2014 A1
20140228901 Vogt Aug 2014 A1
20140228926 Della Santina et al. Aug 2014 A1
20140235950 Miles et al. Aug 2014 A1
20140236249 Rao et al. Aug 2014 A1
20140236847 Hamilton Aug 2014 A1
20140243616 Johnson Aug 2014 A1
20140243932 Libbus et al. Aug 2014 A1
20140249395 Zhou et al. Sep 2014 A1
20140255461 McMurtrey Sep 2014 A9
20140257063 Ong et al. Sep 2014 A1
20140257437 Simon et al. Sep 2014 A1
20140267123 Ludwig Sep 2014 A1
20140275737 Shore et al. Sep 2014 A1
20140276718 Turovskiy et al. Sep 2014 A1
20140276760 Bonyak et al. Sep 2014 A1
20140277031 Ballakur et al. Sep 2014 A1
20140277033 Taylor et al. Sep 2014 A1
20140277220 Brennan et al. Sep 2014 A1
20140277237 Maskara et al. Sep 2014 A1
20140277271 Chan et al. Sep 2014 A1
20140277310 Beetel et al. Sep 2014 A1
20140277582 Leuthardt et al. Sep 2014 A1
20140288379 Miles et al. Sep 2014 A1
20140296646 Wingeier et al. Oct 2014 A1
20140300490 Kotz et al. Oct 2014 A1
20140303525 Sitharaman Oct 2014 A1
20140303548 Jolly et al. Oct 2014 A1
20140304773 Woods et al. Oct 2014 A1
20140309548 Merz et al. Oct 2014 A1
20140316398 Kelly et al. Oct 2014 A1
20140320289 Raichman Oct 2014 A1
20140324120 Bogie et al. Oct 2014 A1
20140330337 Linke et al. Nov 2014 A1
20140336631 Wu et al. Nov 2014 A1
20140336722 Rocon De Lima et al. Nov 2014 A1
20140350041 Yun et al. Nov 2014 A1
20140350633 Gustafson et al. Nov 2014 A1
20140357453 Tamanaha Dec 2014 A1
20140357933 Lee et al. Dec 2014 A1
20140360511 Mohler Dec 2014 A1
20140371547 Gartenberg et al. Dec 2014 A1
20140371564 Anikeeva et al. Dec 2014 A1
20140371622 Hausman et al. Dec 2014 A1
20140375457 Diaz Dec 2014 A1
20140378779 Freeman et al. Dec 2014 A1
20140378789 McKinley et al. Dec 2014 A1
20140378946 Thompson et al. Dec 2014 A1
20140379045 Rahimi et al. Dec 2014 A1
20140379049 Mashiach et al. Dec 2014 A1
20150005607 Cui et al. Jan 2015 A1
20150005680 Lipani Jan 2015 A1
20150005840 Pal et al. Jan 2015 A1
20150005841 Pal et al. Jan 2015 A1
20150005851 Bradley Jan 2015 A1
20150010607 Francis et al. Jan 2015 A1
20150012079 Goroszeniuk et al. Jan 2015 A1
20150016647 Segovia Martinez Jan 2015 A1
20150017140 Bhatia et al. Jan 2015 A1
20150018659 Ware et al. Jan 2015 A1
20150032044 Peyman Jan 2015 A9
20150032178 Simon et al. Jan 2015 A1
20150032184 Muccio Jan 2015 A1
20150038886 Snow Feb 2015 A1
20150039055 Wagner et al. Feb 2015 A1
20150049325 Curtis Feb 2015 A1
20150051439 Hillbratt Feb 2015 A1
20150051684 Greenberg et al. Feb 2015 A1
20150057736 Zachar Feb 2015 A1
20150059390 Hayes Mar 2015 A1
20150062018 Naidu et al. Mar 2015 A1
20150066126 Marx et al. Mar 2015 A1
20150067422 Hamilton Mar 2015 A1
20150073232 Ahmad et al. Mar 2015 A1
20150073520 Strahl et al. Mar 2015 A1
20150080709 Chaturvedi Mar 2015 A1
20150080926 Emery Mar 2015 A1
20150088030 Taylor Mar 2015 A1
20150088223 Blum et al. Mar 2015 A1
20150088224 Goldwasser et al. Mar 2015 A1
20150088225 Noble et al. Mar 2015 A1
20150102925 Foldyna et al. Apr 2015 A1
20150105794 Dhanasingh et al. Apr 2015 A1
20150105795 Lenarz et al. Apr 2015 A1
20150112234 McCaffrey et al. Apr 2015 A1
20150112321 Cadouri Apr 2015 A1
20150112359 Gillbe Apr 2015 A1
20150112360 Pellinen et al. Apr 2015 A1
20150112404 Holding et al. Apr 2015 A1
20150112405 Brown et al. Apr 2015 A1
20150112408 Kals Apr 2015 A1
20150119673 Pellinen et al. Apr 2015 A1
20150119790 Moffitt et al. Apr 2015 A1
20150119954 Bhadra et al. Apr 2015 A2
20150119989 Pimenta et al. Apr 2015 A1
20150126997 Beetel et al. May 2015 A1
20150133761 Vetter et al. May 2015 A1
20150133956 Dayan et al. May 2015 A1
20150135840 Sato et al. May 2015 A1
20150148643 Small et al. May 2015 A1
20150148644 Vaidyanathan et al. May 2015 A1
20150148736 Jolly et al. May 2015 A1
20150148869 Dorvall, II et al. May 2015 A1
20150148878 Yoo et al. May 2015 A1
20150150508 Glenn et al. Jun 2015 A1
20150157398 Zarins et al. Jun 2015 A1
20150157851 Sefkow et al. Jun 2015 A1
20150157854 Hetke et al. Jun 2015 A1
20150157862 Greenberg et al. Jun 2015 A1
20150164360 Kipke et al. Jun 2015 A1
20150164401 Toth et al. Jun 2015 A1
20150173673 Toth et al. Jun 2015 A1
20150173918 Herr et al. Jun 2015 A1
20150174403 Pal et al. Jun 2015 A1
20150174418 Tyler et al. Jun 2015 A1
20150182753 Harris et al. Jul 2015 A1
20150190635 Neuvonen et al. Jul 2015 A1
20150190636 Simon et al. Jul 2015 A1
20150190637 Simon et al. Jul 2015 A1
20150196767 Ahmed Jul 2015 A1
20150201855 Pellinen et al. Jul 2015 A1
20150202331 Blumenfeld et al. Jul 2015 A1
20150202437 Franke et al. Jul 2015 A1
20150209104 Tran et al. Jul 2015 A1
20150209577 Golestanirad et al. Jul 2015 A1
20150209586 Silva et al. Jul 2015 A1
20150217125 Chornenky et al. Aug 2015 A1
20150223731 Sahin Aug 2015 A1
20150224300 Hagr Aug 2015 A1
20150224330 Kaib et al. Aug 2015 A1
20150230749 Gharib et al. Aug 2015 A1
20150231396 Burdick et al. Aug 2015 A1
20150235529 Deschamps Aug 2015 A1
20150238104 Tass Aug 2015 A1
20150238253 Wu et al. Aug 2015 A1
20150238764 Franke Aug 2015 A1
20150246072 Bhatia et al. Sep 2015 A1
20150248470 Coleman et al. Sep 2015 A1
20150251004 Imran et al. Sep 2015 A1
20150254992 Sethi Sep 2015 A1
20150257824 Mauch Sep 2015 A1
20150272805 Burnett et al. Oct 2015 A1
20150273206 Monteiro Oct 2015 A1
20150283365 Dacey, Jr. et al. Oct 2015 A1
20150284416 Zhao Oct 2015 A1
20150290439 Eldredge et al. Oct 2015 A1
20150290450 Kolb et al. Oct 2015 A1
20150290464 Monteiro Oct 2015 A1
20150290472 Maguire et al. Oct 2015 A1
20150297104 Chen et al. Oct 2015 A1
20150297444 Tass Oct 2015 A1
20150297914 Hamid et al. Oct 2015 A1
20150305667 Durand Oct 2015 A1
20150305686 Coleman et al. Oct 2015 A1
20150310762 Seim et al. Oct 2015 A1
20150313498 Coleman et al. Nov 2015 A1
20150313512 Hausman et al. Nov 2015 A1
20150314017 Zhao Nov 2015 A1
20150320560 Mulliken et al. Nov 2015 A1
20150320588 Connor Nov 2015 A1
20150321000 Rosenbluth et al. Nov 2015 A1
20150321010 Marnfeldt Nov 2015 A1
20150321017 Perryman et al. Nov 2015 A1
20150322155 Zhao Nov 2015 A1
20150328454 Lambert Nov 2015 A1
20150328455 Meadows et al. Nov 2015 A1
20150335288 Toth et al. Nov 2015 A1
20150335876 Jeffery et al. Nov 2015 A1
20150335877 Jeffery et al. Nov 2015 A1
20150335883 Halpern et al. Nov 2015 A1
20150335888 Demers et al. Nov 2015 A1
20150343196 Vasapollo Dec 2015 A1
20150343215 De Ridder Dec 2015 A1
20150343242 Tyler et al. Dec 2015 A1
20150354922 Carriere Dec 2015 A1
20150359704 Imboden et al. Dec 2015 A1
20150364018 Mirov et al. Dec 2015 A1
20150374515 Meijer et al. Dec 2015 A1
20150379880 Sethi Dec 2015 A1
20160015962 Maragheh et al. Jan 2016 A1
20170001003 Pivonka et al. Jan 2017 A1
20170080216 Pham Mar 2017 A1
20170209693 An et al. Jul 2017 A1
20170224990 Goldwasser et al. Aug 2017 A1
20170312512 Creasey et al. Nov 2017 A1
20170312526 Steinke et al. Nov 2017 A1
20170333695 Kaplan et al. Nov 2017 A1
20180116877 Ineichen May 2018 A1
20180133479 Bennett et al. May 2018 A1
20180318585 Pfeifer Nov 2018 A1
20200069941 Campean et al. Mar 2020 A1
20200069942 Campean et al. Mar 2020 A1
Foreign Referenced Citations (12)
Number Date Country
101868279 Oct 2010 CN
107362447 Nov 2017 CN
2646779 Jul 1993 FR
2011502707 Jan 2011 JP
2012512682 Jun 2012 JP
2013500080 Jan 2013 JP
2013512076 Apr 2013 JP
2009064641 May 2009 WO
2011011748 Jan 2011 WO
2011053607 May 2011 WO
2012129574 Sep 2012 WO
2015183620 Apr 2016 WO
Non-Patent Literature Citations (775)
Entry
US 8,398,630 B2, 03/2013, Demarais et al. (withdrawn)
US 8,613,701 B2, 12/2013, Rao et al. (withdrawn)
US 8,652,133 B2, 02/2014, Zarins et al. (withdrawn)
White, N, et al.; Overactive Bladder; Obstet Gynecol Clin North Am; 2016; 59-68; 43.
Vigil, HR, et al.; Urinary tract infection in the neurogenic bladder; Transl Androl Urol; 2016; 72-87; 5.
Su, X, et al.; Optimization of Neuromodulation for Bladder Control in a Rat Cystitis Model; Neuromodulation; 2016; 101-107; 19.
Speer, LM, et al.; Chronic Pelvic Pain in Women; Am Fam Physician; 2016; 380-387; 93.
Shah, P, et al.; Unique spatiotemporal neuromodulation of the lumbosacral circuitry shapes locomotor success after spinal cord injury; J Neurotrauma; 2016;Abstract,
Sanford, MT, et al.; Neuromodulation in neurogenic bladder; Transl Androl Urol; 2016; 117-126; 5.
Roth, TM; Safe Simultaneous Use of Sacral Neuromodulation and Vagal Nerve Stimulation; Female Pelvic Med Reconstr Surg; 2016; e1-2; 22;Abstract,
Puccini, F, et al.; Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis; Int Urogynecol J; 2016; 347-354; 27.
Penson, DF; Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladded and Urinary Retention; J Urol; 2016; 689; 195.
Olivera, CK, et al.; Non-antimuscarinic treatment for overactive bladder: a systematic review; Am J Obstet Gynecol; 2016;Abstract.
Noblett, K, et al.; Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder: Neurourol Urodyn: 2016: 246-251: 35.
Musco, S, et al.; Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women With Overactive Bladder Syndrome; J Sex Med; 2016
Mason, MD, et al.; Prospective Evaluation of Sacral Neuromodulation in Children: Outcomes and Urodynamic Predictors of Success; J Urol; 2016.
Manriquez, V, et al.; Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial: Eur J Obstet Gynecol Reprod Biol: 2016: 42531: 196.
Lyon, TD, et al.; Pudendal but not tibial nerve stimulation inhibits bladder constractions induced by stimulation of pontine micturition center in cats; Am J Physiol Regul Integr Comp Physiol: 2016: R366-374: 310.
Iqbal, F, et al.; Bilateral transcutaneous tibial nerve stimulation for chronic constipation; Colorectal Dis; 2016; 173-178; 18.
Frokjaer, JB, et al.; Modulation of vagal tone enhances gastroduodenal motility and reduces somatic pain sensitivity; Neurogastroenterol Motil; 2016.
Evers, J, et al.; Reversal of sensory deficit through sacral neuromodulation in an animal model fo fecal incontinence; Neurogastroenterol Motil; 2016;Abstract.
Devane, LA, et al.; Acute lumbosacral nerve stimulation does not affect anorectal motor function in a rodent model; Neurogastroenterol Motil; 2016; 358-363; 28.
Choudhary, M, et al.; Inhibitory effects of tibial nerve stimulation on bladder neurophysiology in rats; Springerplus; 2016; 35; 5.
Cadish, LA, et al.; Stimulation latency and comparison of cycling regimens in women using sacral neuromodulation; Neurourol Urodyn; 2016;Abstract.
Batla, A, et al.; Lower urinary tract dysfunction in patients with functional movement disorders; J Neurol Sci; 2016; 192-194; 361.
Baron, M, et al.; [Does urinary sacral neuromodulation improve bowel symptoms other than fecal incontinence: A systematic review]; Prog Urol; 2016;Abstract.
Zecca, C, et al.; Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis; Int Urogynecol J; 2015.
Zariffa, J, et al.; A Phase-Based Electrical Plethysmography Approach to Bladder Volume Measurement; Ann Biomed Eng; 2015.
Yamanishi, T, et al.; Neuromodulation for the Treatment of Lower Urinary Tract Symptoms; Low Urin Tract Symptoms; 2015; 121-132; 7.
Williams, MJ, et al.; Self-Reported Medication Costs in Patients Receiving Sacral Neuromodulation for Overactive Bladder; Value Health; 2015; A352; 18.
Wexner, SD, et al.; Current surgical strategies to treat fecal incontinence; Expert Rev Gastroenterol Hepatol; 2015; 1577-1589; 9;Abstract.
Wenzler, DL, et al.; Proof of concept trial on changes in current perception threshold after sacral neuromodulation; Neuromodulation; 2015; 228-231; discussion 232; 18.
Wein, AJ; Re: Results of a Prospective, Randomized, Multicenter Study Evaluating Sacral Neuromodulation with InterStim Therapy Compared to Standard Medical Therapy at 6-Months in Subjects with Mild Symptoms of Overactive Bladder; J Urol; 2015; 1051-1052; 194.
Wark, HA, et al.; Restoration from acute urinary dysfunction using Utah electrode arrays implanted into the feline pudendal nerve; Neuromodulation; 2015; 317-323; 18.
Veit-Rubin, N, et al.; [Overactive bladder syndrome—a public health challenge]; Rev Med Suisse; 2015; 2016-2021; 11;Abstract.
Trevizol, AP, et al.; Trigeminal Nerve Stimulation (TNS) for the Treament of Irritable Bowel Syndrome in an Elderly Patient with Major Depressive Disorder: A Case Study; Brain Stimul; 2015; 1235-1236; 8.
Tian, Y, et al.; Inhibitory Effect and Possible Mechanism of Intraurethral Stimulation on Overactive Bladder in Female Rats; Int Neurourol J; 2015; 151-157; 19.
Thin, NN, et al.; Randomized clinical trial of sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence; Br J Surg; 2015; 349-358; 102.
Tweel, WA, et al.; Neurogenic bladder in spinal cord injury patients; Res Rep Urol; 2015; 85-99; 7.
Suskind, AM, et al.; Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention; Urology; 2015; 30-34;86.
Su, X, et al.; Differentiation and interaction of tibial versus spinal nerve stimulation for micturition control in the rat; Neurourol Urodyn; 2015; 92-97; 34.
Su, X, et al.; Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex; BMC Urol; 2015; 50; 15.
Siegel, S, et al.; Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder; Neurourol Urodyn; 2015; 224-230; 34.
Shvarts, PG, et al.; [The modern methods of the electical stimulation for the management of neurogenic disturbances of urination]; Vopr Kurortol Fizioter Lech Fiz Kult; 2015; 18-21; 92.
Shi, P, et al.; Bladder response to acute sacral neuromodulation while treating rats in different phases of complete spinal cord injury: a preliminary study; Int Braz J Urol; 2015; 1194-1201; 41.
Schurch, B, et al.; Dysfunction of lower urinary tract in patients with spinal cord injury; Handb Clin Neurol; 2015; 247-267; 130.
Scheiner, DA, et al.; [Interstitial cystitis/bladder pain syndrom (IC/BPS)]; Praxis (Bern 1994); 2015; 909-918; 104.
Sadiq, A, et al.; Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients; Curr Urol Rep; 2015; 44; 16.
Saber-Khalaf, M, et al.; Sacral neuromodulation outcomes in male patients with chronic urinary retention; Neuromodulation; 2015; 329-334; discussion 334; 18.
Rogers, MJ, et al.; Propranolol, but not naloxone, enhances spinal reflex bladder activity and reduces pudendal inhibition in cats; Am J Physiol Integr Comp Physiol; 2015; R42-49; 308.
Rogers, MJ, et al.; Role of glycine in nociceptive and non-nocicpetive bladder reflexes and pudendal afferent inhibition of these reflexes in cats; Neurourol Urodyn; 2015;Abstract.
Rimmer, CJ, et al.; Short-term Outcomes of a Randomized Pilot Trial of 2 Treatment Regimens of Transcutaneous Tibial Nerve Stimulation for Fecal Incontinence; Dis Colon Rectum; 2015; 974-982; 58.
Reese, JN, et al.; Role of spinal metabotropic glutamate receptor 5 in pudendal inhibition of the nociceptive bladder reflex in cats; Am J Physiol Renal Physiol; 2015; F832-838; 308.
Ramage, L, et al.; A systematic review of sacral nerve stimulation for low anterior resection syndrome; Colorectal Dis; 2015; 762-771; 17.
Rahnama'l, MS, et al.; Evidence for prostaglandin E2 receptor expression in the intramural ganglia of the guinea pig urinary bladder; J Chem Neuroanat; 2015; 43-47; 64-65.
Phe, V, et al.; How to define a refractory idiopathic overactive bladder?; Neurourol Urodyn; 2015; 42411; 34.
Peyronnet, B, et al.; [Management of overactive bladder in women]; Prog Urol; 2015; 877-883; 25;Abstract.
Peters, KM, et al.; Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients; Neurourol Urodyn; 2015;Abstract.
Peters, KM, et al.; Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients; Low Urin Tract Symptoms; 2015; 77-83; 7.
Patidar, N, et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder: A preliminary report; J Pediatr Urol; 2015; 351.e351-356; 11.
Parnell, BA, et al.; The effect of sacral neuromodulation on pudendal nerve function and female sexual function; Neurourol Urodyn; 2015; 456-460; 34.
Panicker, JN, et al.; Lower urinary tract dysfunction in the neurological patient: clinical assessment and management; Lancet Neurol; 2015; 720-732; 14.
Mishra, NN; Clinical presentation and treament of bladder pain syndrome/interstitial cystitis (BPS/IC) in India; Transl Androl Urol; 2015; 512-523; 4.
Meissnitzer, T, et al.; CT-Guided Lead Placement for Selective Sacral Neuromodulation to Treat Lower Urinary Tract Dysfunctions; AJR Am J Roentgenol; 2015; 1139-1142; 205.
Marinkovic, SP, et al.; Neuromodulation for Overactive Bladder Symptoms in Women Utilizing Either Motor or Sensory/Motor Provocation With a Minimum Nine-Year Follow-Up; Neuromodulation; 2015; 517-521; discussion 521; 18.
Maeda, Y, et al.; Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement; Colorectal Dis; 2015; O74-87; 17.
Lombardi, G, et al.; Sacral neuromodulation and female sexuality; Int Urogynecol J; 2015; 1751-1757; 26.
Lin, YT, et al.; Effects of pudendal neuromodulation on bladder function in chronic spinal cord-injured rats; J Formos Med Assoc; 2015.
Laudano, MA, et al.; Disparities in the Use of Sacral Neuromodulation among Medicare Beneficiaries; J Urol; 2015; 449-453; 194.
La, TH, et al.; Intermittent sacral neuromodulation for idiopathic urgency urinary incontinence in women; Neurourol Urodyn; 2015;Abstract.
Kuo, TL, et al.; Pelvic floor spasm as a cause of voiding dysfunction; Curr Opin Urol; 2015; 311-316; 25.
Kumsar, S, et al.; Effects of sacral neuromodulation on isolated urinary bladder function in a rat model of spinal cord injury; Neuromodulation; 2015; 67-74; discussion 74-65; 18.
Kovacevic, M, et al.; Reflex neuromodulation of bladder function elicited by posterior tibial nerve stimulation in anesthetized rats; Am J Physiol Renal Physiol; 2015; F320-329; 308.
Knowles, CH, et al.; Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial; Lancet; 2015; 1640-1648; 386.
Karmarkar, R, et al.; Emergin drugs for overactive baldder; Expert Opin Emerg Drugs; 2015; 613-624; 20;Abstract.
Karam, R, et al.; Real-Time Classification of Bladder Events for Effective Diagnosis and Treatment of Urinary Incontinence; IEEE Trans Biomed Eng; 2015.
Joussain, C, et al.; Electrical managment of neurogenic lower urinary tract disorders; Ann Phys Rehabil Med; 2015; 245-250; 58.
Jin, H, et al.; Electrical neuromodulation at acupoint ST36 normalizes impaired colonic motility induced by rectal distension in dogs; Am J Physiol Gastrointest Liver Physiol; 2015; G368-376; 309.
Jimenez-Toscano, M, et al.; Efficacy and quality of life after transcutaneous posterior tibial neuromodulation for faecal incontinence; Colorectal Dis; 2015; 718-723; 17.
Jesus, LE, et al.; Psychosocial and respiratory disease related to severe bladder dysfunction and non-monosymptomatic enuresis; J Pediatr Urol; 2015;Abstract.
Horrocks, EJ, et al.; Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial); Health Technol Assess; 2015; 1-164; 19.
Hoag, N, et al.; Underactive Bladder: Clinical Features, Urodynamic Parameters, and Treatment; Int Neurourol J; 2015; 185-189; 19.
Hill, AJ, et al.; Resolution of Chronic Vulvar Pruritus With Replacement of a Neuromodulation Device; J Minim Invasive Gynecol; 2015; 889-891; 22.
Heinze, K, et al.; [Neuromodulation—new techniques]; Urologe A; 2015; 373-377; 54.
Hassouna, MM, et al.; Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective; Can Urol Assoc J; 2015; 242-247; 9.
Hashim, H, et al.; Patient preferences for treating refractory overactive bladder in the UK; Int Urol Nephrol; 2015; 1619-1627; 47.
Gupta, P, et al.; Percutaneous tibial nerve stimulation and sacral neuromodulation: an update; Curr Urol Rep; 2015; 4; 16.
Gormley, EA, et al.; Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment; J Urol; 2015; 1572-1580; 193.
Franzen, K, et al.; Surgery for urinary incontinence in women 65 years and older: a systematic review; Int Urogynecol J; 2015; 1095-1102; 26.
Ford, AP, et al.; P2X3 receptors and sensitization of autonomic reflexes; Auton Neurosci; 2015; 16-24; 191.
Ferroni; MC, et al.; Role of the brain stem in tibial inhibition of the micturition reflex in cats; Am J Physiol Renal Physiol; 2015; F242-250; 309.
Drossaerts, J, et al.; Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation: Neurourol Urodyn: 2015:Abstract.
Drossaerts, J, et al.; The value of urodynamic tools to guide patient selection in sacral neuromodulation; World J Urol; 2015; 1889-1895; 33.
Drake, MJ; Management and rehabilitation of neurologic patients with lower urinary tract dysfunction; Handb Clin Neurol; 2015; 451-468; 130.
Di Giovangiulio, M, et al.; The Neuromodulation of the Intestinal Immune System and its Relevance in Inflammatory Bowel Disease; Front Immunol; 2015; 590; 6.
Desrosiers, L, et al.; Urogynecologic conditions: interstitial cystitis/painful bladder syndrome; FP Essent; 2015; 17-22; 430;Abstract.
De Groat, WC, et al.; Impact of Bioelectronic Medicine on the Neural Regulation of Pelvic Visceral Function; Bioelectron Med; 2015; 25-36; 2015.
Comiter, CV; Conscious Neuromodulation of the Bladder before Clinical Use; J Urol; 2015; 16-17; 194.
Colaco, M, et al.; Current guidelines in the management of interstitial cystitis; Tranl Androl Urol; 2015; 677-683; 4.
Chan, DK, et al.; Effective treatment of dyssynergic defecation using sacral neuromodulation in a patient with cerebral palsy; Female Pelvic Med Reconstr Surg; 2015; e27-29; 21;Abstract.
Canbaz Kabay, S, et al.; Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients; 12-months results; Neurourol Urodyn; 2015;Abstract.
Brown, ET, et al.; New evidence in the treatment of overactive bladder; Curr Opin Obstet Gynecol; 2015; 366-372; 27.
Brink, TS, et al.; A Chronic, Conscious Large Animal Platform to Quantify Therapeutic Effects of Sacral Neuromodulation on Bladder Function; J Urol; 2015; 252-258; 194.
Beusterien, K, et al.; Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder; Neurourol Urodyn; 2015;Abstract.
Bertapelle, MP, et al.; Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System; World J Urol; 2015; 1109-1117; 33.
Bayrak, O, et al.; Botulinum toxin injections for treating neurogenic detrusor overactivity; Turk J Urol; 2015; 221-227; 41.
Banakhar, M, et al.; Sacral neuromodulation for Genitourinary Problems; Prog Neurol Surg; 2015; 192-199; 29;Abstract.
Aoun, F, et al.; [Lower urinary tract dysfunction following radical hysterectomy]; Prog Urol; 2015; 1184-1190; 25;Abstract.
Zheng, J, et al.; [Sacral Neuromodulation in the treatment of intractable constipation]; Zhonghua Wei Chang Wai Ke Za Zhi; 2015; 1175-1178; 17;Abstract.
Zhao, X, et al.; Diffused and sustained inhibitory effects of intestinal electrical stimulation on intestinal motility mediated via sympathetic pathway; Neuromodulation; 2014; 373-379; discussion 380; 17.
Zhang, N, et al.; Transcutaneous Neuromodulation at Posterior Tibial Nerve and ST36 for Chronic Constipation; Evid Based Complement Alternat Med; 2014; 560802; 2014.
Zecca, C, et al.; Motor and sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practive; Eur J Neurol; 2014; 506-511; 21.
Yang, G, et al.; Pudendal nerve stimulation and block by a wireless-controlled implantable stimulator in cats; Neuromodulation; 2014; 490-496; discussion 496; 17.
Xiao, Z, et al.; Somatic modulation of spinal reflex bladder activity mediated by nociceptive bladder afferent nerve fibers in cats; Am J Physiol Renal Physiol; 2014; F673-679; 307.
Xiao, Z, et al.; Role of spinal GABAA receptors in pudendal inhibition of nociceptive and nonnociceptive bladder reflexes in cats; Am J Physiol Renal Physiol; 2014; F781-789; 306.
Wood, LN, et al.; Urinary incontinence in women; Bmj; 2014; g4531; 349.
Withington, J, et al.; The changing face of urinary continence surgery in England: a perspective from the Hospital Episode Statistics databse; BJU Int; 2014; 268-277; 114.
Wein, AJ; Re: inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; J Urol; 2014; 868-869; 191.
Unger, CA, et al.; Fecal incontinence: the role of the urologist; Curr Urol Rep; 2014; 388; 15.
Tang, H, et al.; Combination of sacral neuromodulation and tolterodine of treatment of idiopathic overactive bladder in women: a clinical trial; Urol J; 2014; 1800-1805; 11.
Sillen, U, et al.; Effects of transcutaneous neuromodulation (TENS) on overactive bladder symptoms in children: a randomized controlled trial; J Pediatr Urol; 2014; 1100-1105; 10.
Shalom, DF, et al.; Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity; Am J Obstet Gynecol; 2014; 561 e561-565; 211.
Schwen, Z, et al.; Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats; Neurourol Urodyn; 2014; 1266-1271; 33.
Possover, M; A novel implantation technique for pudendal nerve stimulation for treatment of overactive bladder and urgency incontinence; J Minim Invasive Gynecol; 2014; 888-892; 21.
Pescatori, LC, et al.; Sphincteroplasty for anal incontinence; Gastroenterol Rep (Oxf); 2014; 92-97; 2.
Peeters, K, et al.; Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction; BJU Int; 2014; 789-794; 113.
Osman, NI, et al.; Fowler's syndrome—a cause of unexplained urinary retention in young women?; Nat Rev Urol; 2014; 87-98; 11;Abstract.
Noblett, KL, et al.; Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction; Am J Obstet Gynecol; 2014; 99-106; 210.
Nambiar, A, et al.; Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO); Neurourol Urodyn; 2014; S21-25; 33 Suppl. 3.
Moon, KH, et al.; Prospective Trial of Sacral Neuromodulation for Refractory Overactive Bladder Syndrome in Korean Patients; Low Urin Tract Symptoms; 2014; 175-179; 6.
Mehnert, U, et al.; The management of urinary incontinence in the male neurological patient; Curr Opin Urol; 2014; 586-592; 24.
Mcnevin, MS, et al.; Outcomes associated with Interstim therapy for medically refractory fecal incontinence; Am J Surg; 2014; 735-737; discussion 737-788; 207.
Mayr, CA, et al.; Cost-effectiveness of novel therapies for overactive bladder; Expert Rev Pharmacoecon Outcomes Res; 2014; 527-535; 14.
Matsuta, Y, et al.; Poststimlation inhibition of the micturition reflex induced by tibial nerve stimulation in rats; Physiol Rep; 2014; e00205; 2.
Mamopoulos, A, et al.; Active sacral neuromodulation during pregnancy: a unique case report; Am J Obstet Gynecol; 2014; e4-5; 211.
Lowette, K, et al.; Role of corticosterone in the murine enteric nervous system during fasting; Am J Physiol Gastointest Liver Physiol; 2014; G905-913; 307.
Lopez-Delgado, A, et al.; Effect on anal pressure of percutaneous posterior tibial nerve stimulation for faecal incontinence; Colorectal Dis; 2014; 533-537; 16.
Lombardi, G, et al.; Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience; Spinal Cord; 2014; 241-245; 52.
Lippmann, QK, et al.; Successful use of sacral neuromodulation in a 12-year-old with cerebral palsy and neurogenic bladder; Neuromodulation; 2014; 396-398; 17.
Levy, RM; The evolving definition of neuromodulation, Neuromodulation; 2014; 207-210; 17.
Levin, PJ, et al.; Psychosocial factors related to the use of InterStim(R) for the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2014; 272-275; 20;Abstract.
Lee, YY; What's New in the Toolbox for Constipation and Fecal Incontinence?; Front Med (Lausanne); 2014; 5; 1.
Laviana, A, et al.; Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome; Neurosurg Clin N Am; 2014; 33-46; 25.
Kurpad, R, et al.; The evaluation and management of refractory neurogenic overactive bladder; Curr Urol Rep; 2014; 444; 15.
Knupfer, SC, et al.; Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction; BMC Urol; 2014; 65; 14.
Kessler, TM, et al., Urologists' referral attitude for sacral neuromodulationfor treating refractory idiopathic overactive bladder syndrome: discrete choice experiment; Neurourol Urodyn; 2014; 1240-1246; 33.
Johnsen, NV, et al.; The role of electrical stimulation techniques in the management of the male patient with urgency incontinence; Curr Opin Urol; 2014; 560-565; 24.
Jacobs, SA, et al.; Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet; Neurourol Urodyn; 2014; 488-492; 33.
Hotouras, A, et al.; Prospective clinical audit of two neuromodulatory treatments for fecal incontinence: sacral nerve stimulation (SNS) and percutaneouls tibial nerve stimulation (PTNS); Surg Today; 2014; 2124-2130; 44.
Hamann, MF, et al.; [Urinary incontinence in men and woman. Diagnostics and conservative therapy]; Urologe A; 2014; 1073-1084; quiz 1085-1076; 53.
Grossi, U, et al.; Sacral neuromodulation for anorectal dysfunction secondary to congenital imperforate anus: report of two cases; Int J Colorectal Dis; 2014; 889-890; 29.
Giarenis, I, et al.; Managing urinary incontinence: what works?; Climacteric; 2014; 26-33; 17 Suppl 2;Abstract.
Foditsch, EE, et al.; Laparoscopic placement of a tined lead electrode on the pudendal nerve with urodynamic monitoring of bladder function during electrical stimulation: an acute experimental study in healthy female pigs; Springerplus; 2014; 309; 3.
Faucheron, JL, et al.; Sacral neuromodulation for bowel dysfunction; Tech Coloproctol; 2014; 42433; 18.
Falletto, E, et al.; Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group; Tech Coloproctol; 2014; 53-64; 18.
Evers, J, et al.; Effects of stimulation frequency and intensity in sacral neuromodulation on anorectal inputs to the somatosensory cortex in an experimental model; Br J Surg; 2014; 1317-1328; 101.
Elneil, S, et al.; Optimizing the duration of assessment of stage-1 sacral Neuromodulation in nonobstructive chronic urinary retention; neuromodulation; 2014; 66-70; discussion 70-61; 17.
Duelund-Jakobsen, J, et al.; Baseline factors predictive of patient satisfaction with sacral neuromodulation for idiopathic fecal incontinence; Int J Colorectal Dis; 2014; 793-798; 29.
Donon, L, et al.; [Sacral neuromodulation: results of a monocentric study of 93 patients]; Prog Urol; 2014; 1120-1131; 24;Abstract.
Chen, ML, et al.; Electrical stimulation of somatic afferent nerves in the foot increases bladder capacity in healthy human subjects; J Urol; 2014; 1009-1013; 191.
Chen, G, et al.; Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease; Spinal Cord; 2014;Abstract.
Chandra, A, et al.; Neuromodulation of perineally transposed antropylorus with pudendal nerve anastomosis following total anorectal reconstruction in humans; Neurogastroenterol Motil; 2014; 1342-1348; 26.
Carrington, EV, et al.; A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal incontinence and constipation; Neurogastroenterol Motil; 2014; 1222-1237; 26.
Carlucci, L, et al.; Functional variability of sacral roots in bladder control; J Neurosurg Spine; 2014; 961-965; 21.
Campin, L, et al.; [Urinary functional disorders bound to deep endometriosis and to its treatment: review of the literature]; J Gynecol Obstet Biol Reprod (Paris); 2014; 431-442; 43;Abstract.
Burnstock, G; Purinergic signalling in the gastrointestinal tract and related organs in health and disease; Purinergic Signal; 2014; 18323; 10.
Buhmann, H, et al.; [Update on fecal incontinence]; Praxis (Bern 1994); 2014; 1313-1321; 103.
Gross, T, et al.; Transcutaneous Electrical Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review; Eur Urol; 2016;Abstract.
Bouguen, G, et al.; Effects of transcutaneous tibial nerve stimulation on anorectal physiology in fecal incontinence: a double-blind placebo-controlled cross-over evaluation; Neurogastroenterol Motil; 2014; 247-254; 26.
Banakhar, M, et al.; Effect of sacral neuromodulation on female sexual function and quality of life: Are they correlated?; Can Urol Assoc J; 2014; E762-767; 8.
Balchandra, P, et al.; Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anitcholinerig treatment; Int Urogynecol J; 2014; 1059-1064; 25.
Anger, JT, et al.; The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population; Neuromodulation; 2014; 72-74; discussion 74; 17.
Amundsen, CL, et al.; The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial; Contemp Clin Trials; 2014; 272-283; 37
Abraham, N, et al.; Urgency after a sling: review of the management; Curr Urol Rep; 2014; 400; 15.
Zhang, F, et al.; Neural pathways involved in sacral neuromodulation of reflex bladder activity in cats; Am J Physiol Renal Physiol; 2013; F710-717; 304.
Yih, JM, et al.; Changes in sexual functioning in women after neuromodulation for voiding dysfunction; J Sex Med; 2016; 2477-2483; 10.
Wein, AJ; Re: is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?; J Urol; 2013; 610-611; 189.
Veeratterapillay, R, et al.; Augmentation cystoplasty: Contemporary indications, techniques and complications; Indian J Urol; 2013; 322-327; 29.
Tirlapur, Sa, et al.; Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review; Acta Obstet Gynecol Scand; 2013; 881-887; 92
Thomas, GP, et al.; A pilot study of transcutaneous sacral nerve stimulation for faecal incontinence; Colorectal Dis; 2013; 1406-1409; 15.
Thomas, GP, et al.; Sacral nerve stimulation for faecal incontinence secondary to congenital imperforate anus; Tech Coloproctol; 2013; 227-229; 17.
Thin, NN, et al.; Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence; Br J Surg; 2013; 1430-1447; 100.
Suskin, AM, et al.; Understanding the dissemination of sacral neuromodulation; Surg Innov; 2013; 625-630; 20.
Su, X, et al., Role of the endogenous opioid system in modulation of urinary bladder activity by spinal nerve stimulation; Am J Physiol Renal Physiol; 2013; F52-60; 305.
Su, X, et al.; Quantification of effectivenss of bilateral and unilateral neuromodulation in the rat bladder rhythmic contraction model; BMC Urol; 2013; 34; 13.
Su, X, et al.; Neuromodulation attenuates bladder hyperactivity in a rat cystitis model; BMC Urol; 2013; 70; 13.
Stephany, HA, et al.; Prospective evaluation of sacral nerve modulation in children with validated questionnaires; J Urol; 2013; 1516-1522; 190.
Smits, MA, et al.; Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy; J Urol; 2013; 2148-2152; 190.
Shi, P, et al.; Effects of acute sacral neuromodulation on bladder reflex in complete spinal cord injury rats; Neuromodulation; 2013; 583-589; discussion 589; 16.
Sherif, H, et al.; Posterior tibial nerve stimulation as treatment for the overactive bladder; Arab J Urol; 2013; 131-135; 11.
Sharma, A, et al.; Review of sacral neuromodulation for management of constipation; Surg Innov; 2013; 614-624; 20.
Schwen, Z, et al.; Involvement of 5-HT3 receptors in pudendal inhibition of bladder overactivity in cats; Am J Physiol Renal Physiol; 2013; F663-671; 305.
Schwen, Z, et al.; Inhibition of bladder overactivity by duloxetine in combination with foot stimulation or WAY-100635 treatment in cats; Am J Physiol Renal Physiol; 2013; F1663-1668; 305.
Schuns, O, et al.; Development and characterization of [123]iodotiagabine for in-vivo GABA-transporter imaging; Nucl Med Commun; 2013; 175-179; 34;Abstract.
Robinson, D, et al.; The medical management of refractory overactive bladder; Maturitas; 2013; 386-390; 74.
Robinson, D, et al.; The management of overactive bladder refractory to medical therapy; Maturitas; 2013; 101-104; 75.
Rashid, TG, et al.; Male incontinence: onabotulinum toxin A and sacral nerve stimulation; Curr Opin Urol; 2013; 545-551; 23.
Rana, MV, et al.; Tripolar spinal cord stimulation for the treatment of abdominal pain associated with irritable bowel syndrome; Neuromodulation; 2013; 73-77; discussion 77; 16.
Pucciani, F; A review on functional results of sphincter-saving surgery for rectal cancer: the anterior resection syndrome; Updates Surg; 2013; 257-263; 65.
Peters, KM, et al.; Effect of Sacral Neuromodulation Rate on Overactive Bladder Symptoms: A Randomized Crossover Feasibility Study; Low Urin Tract Symptoms; 2013; 129-133; 5.
Peters, KM, et al.; Does patient age impact outcomes of neuromodulation?; Neurourol Urodyn; 2013; 30-36; 32.
Peters, KM, et al.; Clinical outcomes of sacral neuromodulation in patients with neurologic conditions; Urology; 2013; 738-743; 81.
Peters, KM, et al.; Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study; J Urol; 2013; 2194-2201; 189.
Peng, CW, et al.; Pudendal neuromodulation with a closed-loop control strategy to improve bladder functions in the animal study; Conf Proc IEEE Eng Med Biol Soc; 2013; 3626-3629; 2013.
Osman, NI, et al.; Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches; Arab J Urol; 2013; 313-318; 11.
Offiah, I, et al.; Interstitial cystitis/bladder pain syndrome: diagnosis and management; Int Urogynecol J; 2013; 1243-1256; 24.
Schneider, MP, et al.; Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review; Eur Urol; 2015; 859-867; 68.
Natalin, R, et al., Management of OAB in those over age 65; Curr Urol Rep; 2013; 379-385; 14.
Murphy, AM, et al., Treatment of overactive bladder: what is on the horizon?; Int Urogynecol J; 2013; 42503; 24.
Matsuta, Y, et al.; Effect of methysergide on pudendal inhibition of micturition reflex in cats; Exp Neurol; 2013; 250-258; 247.
Matsuta, Y, et al.; Contribution of opioid and metabotropic glutamate receptor mechanisms to inhibition of bladder overactivity by tibial nerve stimulation; Am J Physiol Regul Integr Comp Physiol; 2013; R126-133; 305.
Martinson, M, et al.; Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation; J Urol; 2013; 2010-216; 189.
Mally, AD, et al.; Role of opioid and metabotropic glutamate 5 receptors in pudendal inhibition of bladder overactivity in cats; J Urol; 2013; 1574-1579; 189.
Maher, RM, et al.; A novel externally applied neuromuscular stimulator for the treatment of stress urinary incontinence in women—a pilot study; Neuromodulation; 2013; 590-594; discussion 594; 16.
Lombardi, G, et al.; Intravesical electrostimulation versus sacral neuromodulation for incomplete spinal cord patients suffering from neurogenic non-obstructive urinary retention; Spinal Cord; 2013; 571-578; 51.
Kantartzis, KL, et al.; Cost-effectiveness of test phase implantation strategies for InterStim(R) sacral neuromodulation; Female Pelvic Med Reconstr Surg; 2013; 322-327; 19;Abstract.
Kacker, R, et al.; Electrical and mechanical office-based neuromodulation; Urol Clin North Am; 2013; 581-589; 40.
Jadav, AM, et al.; Does sacral nerve stimulation improve global pelvic function in women?; Colorectal Dis; 2013; 848-857; 15.
Hyun, SJ, et al.; Comparative analysis between thoracic spinal cord and sacral neuromodulation in a rat spinal cord injury model: a preliminary report of a rat spinal cord stimulation model; Korean J Spine; 2013; 14-18; 10.
Hull, T, et al.; Long-term durability of sacral stimulation therapy for chronic fecal incontinence; Dis Colon Rectum; 2013; 234-245; 56.
Hersh, L, et al.; Clinical management of urinary incontinence in women; Am Fam Physician; 2013; 634-640; 87.
Hellstrom, PA, et al.; Sacral nerve stimulation lead implantation using the O-arm; BMC Urol; 2013; 48; 13.
Hassouna, M; Sacral neuromodulation for overactive bladder: Is it worth it?; Can Urol Assoc J; 2013; E454; 7.
Gleason, JL, et al.; Sacral neuromodulation effects on periurethral sensation and urethral sphincter activity; Neurourol Urodyn; 2013; 476-479; 32.
Gibbons, SJ et al.; Review article: carbon monoxide in gastrointestinal physiology and its potential in therapeutics; Aliment Pharmacol Ther; 2013; 689-702; 38.
Giarenis, I, et al.; Management of refractory overactive bladder; Minerva Ginecol; 2013; 41-52; 65;Abstract.
Firoozi, F, et al.; Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged; J Urol; 2013; 594-597; 190.
Ellsworth, P, et al.; Neurogenic detrusor overactivity: an update on management options; R I Med J (2013); 2013; 38-40; 96.
Dudding, TC, et al.; Sacral nerve stimulation: an effective treatment for chronic functional anal pain?; Colorectal Dis; 2013; 1140-1144; 15.
Davis, T, et al.; Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability; Can Urol Assoc J; 2013; 176-178; 7.
Cornu, JN; Actual treatment of overactive bladder and urge urinary incontinence; Minerva Urol Nefrol; 2013; 21-35; 65;Abstract.
Chiarioni, G, et al.; Neuromodulation for fecal incontinence: an effective surgical intervention; World J Gastroenterol; 2013; 7048-7054; 19.
Chen, SC, et al.; Pudendal neuromodulation improvies voiding efficiency in diabetic rats; Neurourol Urodyn; 2013; 293-300; 32.
Carlson, JJ, et al.; Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States; Clin Ther; 2013; 414-424; 35.
Cameron, AP, et al.; Battery explanation after sacral neuromodulation in the Medicare population; Neurourol Urodyn; 2013; 238-241; 32.
Burnstock, G; Introduction and perspective, historical note; Front Cell Neurosci; 2013; 227; 7.
Brown, SR, et al.; Surgery for faecal incontinence in adults; Cochrane Database Syst Rev; 2013; Cd001757; 7.
Bleier, JI, et al.; Surgical management of fecal incontinence; Gastroenterol Clin North Am; 2013; 815-836; 42.
Biemans, JM, et al.; Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review; Neuromodulation; 2013; 25-33; discussion 33; 16.
Benson-Cooper, S, et al.; Introduction of sacral neuromodulation for the treatment of faecal incontinence; N Z Med J; 2013; 47-53; 126.
Bartley, JM, et al.; Understanding clinic options for overactive bladder; Curr Urol Rep; 2013; 541-548; 14.
Bartley, J, et al.; Neuromodulation for overactive bladder; Nat Rev Urol; 2013; 513-521; 10.
Barroso, U, JR., et al.; Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children; J Urol; 2013; 673-677; 190.
Barnett, G, et al.; Re: Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation: m. Martinson, S. MacDiarmid and E. Black J Urol 2013; 189; 210-216; J Urol; 2013; 1444-1445; 190.
Amend, B, et al.; Prolonged percutaneous SNM testing does not cause infection-related explanation; BJU Int; 2013; 485-491; 111.
Abdel Raheem, A, et al.; Voiding dysfunction in women: How to manage it correctly; Arab J Urol; 2013; 319-330; 11.
Zhang, F, et al.; Inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; Am J Physiol Renal Physiol; 2012; F1576-1582; 302.
Worsoe, J, et al.; Turning off sacral nerve stimulation does not affect gastric and small intestinal motility in patients treated for faecal incontinence; Colorectal Dis; 2012; e713-720; 14.
Van Wunnik, BP, et al.; Cost-effectiveness analysis of sacral neuromodulation for faecal incontinence in The Netherlands; Colorectal Dis; 2012; e807-814; 14.
Van Wunnik, BP, et al.; Sacral neuromodulation therapy: a promising treatment for adolescents with refractory functional constipation; Dis Colon Rectum; 2013; 278-285; 55.
Van Ophoven, A, et al., [The future of invasive neuromodulation: new techniques and expanded indications]; Urologe A; 2012; 212-216; 51.
Tai, C, et al.; Bladder inhibition by intermittent pudendal nerve stimulation in cat using transdermal amplitude-modulated signal (TAMS); Neurourol Urodyn; 2012; 1181-1184; 31.
Tai, C, et al.; Inhibition of bladder overactivity by stimulation of feline pudendal nerve using transdermal amplitude-modulated signal (TAMS); BJU Int; 2012; 782-787; 109.
Su, X, et al.; Neuromodulation in a rat model of the bladder micturition reflex; Am J Physiol Renal Physiol; 2012; F477-486; 302.
Su, X, et al.; Comparison of neural targets for neuromodulation of bladder micturition reflex in the rat; Am J Physiol Renal Physiol; 2012; F1196-1206; 303.
Steanu, ID, et al,; The Place of the Ice Water Test (IWT) in the Evaluation of the Patients with Traumatic Spinal Cord Injury; Maedica (Buchar); 2012; 125-130; 7.
Srivastava, D; Efficacy of sacral neuromodulation in treating chronic pain related to painful bladder syndrome/interstitial cystitis in adults; J Anaesthesiol Clin Pharmacol. 2012; 428-435; 28.
Snellings, AE, et al.; Effects of stimulation site and stimulation parameters on bladder inhibition by electrical nerve stimulation; BJU Int; 2012; 136-143; 110
Smits, MA, et al.; [Neuromodulation as a treatment for overactive bladder syndrome]; Ned Tijdschr Geneeskd; 2012; A4135; 156;Abstract.
Smith, AL, et al.; Contemporary management of overactive bladder; Postgrad Med; 2012; 104-116; 124;Abstract.
Sivalingam, N, et al.; Concepts in the management of the overactive bladder in women; Med J Malaysia; 2012; 137-141; quiz 142; 67.
Sievert, KD, et al.; [Unconventional treatment procedures of the bladder in paraplegia and myelomeningocele]; Urologe A; 2012; 1692-1696; 51.
Schwalenberg, T, et al.; [Sacral neuromodulation in urology—development and current status]; Aktuelle Urol; 2012; 39-48; 43;Abstract.
Sajadi, KP, et al.; Bladder augmentation and urinary diversion for neurogenic LUTS: current indications; Curr Urol Rep; 2012; 389-393; 13.
Robinson, D, et al.; Overactive bladder: diagnosis and management; Maturitas; 2012; 188-193; 71.
Rawashdeh, YF, et al.; International Children's Continence Society's recommendations for therapeutic intervention in congenital neurophatic bladder and bowel dysfunction in children; Neurourol Urodyn; 2012; 615-620; 31.
Rai, BP, et al.; Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults; Cochrane Database Syst Rev; 2012; Cd003193; 12;Abstract.
Qin, C, et al.; Is constant current or constant voltage spinal cord stimulation superior for the suppression of nociceptive visceral and somatic stimuli? A rat model; Neuromodulation; 2012; 132-142; discussion 143; 15.
Peters, KM; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: pro; J Urol; 2012; 2043-2044; 188.
Penson, DF; Re: Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin a treatment for patients with idiopathic overactive bladder; J Urol; 2012; 2157-2158; 187.
Otto, W, et al.; [Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a German high-volume clinic]; Aktuelle Urol; 2012; 162-166; 43;Abstract.
Meurette, G, et al.; Sacral nerve stimulation enhances epithelial barrier of the rectum: results from a porcine model; Neurogastroenterol Motil; 2012; 267-273, e110; 24.
Mehnert, U, et al.; [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options]; Urologe A; 2012; 189-197; 51.
Majerus, SJ, et al.; Wireless, Ultra-Low-Power Implantable Sensor for Chronic Bladder Monitoring; ACM J Emerg Technol Comput Syst; 2012;8.
Madersbacher, H, et al.; What are the causes and consequences of bladder overdistention? ICI-RS 2011; Neurourol Urodyn; 2012; 2012; 317-321; 31.
Levin, PJ, et al.; The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review; Int Urogynecol J; 2012; 1591-1597; 23.
Leicht, W, et al.; [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity]; Urologe A; 2012; 348-351; 51.
Lay, AH, et al.; The role of neuromodulation in patients with neurogenic overactive bladder; Curr Urol Rep; 2012; 343-347; 13.
Koldewun; EL; [What to do if pills do not work for urge incontinence—still many questions and ambiguities]; Ned Tijdschr Geneeskd; 2012; A5099; 156;Abstract.
Kessler, TM, et al.; [Sacral neuromodulation for neurogenic bladder dysfunction]; Urologe A; 2012; 179-183; 51.
Kantartzis, K, et al.; Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder; Curr Opin Obstet Gynecol; 2012; 331-336; 24.
Hubsher, CP, et al.; Sacral nerve stimulation for neuromodulation of the lower urinary tract; Can J Urol; 2012; 6480-6484; 19.
Guerci, B, et al.; Gastric electrical stimulation for the treatment of diabetic gastroparesis; Diabetes Metab; 2012; 393-402; 38.
Groen, LA, et al.; Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms; 15-year experience; J Urol; 2012; 1313-1317; 188.
Gill, BC, et al.; Improvement of bower dysfunction with sacral neuromodulation for refractory urge urinary incontinence; Int Urogynecol J; 2012; 735-741; 23.
Ghiselli, R, et al.; Nitric oxide synthase expression in rat anorectal tissue after sacral neuromodulation; J Surg Res; 2012; 29-33; 176.
Evans, RJ; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: con; J Urol; 2012; 2044-2045; 188.
Elser, DM; Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management; Postgrad Med; 2012; 42-49; 124;Abstract.
Elkelini, MS, et al.; Mechanism of action of sacral nerve stimulation using a transdermal amplitude-modulated signal in a spinal cord injury rodent model; Can Urol Assoc J; 2012; 227-230; 6.
Dwyer, ME, et al.; The dysfunctional elimination syndrome in children—is sacral neuromodulation worth the trouble?; J Urol; 2012; 1076-1077; 188.
Devroede, G, et al.; Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation; Female Pelvic Med Reconstr Surg; 2012; 103-112; 18;Abstract.
Denzinger, S, et al.; Does sacral neuromodulation lead to relevant reduction in the need for intermittent catheterization? A single-center experience on patients with chronic urinary retention; Neuromodulation; 2012; 586-591; discussion 591; 15.
Del Popolo, G, et al.; [Standard pharmacological treatment and new therapies for overactive bladder]; Urologia; 2012; 42534; 79.
Crock, LW, et al.; Central amygdala metabotropic glutamate receptor 5 in the modulation of visceral pain; J Neurosci; 2012; 14217-14226; 32.
Chen, G, et al.; The inhibitory effects of pudendal nerve stimulation on bladder overactivity in spinal cord injury dogs: is early stimulation necessary?; Neuromodulation; 2012; 232-237; discussion 237; 15.
Cardarelli, S, et al.; Efficacy of sacral neuromodulation on urological diseases: a multicentric research project; Urologia; 2012; 90-96; 79.
Burnstock, G; Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future; Bioessays; 2012; 218-225; 34.
Banakhar, MA, et al.; Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem; Ther Adv Urol; 2012; 179-185; 4.
Arrabal-Polo, MA, et al.; Clinical efficacy in the treatment of overactive bladder refractory to anticholinergics by posterior tibial nerve stimulation; Korean J Urol; 2012; 483-486; 53.
Arnold, J, et al.; Overactive bladder syndrome—management and treatment options; Aust Fam Physician; 2012; 878-883; 41.
Allahdin, S, et al.; An overview of treatment of overactive bladder syndrome in women; J Obstet Gynaecol; 2012; 217-221; 32.
Zullo, MA, et al.; Sacral neuromodulation after stabilization of L2-S1 vertebrae with metallic fixation devices: is it feasbile?; Int Urogynecol J; 2011; 373-375; 22.
Yazdany, T, et al.; Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women; Int Urogynecol J; 2011; 1549-1554; 22.
Wu, JM, et al.; Patient preferences for different severities of and treatments for overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 184-189; 17;Abstract.
Van Wunnik, BP, et al.; Patient experience and satisfaction with sacral neuromodulation: results of a single-center sample survey; Dis Colon Rectum; 2011; 95-100; 54.
Van Wunnik, BP, et al.; Neuromodulation for constipation: sacral and transcutaneous stimulation; Best Pract Res Clin Gastroenterol; 2011; 181-191; 25.
Van Koeveringe, GA, et al.; Detrusor underactivity: a plea for new approaches to a common bladder dysfunction; Neurourol Urodyn; 2011; 723-728; 30.
Van Kerrebroeck, P; Editorial comment re: Killinger et al. “Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation”; Neurourol Urodyn; 2011; 1403; 30.
Vaarala, MH, et al.; Sacral neuromodulation in urological indications: the Finnish experience; Scand J Urol Nephrol; 2011; 46-51; 45.
Uludag, O, et al.; Sacral neuromodulation: long-term outcome and quality of life in patients with faecal incontinence; Colorectal Dis; 2011; 1162-1166; 13.
Ullah, S, et al.; Temporary gastric neuromodulation for intractable nausea and vomiting; Ann R Coll Surg Engl; 2011; 624-628; 93.
Thoua, NM, et al.; Internal anal sphincter atropy in patients with systemic sclerosis; Rheumatology (Oxford); 2011; 1596-1602; 50.
Tai, C, et al.; Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats; Am J Physiol Renal Physiol; 2011; F385-392; 300.
Tai, C, et al.; Irritation induced bladder overactivity is suppressed by tibial nerve stimulation in cats; J Urol; 2011; 326-330; 186.
Signorello, D, et al.; Impact of sacral neuromodulation on female sexual function and his correlation with clinical outcome and quality of life indexes: a monocentric experience; J Sex Med; 2011; 1147-1155; 8.
Shepherd, JP, et al.; InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence: A Decision Analysis Comparing Outcomes Including Efficacy and Complications; Female Pelvic Med Reconstr Surg; 2011; 199-203; 17;Abstract.
Shen, B, et al.; Neuromodulation of bladder activity by stimulation of feline pudendal nerve using a transdermal amplitude modulated signal (TAMS); Neurourol Urodyn; 2011; 1686-1694; 30.
Sharma, A, et al.; Sacral neuromodulation for the management of severe constipation: development of a constipation treatment protocol; Int J Colorectal Dis; 2011; 1583-1587; 26.
Sahai, A, et al.; Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management; Curr Urol Rep; 2011; 404-412; 12.
Richter, EO, et al.; Percutaneous cephalocaudal implantation of epidural stimulation electrodes over sacral nerve roots—a technical note on the importance of the lateral approach; Neuromodulation; 2011; 62-67; discussion 67; 14.
Possover, M, et al.; Risks, symptoms, and management of pelvic nerve damage secondary to surgery for pelvic organ prolapse: a report of 95 cases; Int Urogynecol J; 2011; 1485-1490; 22.
Peters, KM, et al.; Is sensory testing during lead placement crucial for achieving positive outcomes after sacral neuromodulation?; Neurourol Urodyn; 2011; 1489-1492; 30.
Pena, G, et al.; Cholinergic regulatory lymphocytes re-establish neuromodulation of innate immune responses in sepsis; J Immunol; 2011; 718-725; 187.
Pascual, I, et al.; Sacral nerve stimulation for fecal incontinence; Rev Esp Enferm Dig; 2011; 355-359; 103.
Oerlemans, DJ, et al.; Is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?; Neurourol Urodyn; 2011; 1493-1496; 30.
Miotla, P, et al.; [Sacral nerve stimulation in the treatment of the lower urinary tract function disorders]; Ginekol Pol; 2011; 851-856; 82.
Marcelissen, TA, et al.; The use of bilateral sacral nerve stimulation in patients with loss of unilateral treatment efficacy; J Urol; 2011; 976-980; 185.
Marcelissen, TA, et al.; Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment; BJU Int; 2011; 1834-1838; 108.
Marcelissen, TA, et al.; The effect of pulse rate changes on the clinical outcome of sacral neuromodulation; J Urol; 2011; 1781-1785; 185.
Marcelissen, T, et al.; Is the screening method of sacral neuromodulation a prognostic factor for long-term success?; J Urol; 2011; 583-587; 185.
Marcelissen, T, et al.; Sacral neuromodulation as a treatment for chronic pelvic pain; J Urol; 2011; 387-393; 186.
Majerus, SJ, et al.; Low-power wireless micromanometer system for acute and chronic bladder-pressure monitoring; IEEE Trans Biomed Eng; 2011; 763-767; 58.
Lombardi, G, et al.; Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in patients with incomplete spinal cord injury; Spinal Cord; 2011; 629-636; 49.
Liberman, D, et al.; Concerns regarding sacral neuromodulation as a treatment option for medical-refractory overactive bladder; Can Urol Assoc J; 2011; 285-287; 5.
Leong, RK, et al.; Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey; J Urol. 2011; 588-592; 185.
Leong, RK, et al.; PNE versus 1st stage tine lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy; Neurourol Urodyn; 2011; 1249-1252; 30.
Leong, RK, et al.; Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder; BJU Int; 2011; 558-564; 108.
Le, NB, et al.; Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery; Curr Bladder Dysfunct Rep; 2011; 25-30; 6.
Kubota, M, et al.; Effect of neuromodulation with sacral magnetic stimulation for intractable bowel or bladder dysfunction in postoperative patients with anorectal malformation; a preliminary report; Pediatr Surg Int; 2011; 599-603; 27.
Knupfer, S, et al.; [Therapy-refractory overactive bladder: alternative treatment approaches]; Urologe A; 2011; 806-809; 50.
Killinger, KA, et al.; Seconary changes in bowel function after successful treatment of voiding symptoms with neuromodulation; Neurourol Urodyn; 2011; 133-137; 30.
Griffin, KM, et al.; Sacral nerve stimulation increases activation of the primary somatosensory cortex by anal canal stimulation in an experimental model; Br J Surg; 2011; 1160-1169; 98.
Gill, BC, et al.; Improved sexual and urinary function in women with sacral nerve stimulation; Neuromodulation; 2011; 436-443; discussion 443; 14.
Ghazwani, YQ, et al.; Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up; Neurourol Urodyn; 2011; 1271-1275; 30.
George, E, et al.; Use of combined anticholinergic medication and sacral neuromodulation in the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 97-99; 17;Abstract.
Gajewski, JB, et al.; The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre; BJU Int; 2011; 1258-1264; 107.
Gaj, F, et al.; [Chronic pelvic pain treatment with posterior tibial nerve stimulation]; Clin Ter; 2011; e111-114; 162;Abstract,
Duthie, JB, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2011; Cd005493.
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: optimizing outcome and managing complications; Colorectal Dis; 2011; e196-202; 13.
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: patient selection, service provision and operative technique; Colorectal Dis; 2011; e187-195; 13.
Dudding, TC; Future indications for sacral nerve stimulation; Colorectal Dis; 2011; 23-28; 13 Suppl 2.
De Gennaro, M, et al.; Current state of nerve stimulation technique for lower urinary tract dysfunction in children; J Urol; 2011; 1571-1577; 185.
Chartier-Kastler, E, et al.; [Sacral neuromodulation with InterStim system: Results from the French national register]; Prog Urol; 2011; 209-217; 21;Abstract.
Chaabane, W, et al.; Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study; Neurourol Urodyn; 2011; 547-550; 30.
Burnstock, G, et al.; P2X receptors in health and disease; Adv Pharmacol; 2011; 333-372; 61;Abstract.
Burnstock, G; Intrductory overview of purinergic signalling; Front Biosci (Elite Ed); 2011; 896-900; 3;Abstract.
Baeten, CG; Status of sacral neuromodulation for refractory constipation; Colorectal Dis; 2011; 19-22; 13 Suppl 2.
Atnip, S, et al.; A unique approach to severe constipation; Urol Nurs; 2011; 348-350; 31.
Arlandis, S, et al.; Cost-effectivenss of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder; Value Health; 2011; 219-228; 14.
Apostolidis, A; Neuromodulation for intractable OAB; Neurourol Urodyn; 2011; 766-770; 30.
Al-Zharani, AA, et al.; Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center; J Urol; 2011; 981-986; 185.
Al-Shaui, TF, et al.; Pelvic electrical neuromodulation for the treatment of overactive bladder syndrome; Adv Urol; 2011; 757454; 2011.
Zempleni, MZ, et al.; Cortical substrate of bladder control in SCI and the effect of peripheral pudendal stimulation; Neuroimage; 2010; 2983-2994; 48.
Yoong, W, et al.; Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol; BJU Int; 2010; 1673-1676; 106.
Wolff, K, et al.; Functional outcome and quality of life after stapled transanal rectal resection for obstructed defecation syndrome; Dis Colon Rectum; 2010; 881-888; 53.
Wehbe, SA, et al.; Sacral neuromodulations for femal lower urinary tract, pelvic floor, and bowel disorders; Curr Opin Obstet Gyncol; 2010; 414-419; 22.
Wehbe, SA, et al.; Minimally invasive therapies for chronic pelvic pain syndrome; Curr Urol Rep; 2010; 276-285; 11.
Watanabe, JH, et al.; Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder; Urology; 2010; 835-840; 76.
Vasdev, N, et al.; The surgical management of the refractory overactive bladder; Indian J Urol; 2010; 263-269; 26.
Van Kerrebroeck, PE; Advances in the role of sacral nerve neuromodulation in lower urinary tract symptoms; Int Urogynecol J; 2010; S467-474; 21 Suppl 2.
Vallet, C, et al.; Sacral nerve stimulation for faecal incontinence: response rate, satisfaction and the value of preoperative investigation in patient selection; Colorectal Dis; 2010; 247-253; 12.
Uludag, O, et al.; Sacral neuromodulation: does it affect the rectoanal angle in patients with fecal incontinene?; World J Surg; 2010; 1109-1114; 34.
Thompson, JH, et al.; Sacral neuromodulation: Therapy evolution; Indian J Urol; 2010; 379-384; 26.
Stoffel, JT; Contemporary management of the neurogenic bladder for multiple sclerosis patients; Urol Clin North Am; 2010; 547-557; 37.
Starkman, JS, et al.; Surgical options for drug-refractory overactive bladder patients; Rev Urol; 2010; e97-e110; 12.
Sievert, KD, et al.; Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury; Ann Neurol; 2010; 74-84; 67.
Sancaktar, M, et al.; The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder; Gynecol Endocrinol; 2010; 729-732; 26.
Sajadi, KP, et al.; Overactive bladder after sling surgery; Curr Urol Rep; 2010; 366-371; 11.
Roth, TM; Sacral neuromodulation and cardiac pacemakers; Int Urogynecol J; 2010; 1035-1037; 21.
Roth, TM; Subcapsular relocation for sacral neuromodulation pulse generator implant revision; Neuromodulation; 2010; 145-146; 13.
Riguad, J, et al.; [Specific treatments for painful bladder syndrome]; Prog Urol; 2010; 1044-1053; 20;Abstract.
Ridout, AE, et al.; Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy; J Obstet Gynaecol; 2010; 111-114; 30.
Reyblat, P, et al.; Augmentation enterocystoplasty in overactive bladder: is there still a role?; Curr Urol Rep; 2010; 432-439; 11.
Powell, CR, et al.; Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures; J Urol; 2010; 173-176; 183.
Possover, M; The laparoscopic implantation of neuroprothesis to the sacral plexus for therapy of neurogenic bladder dysfunctions after failure of percutaneous sacral nerve stimulation; Neuromodulation; 2010; 141-144; 13.
Peters, KM, et al.; Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms; Neurourol Urodyn; 2010; 1267-1271; 29.
Peters, KM, et al.; Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial; J Urol; 2010; 1438-1443; 183.
Peters, KM; Alternative approaches to sacral nerve stimulation; Int Urogynecol J; 2010; 1559-1563; 21.
Peirce, C, et al.; Central representation of the inferior rectal nerve of the rat; Dis Colon Rectum; 2010; 315-320; 53.
Oom, DM, et al.; Is sacral neuromodulation for fecal incontinence worthwhile in patients with associated pelvic floor injury?; Dis Colon Rectum; 2010; 422-427; 53.
Occhino, JA, et al.; Sacral nerve modulation in overactive bladder; Curr Urol Rep; 2010; 348-352; 11.
Nilsson, KF, et al.; Estimation of endogenous adenosine activity at adenosine receptors in guinea-pig ileum using a new pharmacological method; Acta Physiol (Oxf); 2010; 231-241; 199.
Mayer, R; Neuromodulation—who, what, when, where and why?; J Urol; 2010; 17-18; 183.
Marcelissen, TA, et al.; Long-term results of sacral neuromodulation with the tined lead procedure; J Urol; 2010; 1997-2000; 184.
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord-injured patients suffering from neurogenic bowel dysfunctions; Spinal Cord; 2010; 154-159; 48.
Leong, RK, et al.; Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review; Urol Int; 2010; 245-253; 84.
Kim, JH, et al.; Sacral nerve stimulation for treatment of intractable pain associated with cauda equina syndrome; J Korean Neurosurg Soc; 2010; 473-476; 47.
Kavia, R, et al.; A funcational magnetic resonance imaging study of the effect of sacral neuromodulation on brain responses in women with Fowler's syndrome; BJU Int; 2010; 366-372; 105.
Karram, MM; Sacral neuromodulation: emerging technology with expanding indications; Int Urogynecol J; 2010; 1443; 21.
Kacker, R, et al.; Selection of ideal candidates for neuromodulation in refractory overactive bladder; Curr Urol Rep; 2010; 372-378; 11.
Indinnimeo, M, et al.; Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness; Dis Colon Rectum; 2010; 1661-1669; 53.
Hull, TL; Sacral neuromodulation stimulation in fecal incontinence; Int Urogynecol J; 2010; 1565-1568; 21.
Hoda, MR, et al.; [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine]; Urologe A; 2010; 1254-1259; 49.
Haddad, M, et al.; Sacral neuromodulation in children with urinary and fecal incontinence: a multicenter, open label, randomized, crossover study; J Urol; 2010; 696-701; 184.
Gulur, DM, et al.; Management of overactive bladder; Nat Rev Urol; 2010; 572-582; 7.
French, JS, et al.; What do spinal cord injury consumers want? A review of spinal cord injury consumer priorities and neuroprosthesis from the 2008 neural interfaces conference; Neuromodulation; 2010; 229-231; 13.
Foon, R, et al.; The overactive bladder; Ther Adv Urol; 2010; 147-155; 2.
Findlay, JM, et al.; Peripheral neuromodulation via posterior tibial nerve stimulation—a potential treatment for faecal incontinence?; Ann R Coll Surg Engl; 2010; 385-390; 92.
Fariello, JY, et al.; Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction; Int Urogynecol J; 2010; 1553-1558; 21.
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2010; 35-48; 57.
Elneil, S; Urinary retention in women and sacral neuromodulation; Int Urogynecol J; 2010; S475-483; 21 Suppl 2.
Ellsworth, P, et al.; Update on the pharmacologic management of overactive bladder: the present and the future; Urol Nurs; 2010; 29-38, 53; 30.
Daniels, DH, et al.; Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction; Neurourol Urodyn; 2010; 578-581; 29.
Carr, MC; Conservative nonsurgical management of spina bifida; Curr Urol Rep; 2010; 109-113; 11.
Cardot, V, et al.; [Guidelines for the treatment of urinary incontinence in women with refractory idiopathic vesical hyperactivity using sacral neuromodulation]; Prog Urol; 2010; S161-169; 20 Suppl 2;Abstract.
Burks, FN, et al.; Neuromodulation and the neurogenic bladder; Urol Clin North Am; 2010; 559-565; 37.
Brouwer, R, et al.; Sacral nerve neuromodulation is effective treatment for fecal incontinence in the presence of a sphincter defect, pudendal neuropathy, or previous sphincter repair; Dis Colon Rectum; 2010; 273-278; 53.
Bosch, JL, et al.; What treatment should we use if drugs fail for OAB; and, what really works after drugs?; Neurourol Urodyn; 2010; 658-661; 29.
Bosch, JL; An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010?; BJU Int; 2010; 1432-1442; 105.
Amend, B, et al.; [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A]; Urologe A; 2010; 245-252; 49.
Wyndaele, JJ; Clinical outcomes of sacral neuromodulation in incomplete spinal cord injured patient suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 427; 47.
Wosnitzer, MS, et al.; The use of sacral neuromodulation for the treatment of non-obstructive urinary retention secondary to Guillain-Barre syndrome; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1145-1147; 20.
Wooldridge, LS; Percutaneous tibial nerve stimulation for the treatment of urinary frequenc, urinary urgency, and urge incontinence: results from a community-based clinic; Urol Nurs; 2009; 177-185; 29.
Vignes, JR, et al.; Animal models of sacral neuromodulation for detrusor overactivity; Neurourol Urodyn; 2009; 42594; 28.
Scaglia, M, et al.; Fecal incontinence treated with acupuncture—a pilot study; Auton Neurosci; 2009; 89-92; 145.
Roth, TM; Blunt trauma leading to delayed extrusion of sacral nerve implant; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 735-737; 20.
Rasmussen, NT, et al.; Successful use of sacral neuromodulation after failed bladder augmentation; Can Urol Assoc J; 2009; E49-50; 3.
Possover, M, et al.; Neuromodulation of the superior hypogastric plexus: a new option to treat bladder atonia secondary to radical pelvic surgery?; Surg Neurol; 2009; 573-576; 72.
Possover, M; The sacral LION procedure for recovery of bladder/rectum/sexual functions in paraplegic patients after explanation of a previous Finetech-Brindley controller; J Minim Invasive Gynecol; 2009; 98-101; 16.
Possover, M; Laparoscopic management of endopelvic etiologies of pudendal pain in 134 consecutive patients; J Urol; 2009; 1732-1736; 181.
Oom, DM, et al.; Anterior sphincteroplasty for fecal incontinence: a single center experience in the era of sacral neuromodulation; Dis Colon Rectum; 2009; 1681-1687; 52.
Moutzouris, DA, et al.; Interstitial cystitis: an unsolved enigma; Clin J Am Soc Nephrol; 2009; 1844-1857; 4.
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 486-491; 47.
Kohli, N, et al.; InterStim Therapy: A Contemporary Approach to Overactive Bladder; Rev Obstet Gyncol; 2009; 18-27; 2.
Kaufmann, S, et al.; Unilateral vs bilateral sacral neuromodulation in pigs with formalin-induced detrusor hyperactivity; BJU Int; 2009; 260-263; 103.
Ingber, MS, et al.; Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit?; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1055-1059; 20.
Herbison, GP, et al.; Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults: Cochrane Database Syst Rev; 2009; Cd004202.
Hartmann, KE, et al.; Treatment of overactive bladder in women; Evid Rep Techol Assess (Full Rep); 2009; 1-120, v.
Govaert, B, et al.; Neuromodulation for functional bowel disorders; Best Pract Res Clin Gastroenterol; 2009; 545-553; 23.
Game, X, et al.; [Alternative treatments for interstitial cystitis]; Prog Urol; 2009; 357-363; 19;Abstract.
Fu, G, et al.; [Neuromodulation for treatment for neurogenic bowel dysfunction]; Zhonghua Wai Ke Za Zhi; 2009; 128-131; 47.
Finazzi-Agro, E, et al.; Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials; Neurourol Urodyn; 2009; 320-324; 28.
Falletto, E, et al.; Is sacral nerve stimulation an effective treatment for chronic idiopathic anal pain?; Dis Colon Rectum; 2009; 456-462; 52.
Chatoor, D, et al.; Constipation and evacuation disorders; Best Pract Res Clin Gastroenterol; 2009; 517-530; 23.
Charter-Kastler, E, et al.; [Update on the second line management of idiopathic overactive bladder]; Prog Urol; 2009; 530-537; 19;Abstract.
Chapple, C, et al.; The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?; BJU Int; 2009; 1188-1190; 104.
Campbell, JD, et al.; Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence; BMC Urol; 2009; 18; 9.
Burnstock, G; Purinergic signalling: past, present and future; Braz J Med Biol Res; 2009; 42437; 42.
Burnstock, G; Purinergic cotransmission; F1000 Biol Rep; 2009; 46; 1.
Burks, FN, et al.; Neuromodulation versus medication for overactive bladder: the case for early intervention; Curr Urol Rep; 2009; 342-346; 10.
Bolton, JF, et al.; Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction?; Curr Opin Urol; 2009; 375-379; 19.
Badlani, GH; Update on lower urinary tract symptoms; ScientificWorldJournal; 2009; 499-500; 9.
Antolak, SJ, JR., et al.; Therapeutic pudendal nerve blocks using corticosteroids cure pelvic pain after failure of sacral neuromodulation; Pain Med; 2009; 186-189; 10.
Zabihi, N, et al.; Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 553-557; 19.
Tjandra, JJ, et al.; Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study; Dis Colon Rectum; 2008; 494-502; 51.
Starkman, JS, et al.; Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 277-282; 19.
Starkman, JS, et al.; The evolution of obstruction induced overactive bladder symptoms following urethrolysis for female bladder outlet obstruction; J Urol; 2008; 1018-1023; 179.
Spinelli, M, et al.; Latest techologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety; Eur Urol; 2008; 1287-1296; 54.
Smaldone, MC, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neurotoxin; Nat Clin Pract Urol; 2008; 120-121; 5.
Skobejko-Wlodarska, L; [Non-neurogenic lower urinary tract dysfunctioin]; Pol Merkur Lekarski; 2008; 131-137; 24 Suppl 4;Abstract.
Seth, A, et al.; What's new in the diagnosis and management of painful bladder syndrome/interstitial cystitis?; Curr Urol Rep; 2008; 349-357; 9.
Robaina Padron, FJ; [Surgical neuromodulation: new frontiers in neurosurgery]; Neurocirugia (Astur); 2008; 143-155; 19;Abstract.
Rittenmeyer, H; Sacral nerve neuromodulation (InterStim). Part I: Review of the InterStim system; Urol Nurs; 2008; 15-20; 28.
Peters, KM, et al.; Characterization of a clinical cohort of 87 women with interstitial cystitis/painful bladder syndrome; Urology; 2008; 634-640; 71.
Perrigot, M, et al., [Perineal electrical stimulation and rehabilitation in urinary incontinence and other symptoms of non-neurologic origin]; Ann Readapt Med Phys; 2008; 479-490; 51;Abstract.
Oerlemans, DJ, et al.; Sacral nerve stimulation for neuromodulation of the lower urinary tract; Neurourol Urodyn; 2008; 28-33; 27.
O'Reilly, BA, et al., A prospective randomised double-blind controlled trial evaluating the effect of trans-sacral magnetic stimulation in women with overactive bladder; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 497-502; 19.
Nitti, VW; Urodynamics, Incontinence, and Neurourology: Highlights from the Society for Urodynamics and Female Urology Annual Winter Meeting, Feb. 28-Mar. 2, 2008; Miami Fl; Rev Urol; 2008; 229-231; 10
Nakib, N, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neuromodulation; Nat Clin Pract Urol; 2008; 118-119; 5.
Minardi, D, et al.; Activity and expression of nitric oxide synthase in rat bladder after sacral neuromodulation; Int J Immunopathol Pharmacol; 2008; 129-135; 21;Abstract.
Milne, JL; Behavioral therapies for overactive bladder: making sense of the evidence; J Wound Ostomy Continence Nurs; 2008; 93-101; quiz 102-103; 35;Abstract.
Mckertich, K; Urinary incontinence-procedural and surgical treatments for women; Aust Fam Physician; 2008; 122-131; 37.
Lombardi, G, et al.; Clinical female sexual outcome after sacral neuromodulation implant for lower urinary tract symptom (LUTS); J Sex Med; 2008; 1411-1417; 5.
Lombardi, G, et al.; Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function; J Sex Med; 2008; 2135-2140; 5.
Liao, KK, et al.; Effect of sacral neuromodulation on the spinal nociceptive reflex of patients with idiopathic overactive bladder; Neuromodulation; 2008; 50-55; 11.
Kutzenberger, J; [Neurogenic urinary incontinence. Value of surgical management]; Urologe A; 2008; 699-706; 47.
Kosan, M, et al.; Alteration in contractile responses in human detrusor smooth muscle from obstructed bladders with overactivity; Urol Int; 2008; 193-200; 80.
Indar, A, et al.; A dual benefit of sacral neuromodulation; Surg Innov; 2008; 219-222; 15.
Groenendijk, PM, et al.; Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence; BJU Int; 2008; 325-329; 101.
Game, X, et al.; Outcome after treatment of detrusor-sphincter dyssynergia by temporary stent; Spinal Cord; 2008; 74-77; 46.
Game, X; [Sacral neuromodulation and sexuality]; Prog Urol; 2008; 167; 18;Abstract.
Ferhi, K, et al.; [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study]; Prog Urol; 2008; 160-166; 18;Abstract.
Faucheron, JL; [Anal incontinence]; Presse Med; 2008; 1447-1462; 37;Abstract.
Fang, Q, et al.; [Morphological study on the role of ICC-like cells in detrusor neuromodulation of rat urinary bladder]; Zhonghua Wai Ke Za Zhi; 2008; 1542-1545; 46.
Doumouchtsis, SK, et al.; Female voiding dysfuncation; Obstet Gynecol Surv; 2008; 519-526; 63.
De Seze, M, et al.; [Peripheral electrical stimulation in neurogenic bladder]; Ann Readapt Med Phys; 2008; 473-478; 51;Abstract.
De Boer, TA, et al.; [Male urinary incontinence]; Ned Tijdschr Geneeskd; 2008; 797-802; 152;Abstract.
Chartier-Kastler, E; Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience; BJU Int; 2008; 417-423; 101.
Burnstock, G; The journey to establish purinergic signalling in the gut; Neurogastroenterol Motil; 2008; 42601; 20 Suppl 1.
Brosa, M, et al.; Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain; Curr Med Res Opin; 2008; 907-918; 24.
Bannowsky, A, et al.; Urodynamic changes and response rates in patients treated with permanent electrodes compared to conventional wire electrodes in the peripheral nerve evaluation test; World J Urol; 2008; 623-626; 26.
Vignes, JR, et al.; Sacral neuromodulation as a functional treatment of bladder overactivity; Acta Neurochir Suppl; 2007; 315-322; 97;Abstract.
Vasavada, SP, et al.; Neuromodulation techniques: a comparison of available and new therapies; Curr Urol Rep; 2007; 455-460; 8.
Van Voskuilen, AC, et al.; Medium-term experience of sacral neuromodulation by tined lead implantation; BJU Int; 2007; 107-110; 99.
Van Kerrebroeck, PE, et al.; Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide-clinical study; J Urol; 2007; 2029-2034; 178.
Van Balken, MR; Percutaneous tibial nerve stimulation: the Urgen PC device; Expert Rev Med Devices; 2007; 693-698; 4.
Unwala, DJ, et al.; Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?; Curr Urol Rep; 2007; 41-424; 8.
Starkman, JS, et al.; Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation, Neurourol Urodyn; 2007; 29-35; discussion 36; 26.
South, MM, et al.; Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation; Int Urogynecol J Pelvic Floor Dysfunct; 2007; 1395-1398; 18.
Sherman, ND, et al.; Current and future techniques of neuromodulation for bladder dysfunction; Curr Urol Rep; 2007; 448-454; 8.
Shamliyan, T, et al.; Prevention of urinary and fecal incontinence in adults; Evid Rep Technol Assess (Full Rep); 2007; 1-379; ;Abstract,
Sevcencu, C; A review of electrical stimulation to treat motility dysfunctions in the digestive tract: effects and stimulation patterns; Neuromodulation; 2007; 85-99; 10.
Sevcencu, C; Gastrointestinal mechanisms activated by electrical stimulation to treat motility dysfunctions in the digestive tract: a review; Neuromodulation; 2007; 100-112; 10.
Schreiber, KL, et al.; Evidence for neuromodulation of enteropathogen invasion in the intestinal mucosa; J Neuroimmune Pharmacol; 2007; 329-337; 2.
Sakas, DE, et al.; An introduction to operative neuromodulation and functional neuroprosthetics, the new frontiers of clinical neuroscience and biotechnology; Acta Neurochir Suppl; 2007; 42439; 97;Abstract.
Reitz, A, et al.; Topographic anatomy of a new posterior approach to the pudendal nerve for stimulation; Eur Urol; 2007; 1350-1355; discussion 1355-1356; 51.
Ratto, C, et al.; Sacral neuromodulation in the treatment of defecation disorders; Acta Neurochir Suppl; 2007; 341-350; 97;Abstract.
Pauls, RN, et al.; Effects of sacral neuromodulation on female sexual function; Int Urogynecol J Pelvic Floor Dysfunct; 2007; 391-395; 18.
Melenhorst, J, et al.; Sacral neuromodulation in patients with faecal incontinence results of the first 100 permanent implantations; Colorectal Dis; 2007; 725-730; 9.
Mcachran, SE, et al.; Sacral neuromodulation in the older woman; Clin Obstet Gynecol; 2007; 735-744; 50.
Lewis, JM, et al.; Non-traditional management of the neurogenic bladder: tissue engineering and neuromodulation; ScientificWorldJournal; 2007; 1230-1241; 7.
Leong, FC, et al.; Neuromodulation for the treatment of urinary incontinence; Mo Med; 2007; 435-439; 104;Abstract.
Kuo, HC; Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction; Urology; 2007; 57-61; discussion; 61-52; 69.
Kessler, TM, et al.; Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland; Eur Urol; 2007; 1357-1363; 51.
Keppene, V, et al.; [Neuromodulation in the managment of neurogenic lower urinary tract dysfunction]; Prog Urol; 2007; 609-615; 17;Abstract.
Karsenty, G, et al.; Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux; J Urol; 2007; 1011-1014; 177.
Iarumov, N, et al.; [Anal incontinence—new methods of surgical treatment using artificial bowel sphincter and sacral nerve stimulation]; Khirurgiia (Soflia); 2007; 40-45;;Abstract.
Hoque, T, et al.; Validation of internal controls for gene expression analysis in the intestine of rats infected with Hymenolepis diminuta; Parasitol Int; 2007; 325-329; 56.
Hashim, H, et al.; Novel uses for antidiuresis; Int J Clin Pract Suppl; 2007; 32-36;;Abstract.
Groenendijk, PM, et al.; Five-Year Follow-up After Sacral Neuromodulation: Single Center Experience; Neuromodulation; 2007; 363-368; 10.
Glinski, RW, et al.; Refractory overactive bladder: Beyond oral anticholinergic therapy; Indian J Urol; 2007; 166-173; 23.
Felt-Bersma, RJ, et al.; Temperature-controlled radiofrequency energy (SECCA) to the anal canal for the treatment of faecal incontinence offers moderate improvement; Eur J Gastroenterol Hepatol; 2007; 575-580; 19;Abstract.
Duthie, J, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2007; Cd005493; ;Abstract,
Dmochowski, R; Neuromodulation and the urinary tract—are we over the rainbow or have we simply stepped through the looking glass?; J Urol; 2007; 1844-1845; 178.
Deffieux, X, et al.; [Voiding dysfunction after surgical resection of deeply infiltrating endometriosis: pathophysiology and management]; Gynecol Obstet Fertil; 2007; S8-13; 35 Suppl 1;Abstract.
Yun, AJ, et al.; Opening the floodgates: benign prostatic hyperplasia may represent another disease in the compendium of ailments causes by the global sympathetic bias that emerges with aging; Med Hyptheses; 2006; 392-394; 67.
Wein, AJ, et al.; Overactive bladder: a better understanding of pathophysiology, diagnosis and management; J Urol; 2006; S5-10; 175.
Van Voskuilen, AC, et al.; Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study; Eur. Urol; 2006; 366-372; 49.
Van Der Pal, F, et al.; Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome: 12-Month Follow-up; Neuromodulation; 2006; 163-171; 9.
Van Der Pal, F, et al.; Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction; Curr Opin Urol; 2006; 261-267; 16.
Van Balken, MR, et al.; Prognostic factors for successful percutaneous tibial nerve stimulation; Eur Urol; 2006; 360-365; 49.
Van Balken, MR, et al.; Sexual functioning in patients with lower urinary tract dysfunction improves after percutaneous tibial nerve stimulation; Int J Impot Res; 2006; 470-475; discussion 476; 18.
Uludag, O, et al.; Sacral neuromodulation; does it affect colonic transit time in patients with faecal incontinence?; Colorectal Dis; 2006; 318-322; 8.
Sherman, ND, et al.; The current use of neuromodulation for bladder dysfunction; Minerva Ginecol; 2006; 283-293; 58;Abstract.
Seif, C, et al.; [Use of permanent electrodes in the peripheral nerve evaluation test (PNE-Test) in comparison to conventional wire electrodes]; Aktuelle Urol; 2006; 277-280; 37;Abstract.
Pelliccioni, G, et al.; External anal sphincter responses after S3 spinal root surface electrical stimulation; Neurourol Urodyn; 2006; 788-791; 25.
Nyarangi-Dix, JN, et al.; [Overactive bladder syndrome. Are there indications for surgical therapy?]; Urologe A; 2006; 1289-1290; 1292; 45.
Nordling, J; Surgical treatment of painful bladder syndrome/interstitial cystitis; Womens Health (Lond Engl); 2006; 233-238; 2.
Ng, CK, et al.; Refractory overactive bladder in men: update on novel therapies; Curr Urol Rep; 2006; 456-461; 7.
Michelsen, HB, et al.; Rectal volume tolerability and anal pressures in patients with fecal incontinence treated with sacral nerve stimulation; Dis Colon Rectum; 2006; 1039-1044; 49.
Lazzeri, M, et al.; The challenge of overactive bladder therapy: alternative to antibuscarinic agents; Int Braz J Urol; 2006; 620-630; 32.
Krivoborodov, GG, et al.; [Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson's disease]; Urologiia; 2006; 42435;;Abstract.
Kenefick, NJ; Sacral nerve neuromodulation for the treatment of lower bowel motility disorders; Ann R Coll Surg Engl; 2006; 617-623; 88.
Humphreys, MR, et al.; Preliminary results of sacral neuromodulation in 23 children; J Urol; 2006; 2227-2231; 176.
Hoch, M, et al.; [Chemical destruction of sacral nerve roots by alcohol injection for the treatment of overactive bladder]; Prog Urol; 2006; 584-587; 16;Abstract.
Hijaz, A, et al.; Complications and troubleshooting of two-stage sacral neuromodulation therapy; a single-institution experience; Urology; 2006; 533-537; 68.
Guys, JM, et al.; [Neurogenic bladder in children: basic principles in diagnosis and treatment]; Ann Urol (Paris); 2006; 15-27; 40;Abstract.
Groen, J, et al.; Sacral neuromodulation women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding; J Urol; 2006; 1005-1009; discussion.
Elkelini, MS, et al.; Safety of MRI at 1.5Tesla in patients with implanted sacral nerve neurostimulator; Eur Urol; 2006; 311-316; 50.
Daneshgari, F; Application for neuromodulation of the lower urinary tract in female urology; Int Braz J Urol; 2006; 262-272; 32.
Corcos, J, et al.; Candian Urological Association guidelines on urinary incontinence; Can J Urol; 2006; 3127-3138; 13;Abstract.
Blok, BF, et al.; Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators; BJU Int; 2006; 1238-1243; 98.
Atiemo, HO, et al.; Evaluation and management of refractory overactive bladder; Curr Urol Rep; 2006; 370-375; 7.
Walter, S; [Duloxetine. A new preparation for patients with urinary incontinence]; Ugeskr Laeger; 2005; 4553-4555; 167;Abstract.
Vignes, JR, et al.; Sacral neuromodulation in lower urinary tract dysfunction; Adv Tech Stand Neurosurg; 2005; 177-224; 30;Abstract.
Spinelli, M, et al.; A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data; Neurourol Urodyn; 2005; 305-309; 24.
Sievert, KD; Neuromodulation; Neurourol Urodyn; 2005; 310; 24.
Sherman, ND, et al.; Sacral neuromodulation for the treatment of refractory urinary urge incontinence after stress incontinence surgery; Am J Obstet Gynecol; 2005; 2083-2087; 193.
Seif, C, et al.; [Pudendal nerve stimulation therapy of the overactive bladder—an alternative to sacral neuromodulation?]; Aktuelle Urol; 2005; 234-238; 36;Abstract.
Riazimand, SH, et al.; Interaction between neurotransmitter antagonists and effect of sacral neuromodulation in rats with chronically hyperactive bladder; BJU Int; 2005; 900-908; 96.
Park, SH, et al.; Overactive bladder: treatment options for the aging woman; Int J Fertil Womens Med; 2005; 37-44; 50;Abstract.
Olujide, LO, et al.; Female voiding dysfunction; Best Pract Res Clin Obstet Gynaecol; 2005; 807-828; 19.
Minardi, D, et al.; Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation: a preliminary report; Neuromodulation; 2005; 176-181; 8.
Miller, JJ, et al.; Diagnosis and treatment of overactive bladder; Minerva Ginecol; 2005; 501-520; 57;Abstract.
Mazo, EB, et al.; [The role of somatosensory evoked potentials in prognosis of efficacy of tibial neuromodulation in patients with hyperactive urinary bladder]; Urologiia; 2005; 49-52; ;Abstract.
Leng, WW, et al.; How sacral nerve stimulation neuromodulation works; Urol Clin North Am; 2005; 42692; 32.
Leclers, F, et al.; [Cystomanometric study of bladder sensation during sacral neuromodulation test]; Prog Urol; 2005; 238-243; 15;Abstract.
Kocjancic, E, et al.; Sacral neuromodulation for urinary retention in a kidney-transplant patient; Urol Int; 2005; 187-188; 75.
Kessler, TM, et al.; Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method?; Eur Urol. 2005; 660-665; 47.
Kavia, R, et al.; Overactive bladder; J R Soc Promot Health; 2005; 176-179; 125;Abstract.
Karsenty, G, et al.; Understanding detrusor sphincter dyssynergia—significance of chronology; Urology; 2005; 763-768; 66.
Karademir, K, et al.; A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation; Scand J Urol Nephrol; 2005; 230-233; 39.
Kapoor, DS, et al.; Combined urinary and faecal incontinence; Int Urogynecol J Pelvic Floor Dysfunct; 2005; 321-328; 16.
Johnston, TE, et al.; Implantable FES system for upright mobility and bladder and bowel function for individuals with spinal cord injury; Spinal Cord; 2005; 713-723; 43.
Jarrett, ME; Neuromodulation for constipation and fecal incontinence, Urol Clin North Am; 2005; 79-87; 32.
Groen, J, et al.; Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mins-stimulator; Neurourol Urodyn; 2005; 226-230; 24.
Freeman, RM, et al.; Overactive bladder; Best Pract Res Clin Obstet Gynaecol; 2005; 829-841; 19.
Everaert, K, et al.; Sacral nerve stimulation for pelvic floor and bladder dysfunction in adults and children; Neuromodulation; 2005; 186-187; 8.
Dasgupta, R, et al.; Changes brain activity following sacral neuromodulation for urinary retention; J Urol; 2005; 2268-2272; 174.
Daneshgari, F, et al.; Future directions in pelvic neuromodulation; Urol Clin North Am; 2005; 113-115, viii; 32.
Craggs, MD; Objective measurement of bladder sensation: use of a new patient-activated device and response to neuromodulation; BJU Int; 2005; 29-36; 96 Suppl 1.
Bernstein, AJ, et al.; Expanding indications for neuromodulation; Urol Clin North Am; 2005; 59-63; 32.
Benson, JT, et al.; Pudendal neuralgia, a severe pain syndrome; Am J Obstet Gynecol; 2005; 1663-1668; 192.
Badawi, JK, et al.; [Current diagnosis and therapy of the overactive bladder and urge incontinence]; Dtsch Med Wochenschr; 2005; 1503-1506; 130;Abstract.
Amundsen, CL, et al.; Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?; Urology; 2005; 746-750; 66.
Amoroso, L, et al.; Sacral-neuromodulation CT-guided; Radiol Med; 2005; 421-429; 109;Abstract.
Van Balken, MR, et al.; The use of electrical devices for the treatment of bladder dysfunction: a review of methods; J Urol; 2004; 846-851; 172.
Uludag, O, et al.; Sacral neuromodulation in patients with fecal incontinence: a single-center study; Dis Colon Rectum; 2004; 1350-1357; 47.
Svensson, L, et al.; Neuromodulation of experimental Shigella infection reduces damage to the gut mucosa; Microbes Infect; 2004; 256-264; 6.
Silveri, M, et al.; Voiding dysfunction in x-linked adrenoleukodystrophy: symptom score and urodynamic findings; J Urol; 2004; 2651-2653; 171.
Seif, C, et al.; Finding with Bilateral Sacral Neurostimulation: Sixty-two PNE-Tests in Patients with Neurogenic and Idiopathic Bladder Dysfunctions; Neuromodulation; 2004; 141-145; 7.
Roupret, M, et al.; Sacral neuromodulation for refractory detrusor overactivity in women with an artificial urinary sphincter; J Urol; 2004; 236-239; 172.
Riazimand, SH, et al.; A rat model for studying effects of sacral neuromodulation on the contractile activity of a chronically inflamed bladder; BJU Int; 2004; 158-163; 94.
Pelaez, E, et al.; [Epidural spinal cord stimulation for interstitial cystitis]; Rev Esp Anestesiol Reanim; 2004; 549-552; 51;Abstract.
Qzyalcin, NS, et al.; [Sacral nerve stimulation in fecal incontinence; efficacy and safety]; Agri; 2004; 35-44; 16;Abstract.
Nijman, RJ; Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children; Urology; 2004; 45-50; 63.
Madersbacher, H; Overactive bladder—a practical approach to evaluation and management; J Med Liban; 2004; 220-226; 52;Abstract.
Krames, E, et al.; Spinal cord stimulation reverses pain and diarrheal episodes of irritable bowel syndrome: a case report; Neuromodulation; 2004; 82-88; 7.
Kessler, TM, et al.; [Urodynamic phenomena in the aging bladder]; Urologe A; 2004; 542-546; 43.
Hashim H, et al.; Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations; Drugs; 2004; 1643-1656; 64.
Guys, JM, et al.; Sacral neuromodulation for neurogenic bladder dysfunction in children; J Urol; 2004; 1673-1676; 172.
Gonzalez-Chamorro, F, et al.; [Neurostimulation and neuromodulation in urinary incontinence]; Rev Med Univ Navarra; 2004; 75-84; 48;Abstract.
Fowler, CJ; The perspective of a neurologist on treatment-related research in fecal and urinary incontinence; Gastroenterology; 2004; S172-174; 126.
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2004; 681-689; 46.
De Gennaro, M, et al.; Percutaneous tibial nerve neuromodulation is well tolerated in children and effective for treating refractory vesical dysfunction; J Urol; 2004; 1911-1913; 171.
Bower, WF, et al.; A review of non-invasive electro neuromodulation as an intervention for non-neurogenic bladder dysfunction in children; Neurourol Urodyn; 2004; 63-67; 23.
Abrams, P; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2004; 1116; 93.
Wein, AJ; Diagnosis and treatment of the overactive bladder; Urology; 2003; 20-27; 62.
Takahashi, S, et al.; Overactive bladder: magnetic versus electrical stimulations; Curr Opin Obstet Gynecol; 2003; 429-433; 15.
Spinelli, M, et al.; New sacral neuromodulation lead for percutaneous implantation using lical anesthesia: description and first experience; J Urol; 2003; 1905-1907; 170.
Shafik, A, et al.; Percutaneous peripheral neuromodulation in the treatment of fecal incontinence; Eur Surg Res; 2003; 103-107; 35.
Seif, C, et al.; Improved sacral neuromodulation in the treatment of the hyperactive detrusor: signal modification in an animal model; BJU Int; 2003; 711-715; 91.
Schurch, B, et al.; Electrophysiological recordings during the peripheral nerve evaluation (PNE) test in complete spinal cord injury patients; World J Urol; 2003; 319-322; 20.
Schonberger, B; [Bladder dysfunction and surgery in the small pelvis. Therapeutic possibilities]; Urologe A; 2003; 1569-1575; 42.
Scheepens, WA, et al.; Urodynamic results of sacral neuromodulation correlate with subjective improvement in patients with an overactive bladder; Eur Urol; 2003; 282-287; 43.
Ruffion, A, et al.; [Two indications for bilateral neuromodulation]; Prog Urol; 2003; 1394-1396; 13;Abstract.
Ruffion, A, et al.; [Sacral root neuromodulation for the treatment of urinary incontinence reported to detrusor hyperactivity]; Neurochirurgie; 2003; 377-382; 49;Abstract.
Romero Maroto, J, et al.; [Techniques and current practice of urodynamics. Problems and traps]; Actas Urol Esp; 2003; 75-91; 27;Abstract.
Ratto, C, et al.; Minimally invasive sacral neuromodulation implant technique: modifications to the conventional procedure; Dis Colon Rectum; 2003; 414-417; 46.
Pannek, J, et al.; [Initial results of Stoller peripheral neuromodulation in disorders of bladder function]; Urologe A; 2003; 1470-1476; 42.
Oliver, S, et al.; Measuring the sensations of urge and bladder during cystometry in urge incontinence and the effects of neuromodulation; Neurourol Urodyn; 2003; 42567; 22.
Martin Braun, P, et al.; [Continuous bilateral sacral neuromodulation as a minimally invasive implantation technique in patients with functional bladder changes]; Arch Esp Urol; 2003; 497-501; 56.
Julius, F, et al.; Catheter tip granuloma associated with sacral region intrathecal drug administration; Neuromodulation; 2003; 225-228; 6.
Hassouna, M, et al.; Update on sacral neuromodulation: indications and outcomes; Curr Urol Rep; 2003; 391-398; 4.
Green, BT, et al.; Neuromodulation of enteropathogen internalization in Peyer's patches from porcine jejunum; J Neuroimmunol; 2003; 74-82; 141.
Fraser, MO, et al.; Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence; BJU Int; 2003; 743-748; 91.
Fjorback, MV, et al.; A portable device for experimental treatment of neurogenic detrusor overactivity; Neuromodulation; 2003; 158-165; 6.
Feler, CA, et al.; Sacral neuromodulation for chronic pain conditions; Anesthesiol Clin North America; 2003; 785-795; 21.
Dasgupta, R, et al.; The management of female voiding dysfunction: Fowler's syndrome—a contemporary update; Curr Opin Urol; 2003; 293-299; 13.
Comiter, CV; Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1369-1373; 169.
Bross, S, et al.; [Sacral neuromodulation in patients with nonobstructive, chronic urinary retention: relevance of the carbachol test and influence of associated nerve lession]; Aktuelle Urol; 2003; 157-161; 34;Abstract.
Bross, S, et al.; The role of the carbachol test and concomitant diseases in patients with nonobstructive urinary retention undergoing sacral neuromodulation; World J Urol; 2003; 346-349; 20.
Brooks, DR, et al.; The Caenorhabditis elegans orthologue of mammalian puromycin-sensitive aminopeptidase has roles in embryogenesis and reproduction; J Biol Chem; 2003; 42795-42801; 278.
Braun, PM, et al.; Stimulation signal modification in a porcine model for suppression of unstable detrusor contractions; Urology; 2003; 839-844; 61.
Bouchelouche, K, et al.; Recent developments in the management of interstitial cystitis; Curr Opin Urol; 2003; 309-313; 13.
Beneton, C, et al.; [The medical treatment of overactive bladder]; Neurochirurgie; 2003; 369-376; 49;Abstract.
Banyo, T; [The role of electrical neuromodulation in the therapy of chronic lower urinary tract dysfunction]; Ideggyogy Sz; 2003; 68-71; 56;Abstract.
Bannowsky, A, et al.; [Sacral neuromodulation in treatment of functional disorders of the lower urinary tract. An overview of basic principles, indications, outcomes]; Urologe A; 2003; 1357-1365; 42.
Antolak, SJ, JR.; Re: Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1956; author reply 1956; 170.
Amarenco, G, et al.; Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder; J Urol; 2003; 2210-2215; 169.
Abrams, P, et al.; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2003; 355-359; 91.
Zhou, Y, et al.; Change of vanilloid receptor 1 following neuromodulation in rats with spinal cord injury; J Surg Res; 2002; 140-144; 107.
Yamanouchi, M, et al.; Integrative control of rectoanal reflex in guinea pigs through lumbar colonic nerves; Am J Physiol Gastrointest Liver Physiol; 2002; G148-156; 283.
Whitemore, KE; Complementary and alternative therapies as treatment approaches for interstitial cystitis; Rev Urol; 2002; S28-35; 4 Suppl 1.
Van Kerrebroeck, PE; Neuromodulation and other electrostimulatory techniques; Scand J Urol Nephrol Suppl; 2002; 82-86.
Uranga, A, et al.; An integrated implantable electrical sacral root stimulator for bladder control; Neuromodulation; 2002; 238-247; 5.
Uludag, O, et al.; [Sacral neuromodulation is effective in the treatment of fecal incontinence with intact sphincter muscles; a prospective study]; Ned Tijdschr Geneeskd; 2022; 989-993; 146;Abstract.
Swinn, MJ, et al.; The cause and natural history of isolated urinary retention in yound women; J Urol; 2002; 151-156; 167.
Scheepens, WA, et al.; Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction; Urology; 2002; 598-602; 60.
Scheepens, WA, et al.; Unilateral versus bilateral sacral neuromodulation in patients with chronic voiding dysfunction; J Urol; 2002; 2046-2050; 168.
Ripetti, V, et al.; Sacral nerve neuromodulation improves physical, psychologica and social quality of life in patients with fecal incontinence; Tech Coloproctol; 2002; 147-152; 6.
Ramundo, JM, et al.; State of the science: pathology and management of the patient with overactive bladder; Ostomy Wound Manage; 2002; 22-27; 48.
Pettit, PD, et al.; Sacral neuromodulation: new applications in the treatment of female pelvic floor dysfunction; Curr Opin Obstet Gynecol; 2002; 521-525; 14.
Ordia, JI, et al.; Continuous intrathecal baclofen infusion delivered by a programmable pump for the treatment of severe spasticity following traumatic brain injury; Neuromodulation; 2002; 103-107; 5.
Mazo, EB, et al.; [Temporary sacral and tibial neuromodulation in treating patients with overactive urinary bladder]; Zh Vopr Neirokhir Im N N Burdenko; 2002; 17-21; Abstract.
Malouf, AJ, et al.; Short-term effects of sacral nerve stimulation for idiopathic slow transit constipation; World J Surg; 2002; 166-170; 26.
Malossi, J, et al.; Sacral neuromodulation for the treatment of bladder dysfunction; Curr Urol Rep; 2002; 61-66; 3.
Linares Quevedo, AI, et al.; [Posterior sacral root neuromodulation in the treatment of chronic urinary dysfunction]; Actas Urol Esp; 2002; 250-260; 26;Abstract.
Krivoborodov, GG, et al.; [Afferent stimulation of the tibial nerve in patients with hyperactive bladder]; Urologiia, 2002; 36-39; ;Abstract.
Kohli, N, et al.; Neuromodulation techniques for the treatment of the overactive bladder; Clin Obstet Gynecol; 2002; 218-232; 45.
Kirkham, AP, et al; neuromodulation through sacral nerve roots 2 to 4 with a Finetech-Brindley sacral posterior and anterior root stimulator; Spinal Cord; 2002; 272-281; 40.
Jezernik, S, et al.; Electrical stimulation for the treatment of bladder dysfunction: current status and future possibilities; Neurol Res; 2002; 413-430; 24;Abstract.
Hedlund, H, et al.; Sacral neuromodulation in Norway: clinical experience of the first three years; Scand J Urol Nephrol Suppl; 2002; 87-95; ;Abstract.
Ferulano, GP, et al.; [Sacral neuromodulation in fecal continence disorders]; Recenti Prog Med; 2002; 403-409; 93;Abstract.
Braun, PM, et al.; [Chronic sacral bilateral neuromodulation. Using a minimal invasive implantation technique in patients with disorders of bladder function]; Urologe A; 2002; 44-47; 41.
Braun, PM, et al.; Alterations of cortical electrical activity in patients with sacral neuromodulation; Eur Urol; 2002; 562-566; discussion 566-567; 41.
Amundsen, CL, et al.; Sacral neuromodulation in an older, urge-incontinent population; Am J Obstet Gynecol; 2002; 1462-1465; discussion 1465; 187.
Wyndaele, JJ, et al.; Conservative treatment of the neuropathic bladder in spinal cord injured patients; Spinal Cord; 2001; 294-300; 39.
Walsh, IK, et al.; Non-invasive antidromic neurostimulation: a simple effective method for improving bladder storage; Neurourol Urodyn; 2001; 73-84; 20.
Scheepens, WA, et al.; [Neuromodulation and neurostimulation in urology]; Ned Tijdschr Geneeskd; 2001; 1730-1734; 145;Abstract.
Mauroy, B, et al.; [Long-term results of interferential current stimulation in the treatment of bladder instability]; Prog Urol; 2001; 34-39; 11; Abstract.
Maher, CF, et al.; Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis; J Urol; 2001; 884-886; 165.
Krolczyk, G, et al.; Effects of continuous microchip (MC) vagal neuromodulation on gastrointestinal function in rats; J Physiol Pharmacol; 2001; 705-715; 52.
Kirkham, AP, et al.; The acute effects of continuous and conditional neuromodulation on the bladder in spinal cord injury; Spinal Cord; 2001; 420-428; 39.
Jarvis, JC, et al.; Functional electrical stimulation for control of internal organ function; Neuromodulation; 2001; 155-164; 4.
Hohenfellner, M, et al.; Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants; Urology; 2001; 887-892; 58.
Hoebeke, P, et al.; Transcutaneous neuromodulation for the urge syndrome in children: a pilot study; J Urol; 2001; 2416-2419; 166.
Hindley, RG, et al.; The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate; BJU Int; 2001; 217-220; 88.
Groen, J, et al.; Computerized assessment of detrusor instability in patients treated with sacral neuromodulation; J Urol; 2001; 169-173; 165.
Groen, J, et al.; Neuromodulation techniques in the treatment of the overactive bladder; BJU Int; 2001; 723-731; 87.
Govier, FE, et al.; Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study; J Urol; 2001; 1193-1198; 165.
Ganio, E, et al.; Neuromodulation for fecal incontinence: outcome in 16 patients with definitive implant. The initial Italian Sacral Neurostimulation Group (GINS) experience; Dis Colon Rectum; 2001; 965-970; 44.
Dorflinger, A, et al.; Voiding dysfunction; Curr Opin Obstet Gynecol; 2001; 507-512; 13.
Carey, M, et al.; Sacral nerve root stimulation for lower urinary tract dysfunction: overcoming the problem of lead migration; BJU Int; 2001; 15-18; 87.
Bugee, M, et al.; An implant for chronic selective stimulation of nerves; Med Eng Phys; 2001; 29-36; 23.
Buback, D; The use of neuromodulation for treatment of urinary incontinence; Aorn J; 2001; 176-178, 181-177, 189-190; uiz 191-176; 76;Abstract.
Bower, WF, et al.; A pilot study of the home application of transcutaneous neuromodulation in children with urgency or urge incontinence; J Urol; 2001; 2420-2422; 166.
Benson, JT; New therapeutic options for urge incontinence; Curr Womens Health Rep; 2001; 61-66; 1;Abstract.
Alo, KM, et al.; Selective Nerve Root Stimulation (SNRS) for the Treatment of Intractable Pelvic Pain and Motor Dysfunction: A Case Report; Neuromodulation; 2001; 19-23; 4.
Alo, KM, et al.; Sacral nerve root stimulation for the treatment of urge incontinence and detrusor dysfunction utilizing a cephalocaudal intraspinal method of lead insertion: a case report; Neuromodulation; 2001; 53-58; 4.
Wyndaele, JJ, et al.; Influence of sacral neuromodulation on electrosensation of the lower urinary tract; J Urol; 2000; 221-224; 163.
Weil, EH, et al.; Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial; Eur Urol; 2000; 161-171; 37;Abstract.
Wang, Y, et al.; Neuromodulation reduces urinary frequency in rats with hydrochloric acid-induced cystitis; BJU Int; 2000; 726-730; 86.
Wang, Y, et al.; Neuromodulation reduces c-fos gene expression in spinalized rats: a double-blind randomized study; J Urol; 2000; 1966-1970; 163.
Sun, Y, et al.; Effects of neural blocking agents on motor activity and secretion in the proximal and distal rat colon: evidence of marked segmental differences in nicotinic receptor activity; Scand J Gastroenterol; 2000; 380-388; 35.
Shaker, H, et al.; Role of C-afferent fibres in the mechanism of action of sacral nerve root neuromodulation in chronic spinal cord injury; BJU Int; 2000; 905-910; 85.
Rovner, ES; Treatment of urinary incontinence; Curr Urol Rep; 2000; 235-244; 1.
Nijman, RJ; Classification and treatment of functional incontinence in children; BJU Int; 2000; 37-42; discussion 45-36; 85 Suppl 3.
Mazo, EB, et al., [Temporary sacral neuromodulation in patients with urge incontinence]; Urologiia; 2000; 42-46; ;Abstract.
Klingler, HC, et al.; Use of peripheral neuromodulation of the S3 regions for treatment of detrusor overactivity: a urodynamic-based study; Urology; 2000; 766-771; 56.
Hohenfellner, M, et al.; [Sacral neuromodulation of the urinary bladder]; Urologe A; 2000; 55-63; 39.
Hohenfellner, M, et al.; Sacral neuromodulation for treatment of lower urinary tract dysfunction; BJU Int; 2000; 10-19; discussion 22-13; 85 Suppl 3.
Grill, WM; Electrical activation of spinal neural circuits: application to motor-system neural prostheses; Neuromodulation; 2000; 97-106; 3.
Dahms, SE, et al.; Sacral neurostimulation and neuromodulation in urological practice; Curr Opin Urol; 2000; 329-335; 10.
Costa, JA, et al.; Spinal cord neuromodulation for voiding dysfunction; Clin Obstet Gynecol; 2000; 676-688; 43.
Chancellor, MB, et al.; Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions; Neuromodulation; 2000; 16-26; 3.
Bosch, JL, et al.; Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study; J Urol; 2000; 1219-1222; 163.
Bosch, JL; Sacral neuromodulation: treatment success is not just a matter of optimal electrode position; BJU Int; 2000; 20-21; discussion 22-23; 85 Suppl 3.
Van Der Aa, HE, et al.; Sacral anterior root stimuation for bladder control: clinical results; Arch Physiol Biochem; 1999; 248-256; 107.
Vaizey, CJ, et al.; Effects of short term sacral nerve stimulation on anal and rectal function in patients with anal incontinence; Gut; 1999; 407-412; 44.
Sullivan, J, et al.; Overactive detrusor; Curr Opin Urol; 1999; 291-296; 9.
Sullivan, J, et al.; The overactive bladder: neuropharmacological basis of clinical management; Curr Opin Obstet Gynecol; 1999; 477-483; 11.
Shaker, H, et al.; Sacral root neuromodulation in the treatment of various voiding and storage problems; Int Urogynecol J Pelvic Floor Dysfunct; 1999; 336-343; 10;Abstract.
Ishigooka, M, et al.; Sacral nerve stimulation and diurnal urine volume; Eur Urol; 1999; 421-426; 36;Abstract.
Craggs, M, et al.; Neuromodulation of the lower urinary tract; Exp Physiol; 1999; 149-160; 84.
Braun, PM, et al.; Tailored laminectomy: a new techniqu for neuromodulator implantation; J Urol; 1999; 1607-1609; 162.
Bemelmans, BL, et al.; Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction; Eur Urol; 1999; 81-91; 36;Abstract.
Anton, PA; Stress and mind-body impact on the course of inflammatory bowel diseases; Semin Gastrointest Dis; 1999; 14-19; 10;Abstract.
Zvara, P, et al.; An animal model for the neuromodulation of neruogenic bladder dysfunction; Br J Urol; 1998; 267-271; 82.
Wallace, JL, et al.; Lack of beneficial effect of a tachykinin receptor antagonist in experimental colitis; Regul Pept; 1998; 95-101; 73.
Van Kerrebroeck, PE; The role of electrical stimulation in voiding dysfunction; Eur Urol; 1998; 27-30; 34 Suppl 1;Abstract.
Shaker, HS, et al.; Sacral root neuromodulation in idiopathic nonobstructive chronic urinary retention; J Urol; 1998; 1476-1478; 159.
Shaker, HS, et al.; Sacral nerve root neuromodulation: an effective treatment for refractory urge incontinence; J Urol. 1998; 1516-1519; 159.
Schultz-Lampel, D, et al.; Experimental results on mechanisms of action of electrical neuromodulation in chronic urinary retention; World J Urol; 1998; 301-304; 16.
Schmidt, RA, et al.; Neurostimulation and neuromodulation: a guide to selecting the right urologic patient; Eur Urol; 1998; 23-26; 34 Suppl 1;Abstract.
Jiang, CH; Modulation on the micturition reflex pathway by intravesical electrical stimulation: an experimental study in the rat: Neurourol Urodyn; 1998; 543-553; 17.
Hohenfellner, M, et al.; Bilateral chronic sacral neuromodulation for treatment of lower urinary tract dysfunction; J Urol; 1998; 821-824; 160.
Hasan, ST, et al.; Neuromodulation in bladder dysfunction; Curr Opin Obstet Gynecol; 1998; 395-399; 10.
Grunewald, V; Neuromodulation/neurostimulation; World J Urol; 1998; 299-300; 16.
Chapple, CR, et al.; Surgery for detrusor overactivity; World J Urol; 1998; 268-273; 16.
Brown, DR, et al.; Delta-opioid receptor mRNA expression and immunohistochemical localization in porcine ileum; Dig Dis Sci; 1998; 1402-1410 ;43.
Bower, WF, et al.; A urodynamic study of surface neuromodulation versus sham in detrusor instability and sensory urgency; J Urol; 1998; 2133-2136; 160.
Bosch, JL, et al.; Neuromodulation: urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperflexia; Behav Brain Res; 1998; 141-150; 92.
Bosch, JL; Sacral neuromodulation in the treatment of the unstable bladder; Curr Opin Urol; 1998; 287-291; 8.
Turner, WH, et al.; Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment; Pharmacol Ther; 1997; 77-110; 75.
Sutherland, RS, et al.; Vesicourethral function in mice with genetic disruption of neuronal nitric oxide synthase; J Urol; 1997; 1109-1116; 157.
Gottwald, T, et al., [Sex differences in neuromodulation of mucosal mast cells in the rat jejunum]; Langenbecks Arch Chir. 1997; 157-163; 382;Abstract.
Gonzalez-Chamorro, F, et al.; [Current status of neurostimulation and neuromodulation for vesicourethral dysfunction]; Arch Esp Urol; 1997; 687-694; 50;Abstract.
Everaert, K, et al.; The urodynamic evaluation of neuromodulation in patients with voiding dysfunction; Br J Urol; 1997; 702-707; 79.
Sheriff, MK, et al.; Neuromodulation of detrusor hyper-reflexia by functional magnetic stimulation of the sacral roots; Br J Urol; 1996; 39-49; 78;Abstract.
Hasan, ST, et al.; Surface localization of sacral foramina for neuromodulation of bladder funtion. An Anatomical study; Eur Urol; 1996; 90-98; 29;Abstract.
Hasan, ST, et al.; Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability; J Urol; 1996; 2005-2011; 155.
Bristow, SE, et al.; TENS: a treatment option for bladder dysfunction; Int Urogynecol J Pelvid Floor Dysfunct; 1996; 185-190; 7.
Traynor, TR, et al.; Neuromodulation of ion transport in porcine distal colon: NPY reduces secretory action of leukotrienes; Am J Physiol; 1995; R426-431; 269;Abstract.
Kinder, MV, et al.; Neuronal circuitry of the lower urinary tract central and peripheral neuronal control of the micturition cycle; Anat Embryol (Berl); 1995; 195-209; 192.
Hassouna, M, et al.; Dog as an animal model for neurostimulation; Neurourol Urodyn; 1994; 159-167; 13.
Duve, H, et al.; Distribution and functional significance of Leu-callatostatins in the blowfly Calliphora vomitoria; Cell Tissue Res; 1994; 367-379; 276.
Wiklund, CU et al.; Modulation of cholinergic and substance P-like neurotransmission by nitric oxide in the guinea-pig ileum; Br J Pharmacol; 1993; 833-839; 110.
Tanagho, EA; Concepts of neuromodulation; Neurourol Urodyn; 1993; 487-488; 12.
Katsuragi, T, et al.; Possible transsynaptic cholinergic neuromodulation by ATP released from ileal longitundinal muscles of giunea pigs; Life Sci; 1993; 911-918; 53.
Dijkema, HE, et al.; Neuromodulation of sacral nerves for incontinence and voiding dysfunctions. Clinical results and complications; Eur Urol; 1993; 72-76; 24;Abstract.
Tanagho, EA; Neuromodulation in the management of voiding dysfunction in children; J Urol; 1992; 655-657; 148;Abstract.
Dijkema, HE, et al.; [Initial experiences with neuromodulation as treatment for incontinence and micturition disorders in The Netherlands]; Ned Tijdschr Geneeskd; 1992; 88-90; 136;Abstract.
Collins, SM; Is the irritable gut an inflamed gut?; Scand J Gastroenterol Suppl; 1992; 102-105; 192;Abstract.
Parija, SC, et al.; Adenosine- and alpha,beta-methylene ATP-induced differential inhibition of cholinergic and non-cholinergic neurogenic responses in rat urinary bladder; Br J Pharmacol; 1991; 396-400; 102.
Kachur, JF, et al.; neuromodulation of guinea pig intestinal electrolyte transport by cholecystokinin octapeptide; Gastroenterology; 1991; 344-349; 100;Abstract.
Katsuragi T, et al.; Involvement of dihydropyridine-sensitive Ca2+ channers in adenosine-evoked inhibition of acetylcholine release from guinea pig ileal preparation; J Neurochem; 1990; 363-369; 55.
Burnstock, G; Innervation of bladder and bowel, Ciba Found Symp; 1990; 2-18; discussion 18-26; 151;Abstract.
Wiklund, NP, et al.; Cholinergic neuromodulation by endothein in guinea pig ileum; Neurosci Lett; 1989; 342-346; 101.
Carey, HV, et al.; Neuromodulation of intestinal transport in the sucking mouse; Am J Physiol; 1989; R481-486; 256;Abstract.
Wiklund, NP, et al.; Neuromodulation by adenine nucleotides, as indicated by experiments with inhibtors of nucleotide inactivation; Acta Physiol Scand; 1986; 217-223; 126;Abstract.
Hoyle, CH, et al.; Ethylcholine mustard aziridinium ion (AF64A) impairs cholinergic neuromuscular transmission in the guinea-pig ileum and urinary bladder, and cholinergic neuromodulation in the enteric nervous system of the guinea-pig distal colon; Gen Pharmacol; 1986; 543-548; 17.
Katsuragi, T, et al.; Cholinergic neuromodulation by ATP, adenosince and its N6-substituted analogues in guinea-pig ileum; Clin Exp Pharmacol Physiol; 1985; 73-78; 12;Abstract.
Barroso U Jr et al.; Electrical nerve stimulation for overactive bladder in children;Nature Reviews Urology; 2011; 402-407; 8.
M. Matsushita et al.; Primary somatosensory evoked magnetic fields elicited by sacralsurface electrical stimulation; Neuroscience Letters; 2008; 77?80; 431.
N. Patidar et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactivebladder: A preliminary report; Journal of Pediatric Urology; 2015; 351.e1-351.e6; 11.
Perissinotto et al.; Transcutaneous Tibial Nerve Stimulation in the Treatment of Lower UrinaryTract Symptoms and Its Impact on Health-Related Quality of Life in Patients With ParkinsonDisease; J Wound, Ostomy and Continence Nurses Society; 2015; 94-99; 42.
Tomonori Yamanishi et al.; Neuromodulation for the Treatment of Lower Urinary TractSymptoms; Low Urin Tract Symptoms; 2015; 121-132; 7.
Christopher J. Chermansky et al., “MP68-15 Electrical Stimulation of Afferent Nerves in the Foot NITH Transcutaneous Adhesive Pad Electrodes Improves Overactive Bladder Symptoms in Women”, The Journal of Urology, vol. 195, No. 4S, Supplement, Monday, May 9, 2016, 2 pages.
Christopher J. Chermansky, “Foot/Hand Neuromodulation for Overactive Bladder (OAB) (FootStim)”; First Posted: Oct. 30, 2013; http://clinicaltrials.govict2/show/NCT01972061; pp. 1-5.
Tai et al., “FootStim: Neuromodulation therapy for overactive bladder”; http://www.engineering.pitt.edu/Sub-Sites/Programs/Coulter/Projects/2013---FootStim/: retrieved on Sep. 26, 2017.
Oliver_et_al—2003—Neurourology_and_Urodynamics.
J. Groen and J.L.H.R. Bosch; Neuromodulation techniques in the treatment of the overactive bladder; BJU International (2001), 87, 723-731.
Michael Craggs and Jonathon McFarlane; Neuromodulation of the lower urinary tract; Experimental Physiology (1999), 84, 149-160.
Yogi A. Patel; Kilohertz Electrical Stimulation Nerve Conduction Block: Effects of Electrode Surface Area; IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol. 25, No. 10, Oct. 2017.
Related Publications (1)
Number Date Country
20170281938 A1 Oct 2017 US
Provisional Applications (1)
Number Date Country
62119134 Feb 2015 US
Continuation in Parts (1)
Number Date Country
Parent 14893946 Nov 2015 US
Child 15048760 US